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Abstract 
In recent decades, the control of cortisol metabolism within tissues by the 11 
beta-hydroxysteroid dehydrogenase (11 β-HSD) enzyme system has been 
studied in detail, however there is limited data regarding the effect of this 
enzyme system on skeletal muscle.   
The results of this thesis show that 11 β-HSD1 is biologically active in skeletal 
muscle. 11 β-HSD1 plays a key role in glucocorticoid (GC) mediated 
myopathy by increasing atrophy pathways, decreasing hypertrophy pathways 
and inhibiting myoblast proliferation. There are many similarities between 
glucocorticoid mediated myopathy and the muscle loss associated with 
ageing (sarcopaenia).  We have shown that 11 β-HSD1 is increased with age 
in murine skeletal muscle and this may have a key role to play in the 
development of sarcopaenia.   Further work is required in this area to examine 
the impact of modulation of 11 β-HSD1 on muscle with ageing. 
We have shown that hypopituitary patients receiving hydrocortisone 
replacement therapy have significant alterations in cortisol metabolites and an 
increase in 11 β-HSD1.  The alterations in cortisol metabolism are associated 
with an adverse body composition.  New modified release hydrocortisone 
preparations, which replace cortisol in a more physiological manner, need to 
be assessed for their impact on cortisol metabolism.  
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1.1  Introduction 
Glucocorticoids are essential for the normal function of most organ systems, 
however, in excess they can lead to several adverse consequences including 
insulin resistance, hypertension, osteoporosis, obesity and muscle loss/ 
weakness (myopathy) (1).  In recent decades, the control of cortisol metabolism 
within tissues by the 11 beta-hydroxysteroid dehydrogenase (11 β-HSD) enzyme 
system has been studied in detail, however there is limited data regarding the 
effect of this enzyme system on skeletal muscle (2).   
The population of western societies are increasing in age and there are a number 
of conditions that increase in prevalence in an ageing population which include 
sarcopaenia (loss of muscle mass and strength), cardiovascular disease, 
metabolic syndrome (and Type 2 diabetes mellitus) and osteoporosis.  Each of 
these conditions place a considerable burden upon limited health care resources 
(3).  One of the commonest complications of ageing is the loss of muscle mass 
and strength, known as ‘sarcopaenia’.  Muscle strength peaks between the 2nd 
and 3rd decade of life and remains the same until approximately 45-50 years.  
After this strength decreases at the rate of 12-15% per decade until the 8th 
decade (4) and up to 24% of people aged <65 years and 50% of people aged >80 
years have sarcopaenia.  There are several similarities between the muscle 
changes reported in sarcopaenia and glucocorticoid mediated myopathy. 
There is some evidence for alterations in cortisol secretion and tissue specific 
metabolism (via 11 β-HSD1) with increasing age in certain tissues including bone 
(5) and skin (6) and 11β-HSD1 KO mice are resistant to hippocampal changes 
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associated with ageing (7).  However, there are no data regarding changes in 11 
β-HSD1 within skeletal muscle with ageing.   
 
1.2 Skeletal muscle  
1.2.1. Skeletal myocyte differentiation   
The regulation of skeletal muscle formation (myogenesis) is essential for normal 
muscle development as well as in pathological conditions (8).  Myogenesis is a 
dynamic process in which mononucleated undifferentiated myoblasts first 
proliferate, then withdraw from the cell cycle and finally differentiate and fuse to 
form the multinucleated mature muscle fibre (8).   
Activation of muscle differentiating-specific genes is controlled by the myogenic 
regulatory factors (MRFs), which belong to the bHLH family of transcription 
factors.  The MRF family consists of four members (Myf5, MyoD, myogenin and 
MRF4) which bind to the sequence specific DNA elements (E box:…CANNTG…) 
present in the promoter region of muscle specific genes (8).  Selective and 
productive recognition of E boxes on muscle promoters require 
heterodimerisation of MyoD with the ubiquitously expressed bHLH E proteins; the 
formation of this functional heterodimer is the key event in initiating skeletal 
myogenesis (8-10). 
Different muscle genes are expressed at different times during myogenesis, 
despite all of them having E boxes in their promoter regions.  Thus, promoter 
specific and temporal constraints are likely to be superimposed upon the basic 
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model of myogenic transcriptional activation by MRFs (8).  Full activation of 
muscle gene expression by MRFs is also dependent on their association with 
members of the MEF2 family of transcription factors (MEF2A-D).  MEF2 cannot 
activate muscle genes on their own but they can potentiate the activity of the 
MRFs (8).  MAP kinases also have a key role in the control of muscle gene 
expression at different stages of the myogenic process (8).  
 
 
 
 
 
 
Figure 1.1.  Skeletal myofibre synthesis is controlled at different stages of 
development by different myogenic regulatory factors.  EP = E protein (Based on 
a figure from Lluis et al.) (8). 
 
A key feature of terminally differentiated myocytes is the presence of multiple 
nuclei per cell.  Each nucleus originated from separate myoblasts which fused 
together to form single, elongated, cylindrical cells referred to as myotubules, 
which no longer have the capacity to proliferate (Figure 1.1).  Within the myofibre 
and between the myotubules (adjacent to the basal lamina) lie myogenic 
progenitor or satellite cells which are essential for growth and regeneration of 
myotubules (11).  In healthy adult skeletal muscle these cells are mitotically 
MYOBLAST MYOCYTE (EARLY DIFFERENTIATION) 
MYOTUBE 
(LATE DIFFERENTIATION) 
MYOFIBRE 
(TERMINAL DIFFERENTIATION) 
•  Myf5/ EP 
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•  Inhibitor of 
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•  Myogenin 
•  MyoD 
•  E protein 
•  MEF2 
•  Protein E 
•  MRF4 
•  α-actin 
•  MHC 
•  MCK 
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quiescent but can be activated in response to various stimuli such as exercise or 
injury, at which point they undergo multiple rounds of cell division generating 
myoblasts which can fuse to form new myotubules. 
 
1.2.2. Skeletal muscle physiology 
Multinucleated myotubule formation from myocytes, leads to tubules of varying 
diameter and length.  Each myofibre contains the contractile proteins myosin and 
actin, which are incorporated into long filaments, which are organised into units 
called sarcomeres.  Sarcomeres in series are referred to as myofibrils, and give 
skeletal muscle a striated appearance (Figure 1.2).   
Movement in muscle is generated by the myosin cross bridges, which interact 
cyclically with actin filaments and transport them past the myosin thick filaments, 
during this process an ATP is hydrolysed (12).  The swinging cross-bridge theory 
for muscle contraction is one in which myosin cross bridges bind to the actin 
filament in an initial conformation and then undergo a swinging motion that ‘rows’ 
the actin filament along (12).  Myosin is a product-inhibited ATPase, which is 
strongly stimulated by binding to actin (which is a nucleotide exchange factor for 
myosin (12).  ATP binding to the catalytic domain of the myosin motor head 
induces a conformational change, leading to the dissociation of myosin from 
actin.  Myosin then hydrolyses ATP and forms a stable myosin-products complex, 
with which actin recombines.  The resultant actin-myosin complex allows the 
cross bridge to undergo a conformational change allowing the products of 
hydrolysis to be released, which allows the rowing-like stroke (power-stroke) 
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causing the myosin filament to slide longitudinally with respect to the actin 
filament (12). 
 
 
 
 
 
 
 
Figure 1.2. Representation of the structure of skeletal muscle.  Sarcomeres 
represent the contractile mechanism of skeletal muscle. Z disk = forms the 
borders of sarcomere, H zone = area at centre of sarcomere that contains only 
myosin, I band = area surrounding Z disk, A band = dark staining zone of the 
sarcomere which contains actin and myosin, M line = middle of sarcomere which 
contains cross connective elements of cytoskeleton. Based on a figure from 
Morgan (13). 
 
 
1.2.3. Human and rodent skeletal muscle fibre Types and 
nomenclature 
Human muscle fibres can be divided into a number of subgroups including slow 
twitch oxidative (Type I fibres), fast twitch oxidative (Type IIa fibres) and fast 
twitch glycolytic (Type IIx or IIb).  Type I fibres contain high levels of slow isoform 
contractile proteins, high volumes of mitochondria, high levels of myoglobin and 
capillary densities and a high oxidative enzyme capacity (14).  Type IIa fibres are 
Nuclei 
Myofibril 
I band A band I band M line 
Z disk Z disk H zone 
Actin filament 
Myosin 
M line 
Myosin 
Myosin 
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characterised by fast contraction with high oxidative capacity.  Type IIb fibres are 
characterised by low volumes of mitochondria, high glycolytic enzyme activity, 
high myosin ATPase activity, increased rate of contraction and low fatigue 
resistance (14) (Table 1.1). 
 
 
Table 1.1.  Representation of key differences in contractile and metabolic 
properties between subclasses of muscle fibres. MyHC = myosin heavy chain. 
 
Along with the ‘pure’ fibre Types, there are also hybrid fibres composed of both 
Type I and IIa myosin heavy chains (MyHC) and Type IIA and IIb MyHC (15).  
In contrast to humans, adult rodents limb muscle contain 4 ‘pure’ fibre Types, 3 of 
which are fast twitch (fast Type IIa, IIb and IId) and 1 slow twitch (Type I).  There 
are also several hybrid fibre Types co-expressing different MyHC (Type I/IIa and 
Fibre Type Type I Fibres Type IIa Fibres Type IIx Fibres Type IIb Fibres 
Contractile Properties 
Predominant MyHC 
isoform 
MYH7 MYH2 MYH1 MYH4 
Speed of contraction Slow Moderately Fast Fast Very Fast 
Exercise type Aerobic Long-term aerobic Short-term aerobic Short-term Anaerobic 
Resistance to fatigue High High Intermediate Low 
Force generated Low Medium High Very High 
Metabolic Properties 
Mitochondrial number High High Medium Low 
Fuel store Triglycerides Creatine phosphate, 
glycogen 
Creatine phosphate, 
glycogen 
Creatine phosphate, 
glycogen 
Oxidative capacity High High Intermediate Low 
Glycolytic capacity Low High High High 
Capillary number High Intermediate Low Low 
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Type IIa/I, known as Type Ic and IIc, respectively), Type IIad, IIda, IIdb and IIbd 
(16). 
1.3 Sarcopaenia 
1.3.1. Background 
The 2001 census showed that for the first time the number of people in England 
and Wales aged 60 and over was greater than the number aged below 16 years 
of age.  People over the age of 60 currently consume 38% of NHS total 
expenditure (17). It is estimated that >20% of the UK population will be >65 years 
by the year 2020 (17).  There are a number of conditions that increase in 
prevalence in an ageing population which include sarcopaenia (age related loss 
of muscle), cardiovascular disease, metabolic syndrome (and Type 2 diabetes 
mellitus) and osteoporosis.  Each of these conditions place a considerable burden 
upon limited health care resources (3).   
In health, skeletal muscle tissue represents 40%-45% of body mass.  For an 80kg 
male and 60kg female, this equates to 32-36kg and 24-27kg and thus represents 
a considerable source of protein where the contractile machinery, actin and 
myosin, can be degraded into amino acids ready for gluconeogenesis, 
immunological and wound healing processes.  The term ‘sarcopaenia’ was coined 
to describe the loss of skeletal muscle mass that occurs with increasing age. 
Baumgartner et al. (18) defined sarcopaenia as an appendicular skeletal mass 
(muscle mass/ height2) more than 2 standard deviations (SD) below the mean of 
a young reference group. Sarcopaenia is associated with a significant decrease in 
muscle strength.  Muscle strength peaks between the 2nd and 3rd decade and 
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remains the same until approximately 45-50 years, after this strength decreases 
at the rate of 12-15% per decade until the 8th decade (4). Using Baumgartners’ 
definition, up to 24% of people aged <65 years and 50% of people aged >80 
years would fulfil the criteria for sarcopaenia as assessed using dual x-ray 
absorptiometry (DEXA). Sarcopaenia was more prevalent in men aged >75 years 
(58%) compared with women of the same age (45%). Several other studies have 
used DEXA to quantify the loss in skeletal muscle mass with age and have 
reported similar dimorphic patterns. Melton et al. (19) and Iannuzzi-Sucich et al. 
(20) demonstrated a greater prevalence of sarcopaenia amongst men (10% to 
~27%) than women (8% to ~23%) in their 6th decade. This increased to 40-45% 
for men and 18-31% in women in their 8th decade (19).  
 
1.3.2. Health consequences of sarcopaenia 
This loss of muscle mass and strength has functional consequences and 
sarcopaenia has been linked to multiple morbid outcomes in older adults 
including falls, functional decline, osteoporosis, impaired thermoregulation and 
glucose intolerance (21-24).  In the UK, 30% of those over the age of 65 will fall at 
least once a year, and 40% of those over 75 will fall at least twice per year.  Falls 
are the commonest reason cited for institutional care and for 40% of admissions 
to nursing homes or residential homes (25). Sarcopaenic subjects are also at 
increased risk of osteoporosis, this combined with increased falls leads to an 
increase risk of fractures in this group.  
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1.3.3. Pathological changes in Sarcopaenic muscle 
There are many pathological changes which occur within muscle with ageing 
including a decrease in muscle mass and cross-sectional area (26-28) and a 
decrease in Type I and II fibre number (predominantly Type II) (29-31).  There is 
an infiltration of fat and connective tissue (32) as shown on both histology and 
conventional imaging (33-36).  Several ultrastructural changes occur including 
accumulation of internal nuclei, ring and ragged fibres, lipofuscin and nemaline 
rod structures (37) with a disarrangement of myofilaments and Z-lines (37) and 
proliferation of the sarcoplasmic reticulum and t-tubular system (37). 
Mitochondrial function is impaired with ageing (38) leading to a decrease in 
muscle respiratory capacity and mitochondrial volume (39). All these factors may 
explain the decrease in aerobic endurance noted with ageing (40).  Myosin heavy 
chain synthesis rate declines with advancing age implying a decreased ability to 
remodel this important muscle contractile protein therefore contributing to the 
declining muscle mass and contractile function in the elderly (41). 
 
1.3.4. Factors associated with the development of Sarcopaenia 
Many factors have been proposed to explain the development of sarcopaenia 
including the effects of oxidative stress, cytokines, endocrine changes, diet and 
exercise.  Elevated levels of cytokines (IL-1, IL-6 and TNFα) have been reported 
with increasing age and TNFα and IL-6 levels have been shown to predict 
sarcopaenia in an elderly community (42, 43). The effects of oxidative stress (44) 
diet and exercise in relation to sarcopaenia have been previously described (4), 
Table 1.2.  
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Mechanism Ref 
Whole Body 
Reduced physical activity and muscle disuse (45) 
Reduced growth hormone and insulin-like growth factor-I production (46) 
Elevated catabolic cytokine production and activity (47) 
Malnutrition (48) 
Disease (49) 
Muscle Specific 
Reduced availability and recruitment of skeletal muscle satellite cells (50) 
Mitochondrial DNA mutations and apoptosis (51) 
Impaired insulin mediated increase in (micro) vascular blood flow (52) 
Insulin resistance of muscle protein synthesis by amino acids (53-55) 
Muscle fibre denervation (56) 
Impaired translation initiation and protein synthesis (54) 
Increased muscle protein breakdown (49) 
 
Table 1.2. Summary of the potential mechanisms underlying sarcopaenia. 
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1.3.5. Molecular mechanisms underpinning sarcopaenia 
The maintenance of muscle mass depends on the balance between muscle 
protein synthesis via anabolic stimuli (feeding, muscle contraction, anabolic 
hormones) and muscle protein breakdown via catabolic stimuli (fasting, 
glucocorticoids, inflammatory cytokines). Where muscle protein synthesis 
exceeds protein breakdown, hypertrophy occurs, whereas the reverse is true for 
muscle atrophy. It is clear, therefore, that sarcopaenia might be associated with a 
decrease in anabolic stimuli, an increase in catabolic stimuli, or a combination of 
the two.  
 
1.3.5.1. Satellite cells in sarcopaenia 
One possible mechanism underpinning sarcopaenia is the decline in regenerative 
capacity of skeletal muscle, possibly as a consequence of a decreased number or 
impaired function of skeletal muscle satellite cells (57). There is conflicting data 
regarding satellite cell number and function in sarcopaenic muscle with some 
authors describing a decrease (58-60) some reporting no change and others 
reporting an increase in satellite cell number with age (61, 62). There is also 
some evidence to suggest that there is fibre Type specificity to the decrease in 
satellite cells with Type II fibres having lower satellite cell number than Type I 
fibres (63).  Some studies have reported an increased expression of key 
regulators of myogenesis (myoD and myogenin) in elderly rat muscle which the 
authors believed to be a compensatory mechanism to combat sarcopaenia (64-
67).  However, there are many other genes and co-factors involved in 
myogenesis which may not be increased with ageing (57).  
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1.3.5.2. Role of Myostatin in sarcopaenia 
Myostatin is a member of the tumour growth factor β family and is a potent 
inhibitor of muscle growth, regulating satellite cell activation, myoblast 
proliferation and terminal differentiation. Cell proliferation requires the completion 
of the G, M and S cell cycle phases and myostatin prevents myoblasts from 
progressing past the G0/G1 and G2 phase (68) through the cyclin CDK inhibitor 
protein 21 (CKIp21), a key component of cell cycle arrest during the G and M 
phase (69).  Thus, fewer cells accumulate in the S-phase and proliferation is 
prevented.  Myostatin also down regulates MyoD1 expression (70) preventing 
myoblast differentiation into multinucleated myotubules (71, 72).  Disruption of the 
myostatin gene in mice increased muscle mass through hypertrophy and 
hyperplasia (70).   
There are conflicting data with regard to the role of myostatin in sarcopaenic 
muscle.  Some rodent studies have shown no change in myostatin expression in 
young vs. old mice (73), whereas other studies have shown an increased 
expression (74).  Similarly, human studies reveal conflicting results with some 
studies reporting no increased expression (75) and other an increase in myostatin 
expression with increasing age (76).  Therefore, further work is needed to clarify 
the role of myostatin in sarcopaenic muscle. 
The calpain system has also been reported to be activated in sarcopaenic muscle 
suggesting an increase in calcium dependent proteolysis (57).  
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1.3.5.3. Protein synthesis in sarcopaenia 
Elderly individuals do not demonstrate a decrease in basal muscle protein 
synthesis despite a reduction in muscle mass with age (77), but do show impaired 
muscle protein synthesis in response to amino acids, in the presence of insulin, 
despite demonstrating normal glucose tolerance and insulin concentrations 
comparable to the younger cohort (78). As such, healthy ageing muscle appears 
to be selectively resistant to anabolic stimuli such as insulin-stimulated muscle 
protein synthesis despite normal insulin-mediated glucose uptake. A gradual, 
long-term diminution of muscle sensitivity to insulin induced protein synthesis may 
contribute to sarcopaenia.  
 
1.3.5.4. Role of MURF-1 and MAFbx-1 in sarcopaenia 
Proteins scheduled for degradation in the proteasome are labelled by conjugation 
with ubiquitin.  The 26s proteasome enzyme complex can then recognise the 
ubiquitin and initiate protein degradation using at least three classes of proteins.  
These include the E1 (ubiquitin activating enzymes), E2 (ubiquitin-conjugating 
enzymes) and E3 (Ubiquitin ligase).  Within skeletal muscle, MAFBX and MURF-
1 are two important E3 ubiquitin ligases clearly associated with many models of 
muscle atrophy such as sepsis (79, 80) and disuse atrophy (81).  These genes 
encode E3 ubiquitin ligase proteins that bind and mediate ubiquitination of 
specific proteins for degradation (82), such as myosin, actin, troponin and 
tropomyosin found within skeletal muscle sarcomere (83). 
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Translocation of the forkhead transcription factor (FOXO-1) into the cell nucleus 
increases MAFbx and MURF-1 mRNA expression (84).  Phosphorylation of 
FOXO-1 by Akt sequesters FOXO-1 from the cell nucleus to the cytoplasm by 14-
3-3 proteins (85) preventing MAFbx and MURF-1 upregulation. 
IGF-I inhibits MAFbx-1 and MURF-1 expression (84, 86), and as IGF-I decreases 
with age (87), one might expect an associated increase in the expression of 
MAFbx-1 and MURF-1 with age, especially in sarcopaenic individuals. However, 
there is conflicting evidence surrounding the role of MURF-1 and MAFbx-1 in 
sarcopaenia. In ageing, MURF-1 and MAFbx-1 mRNA expression in human 
vastus lateralis muscle is unchanged (88, 89), whilst in rodent muscle MURF-1 
and MAFbx-1 mRNA expression is increased 2 to 2.5 fold (90), decreased (91), 
or MURF-1 expression decreases whilst MAFbx-1 expression remains 
unchanged (92) compared with younger control groups. The disagreement 
between studies is likely due to several confounding factors including the species 
sampled, the strains of animals, gender and the types of muscles biopsied. 
Edstrom et al. (91) suggests the reduction in MURF-1 and MAFbx-1 expression in 
the rat gastrocnemius muscle was part of a compensatory effect which was also 
suggested in a human study (93).  However, it is clear from the discordance in the 
above data that further evaluation of the role of these genes is required in 
sarcopaenia. 
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1.3.5.5. Fibre specificity of sarcopaenia 
A post-mortem assessment of the vastus lateralis muscle recovered from men 
aged 19-37 and 70-73 years demonstrated a substantial loss in muscle fibre 
number in the elderly group compared with the younger cohort (~364,000 fibres 
present in the elderly group vs. ~478,000 in the younger cohort) (94).  Andersen 
et al. (95) dissected 2264 single muscle fibres from 12 biopsies of elderly 
individuals and found just 20% of the fibres contained Type I MyHC which is half 
of that found in younger muscle (96). The number of fibres co-expressing Type I 
and Type IIa MyHC (28.5%) increased 5.5 fold compared with younger 
individuals. However, only 0.3% of the fibres contained MyHC Type IIb which is 
very low (95), but is in line with specific apoptosis/ atrophy of Type IIb fibres with 
age. Finally, fibres co-expressing all three MyHC’s together were observed which 
has not been reported in younger individuals (95).  
Whole muscle and individual muscle fibre atrophy is heavily implicated in the 
reduction in cross-sectional area with age, especially Type IIb fibres (29, 39, 56, 
94, 97-99), whereas the cross-sectional area of Type I fibres, although 
undergoing mild atrophy, generally appears well conserved with age (29). Type I 
fibres atrophy by 20% and Type II fibres by 43% in elderly individuals compared 
to their younger counterparts (100). 
The reason for the sensitivity of ageing Type II fibres to atrophy compared with 
Type I fibres remains to be elucidated. However, there are many similarities 
between sarcopaenia and studies reporting muscle fibre atrophy, especially Type 
II muscle fibres, in individuals with excess endogenous or exogenous 
glucocorticoid concentrations (101-108). 
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1.3.6. Endocrinology of ageing and putative role in sarcopaenia 
There are a number of hormonal changes, which occur with ageing which have 
been implicated in the development of sarcopaenia, including a decrease in 
testosterone, DHEA and GH/IGF-I levels. Testosterone levels decrease with 
increasing age and this decrease has been shown to be a strongly correlated with 
muscle mass and strength (109), however the data regarding increased muscle 
strength following testosterone replacement in this cohort is conflicting (110-113). 
The mechanism by which testosterone increases muscle strength and mass is 
not known, however, it may have its effect via IGF-I (114) as, in vitro, testosterone 
increases both IGF-I and IGF-binding proteins in muscle (110, 115).  DHEAS 
levels also decrease with increasing age and studies replacing DHEA in an 
elderly cohort have not shown an increase in muscle strength (116). 
 
1.3.6.1. The GH/ IGF-I system and ageing 
GH secretion declines by approximately 14% per decade (87) with a decrease in 
GH pulse amplitude, but maintenance of pulse frequency (117). However, the 
pituitary GH reserve, determined by the response to GH-releasing hormone 
(GHRH) + GH releasing peptide-6, is not affected by ageing (118). Insulin-like 
growth factor-I (IGF-I) is produced predominantly in the liver and in tissues such 
as bone under the direct influence of GH and serum IGF-I levels also fall with 
increasing age (119).  
The GH/IGF-I axis has been implicated in sarcopaenia following a number of 
studies which have shown a correlation between IGF-I levels and sarcopaenia 
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(42) and GH treatment has been associated with an increase in lean body and 
muscle mass (120-123).  Over expression of IGF-I exclusively in skeletal muscle 
prevents age-related decline in number of dihydropyridine receptor which are 
essential in the basic mechanism for excitation-contraction uncoupling (124) of 
muscle contraction.  However, despite this promising data, the use of GH for 
treatment of sarcopaenia or the GH decrease in ageing (somatopause) is not 
recommended due to a significant incidence of adverse events (125).  
 
1.3.6.2. Glucocorticoids and Ageing 
There are contradictory data regarding the changes in plasma cortisol which 
occur with ageing, with a number of groups reporting there are no changes (126) 
while others reporting that plasma cortisol levels increase with ageing and in a 
sex specific manner (127). Van Cauter et al. have reported that there are a 
number of changes in cortisol which occur with increasing age including an 
increase in mean plasma cortisol levels between 20-50% between 20-80 years, 
an increase in the nocturnal nadir of cortisol and age related dampening of diurnal 
rhythm with an advancement of the timing of the circadian elevation (127). They 
hypothesise that these changes could be due to excess exposure of the 
hippocampal neurons to glucocorticoids with subsequent neuronal degeneration 
and as the hippocampal neurons normally inhibit ACTH release when these 
degenerate there is unchecked ACTH secretion (128).  
There are a number of ultrastructural changes seen in the muscles of people with 
myopathy complicating glucocorticoid excess (Cushing’s syndrome) (129) (which 
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will be reviewed in Section 1.5) which are similar to changes seen in sarcopaenic 
muscles including pronounced mitochondrial damage, with thickening and deep 
invaginations of the sarcolemmal basement membrane and thickening of the 
basement membrane of capillaries.  Muscle fibres in GC mediated myopathy also 
show marked disarray and wide interfibrillar spaces containing large vacuoles 
which represented degenerated mitochondria (129). 
 
1.4 Overview of corticosteroids 
Adrenal corticosteroids are essential for life and can be divided into three main 
types: glucocorticoids (synthesised in the zona fasciculata), mineralocorticoids 
(synthesised in the zona glomerulosa) and sex steroids (synthesised in the zona 
reticularis) (130).   
Cortisol (the main active glucocorticoid in humans) is secreted by the zona 
fasciculata of the adrenal cortex under the tight control of the hypothalamic-
pituitary-adrenal axis. Corticotrophin releasing hormone (CRH) is synthesized and 
secreted from the hypothalamus, which leads to ACTH (corticotrophin) synthesis 
and secretion from the pituitary gland, which acts on the zona fasciculata of the 
adrenal cortex.  Classical endocrine feedback loops are in place to control the 
secretion of GC through a tightly regulated mechanism in the hypothalamus and 
pituitary gland (130). (Figure 1.3) 
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Figure 1.3.  Schema representing the hypothalamic pituitary adrenal axis.  GR = 
glucocorticoid receptor, CRH = corticotrophin releasing hormone, ACTH = 
adrenocorticotrophic hormone.  Bound ‘inactive’ cortisol is bound to cortisol 
binding globulin and albumin.   
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1.4.1. The glucocorticoid receptor 
The glucocorticoid receptor (GR) is a member of the thyroid/ steroid hormone 
receptor superfamily of transcription factors comprising a C-terminal ligand 
binding domain, a central DNA binding domain which interacts with specific DNA 
sequences on target genes and N-terminal hypervariable region (130).  The 
effects of glucocorticoids are mediated by the GC receptor (GR) which is a ligand 
regulated nuclear receptor that in the absence of its GC ligand remains bound to 
other proteins within the cytoplasm such as the 90 kDA and 70 kDA heat shock 
proteins (HSP90, HSP70) (130).  GC binding to the GR leads to dissociation of 
the HSPs and translocation of the GR-ligand complex into the cell nucleus. 
GR 
?????
????????????????????
??????????
?????????
???????? ?????? ????????????????
??????????????????
?????????
Nucleus 
Cytoplasm 
Pre-Receptor 
Regulation 
Chapter 1  Introduction 
 21 
Following translocation to the nucleus, gene transcription is altered following 
binding of the dimerised GR/ ligand complex to the specific DNA sequences 
known as glucocorticoid response elements (GREs) in the promoter region of the 
target gene (131); there are several hundred GC responsive genes (130).  The 
GRβ gene may act as a dominant negative regulator of GRα transactivation and 
the GRγ variant has an additional AA within the DNA binding domain of the 
receptor protein that may reduce GR transactivation (130, 132).  In addition to the 
GR numerous other factors such as co-activators and co-repressors that may 
confer tissue specificity in responses are required (130, 133). 
The GR is vital in mediating muscle atrophy but a reduction in proteolysis with 
chronic exposure to GCs may be attributable to the GC induced down regulation 
of the GR.  GCs down regulate the GR in most (134-138) but not all (139) target 
cells, through the induction of calpains (140) and inhibiting calpains prevents the 
GC induced GR down regulation  (140). A reduction in GR may have important 
implications for GC myopathy since inhibiting the GR with the antagonist 
RU38486 (141) or attenuation of GR activation via shRNA (142) prevents 
upregulation of myostatin (141) and MAFbx and MURF-1 (142) by 
dexamethasone.  This is also supported by Waddell et al. (143) where transgenic 
mice expressing a dimerisation deficient GR prevented dexamethasone induced 
MURF-1 expression. 
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1.4.2. Adrenal Steroidogenesis 
Cholesterol is the precursor molecule for all adrenal steroidogenesis, it is 
principally derived from low density lipoprotein cholesterol (LDL) which attaches 
to specific LDL surface receptors on adrenal cells (144).  The resultant vesicles 
fuse with lysozymes and free cholesterol is produced following hydrolysis. 
Glucocorticoids are secreted in relatively large amounts (between 5.3 and 
9.9mg/m2/day) (145, 146) from the zona fasciculata through expression of 
steroidogenic enzymes in a specific zonal manner (Figure 1.4).  
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Figure 1.4. The zonal distribution of corticosteroid synthesis. StAR = 
steroidogenic acute regulatory protein, 3 β-HSD = 3 beta hydroxysteroid 
dehydrogenase , DHEA = Dehydroepiandrosterone, DHEAS = 
Dehydroepiandrosterone sulphate. 
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1.4.3. Effects of glucocorticoids 
Glucocorticoids affect every organ system with the main physiological and 
pathophysiological effects being on energy metabolism, the cardiovascular/ blood 
pressure system, bone, connective tissue (including muscle), the immune system, 
the central nervous system, the gastrointestinal and the endocrine system (130) 
(Table 1.3).  
 
Table 1.3. Summary of the physiological and pathophysiological effects of GC on 
fuel metabolism, bone, vascular system and the immune system. (PTH = 
parathyroid hormone, GFR = glomerular filtration rate, MR = mineralocorticoid 
receptor, NO = nitric oxide, TG = triglycerides, Ig = immunoglobulin’s, chol = 
cholesterol).  
 
GC also have profound effects on the central nervous system, as the GR is 
abundant in a number of key cortical areas such as the hippocampus, 
hypothalamus, cerebellum and cortex (147).  GC are associated with neuronal 
METABOLISM BONE VASCULAR/  BLOOD PRESSURE IMMUNE 
?  Serum Glucose 
?  Liver Glycogen 
?  Glycogen synthase 
?  Gluconeogenesis 
?  Circulating chol 
?  Circulating TG 
? Glycogen 
phosphorylase 
?  Renal excretion of Ca++ 
?  PTH  
?  Osteoblast activity 
?  Ca++ absorption 
? Sensitivity to pressor 
agents 
?  GFR 
?  Angiotensinogen 
?  Proximal Na+ 
epithelium transport 
?  Free water clearance 
?  MR activity 
? NO mediated 
vasodilatation 
?  Apoptosis 
?  Circulating 
lymphocytes 
?  Ig synthesis 
?  Cytokine production 
?  Monocyte 
differentiation 
?  Phagocytosis 
?  Cytotoxic activity 
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death in the hippocampus which has recently lead to interest in the area of 
glucocorticoid exposure and memory (130).  There are several effects of GC 
excess on the endocrine system including a suppression in the hypothalamic-
pituitary-thyroid and gonadal axis as well as suppressing the GH/ IGF-I axis 
(130).   
 
1.4.4. Cortisol Binding globulin 
Over 90% of circulating cortisol is bound, predominantly to the α2-globulin, 
cortisol binding globulin (CBG) (148), with 9% bound to  albumin.  CBG is a 383 
AA protein synthesised in the liver, which binds cortisol with high affinity.  Levels 
of CBG are approximately 700nmol/l and levels are increased by oestrogens and 
in patients with chronic liver disease, renal disease and hyperthyroidism (148).  
 
1.4.5. Corticosteroid hormone metabolism 
The metabolism of cortisol has been extensively reviewed by Tomlinson et al. (2), 
below I will briefly summarise the pathways involved (Figure 1.5).  The major 
route comprises the interconversion of cortisol (Kendall’s compound F) to 
cortisone (Kendall’s compound E) through the activity of 11 β-HSD isozymes or 
reduction of the C4-5 bond by either 5α-reductase or 5β-reductase to yield 5α-
THF (allo THF) and 5β-THF respectively (2).  In normal subjects the 5β 
metabolites predominate (5β THF:5α, THF 2:1).  THF, allo THF and 
tetrahydrocortisone (THE) are rapidly conjugated with glucuronic acid and 
excreted in the urine (2).  Downstream, cleavage of the THF and THE to the C19 
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steroids 11 hydro or 11-oxo-androsterone or etiocholanolone occur (2).  
Alternatively reduction of the 20-oxo group by 20α or 20β hydroxysteroid 
dehydrogenases yield α and β cortols and cortolones, respectively, with the 
subsequent oxidation at the C21 position to form the extremely polar metabolites 
cortolic and cortolonic acids.  Hydroxylation at C6 to form 6β-hydroxycortisol is 
described as is the reduction of the C20 position which may occur without A ring 
reduction giving rise to 20α and 20β hydroxycortisol (2, 130).  Approximately 50% 
of secreted cortisol appears in the urine as THF, allo THF and THE, 25% appears 
as cortols/ cortolones, 10% as C19 steroids, 10% cortolic/ cortolonic acids and 
remaining are free unconjugated steroids (F, E, 6β and 20α/ 20β-metabolites of F 
and E) (2). 
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Figure 1.5. The major pathways involved in cortisol metabolism (E= cortisone, F= 
cortisol, Et = etiocholanolone, An = androsterone). THE = tetrahydrocortisone, 
THF = tetrahydrocortisol. 
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1.4.5.1. Urinary Gas Chromatography/ Mass spectrometry (GC/MS) 
In GC/MS, the sample is initially separated into its components by gas 
chromatography, following which the individual constituents are ionised and 
separated to their mass to charge ratio, which allows accurate identification.  
Analysis of urinary steroid metabolites by GC/MS identifies and quantifies over 55 
different metabolites or ratios of metabolites.  The technique provides an index of 
cortisol secretion and global 11 β-HSD activity (149), which is estimated from 
renal excretion of steroid metabolites.  Assessment of 11 β-HSD1 activity is made 
via the ratio of cortisol to cortisone metabolites i.e. tetrahydrocortisone (THF) + 
5αTHF: tetrahydrocortisone (THE) ratio, and 11 β-HSD2 activity is estimated by 
measuring the urinary free cortisol: urinary free cortisone ratio (Figure 1.5). 
Measures of 5α-reductase activity can be inferred from 5αTHF, 5αTHF:THE, 
androsterone, androsterone: etiocholanolone (Figure 1.5) (2). 
 
1.4.6. Tissue specific modulation of Glucocorticoid action: 11 β-
hydroxysteroid dehydrogenase (11 β-HSD) isozymes 
Within tissues, GC levels are regulated at the pre-receptor level by the isozymes 
of 11 β-hydroxysteroid dehydrogenase (11 β-HSD), which are located in the 
endoplasmic reticulum (ER). 11 β-HSD2 is predominantly found in tissues 
expressing the mineralocorticoid receptor (MR) where it acts as a 
dehydrogenase, converting the active GC cortisol (corticosterone in rodents) to 
inactive cortisone (11 dehydrocorticosterone in rodents), thus protecting the MR 
[which has equal affinity for cortisol (corticosterone) as for aldosterone] from illicit 
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occupancy by cortisol (150). 11 β-HSD1 is found in many tissues such as adipose 
tissue, liver, brain and skeletal muscle (2). 11 β-HSD1 in vivo acts predominantly 
as an oxoreductase converting inactive cortisone into active cortisol (2), Figure 
1.6.  This oxoreductase activity is determined by nicotinamide adenine 
dinucleotide phosphate (NADPH) co-factor availability produced by the ER 
specific enzyme hexose-6-phosphate dehydrogenase (H6PDH), Figure 1.6.   
 
 
Figure 1.6.  Schema representing the tissue specific regulation of glucocorticoid 
action.  (G6P = glucose-6-phosphate, 6PG = 6 phosphogluconate, NADP = , ER 
= endoplasmic reticulum, GR = glucocorticoid receptor, GRE = glucocorticoid 
response elements, G6PT = glucose-6-phosphate transporter). 
 
Expression of 11 β-HSD1 in skeletal muscle has been reported to be only ~5% 
that reported in liver (151) with conflicting evidence as to whether  11 β-HSD2 is 
present in muscle or not (151, 152). In muscle cells extracted from the vastus 
lateralis of patients with type 2 diabetes, baseline 11 β-HSD1 mRNA was 
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elevated compared with controls.  This was associated with impaired glucose 
transport in response to acute insulin and cortisone stimulation (152).  In 
myocytes, Whorwood et al. (153) demonstrated elevated 11 β-HSD1 activity with 
increasing GC concentration and 11 β-HSD1 activity decreased with insulin and 
IGF-I administration, independently.  Thus, in GC excess, the activity of 11 β-
HSD1 may play a fundamental role in the inhibition of protein synthesis and 
activation of the atrophy program within skeletal muscle.   
 
1.4.6.1. Hexose 6 Phosphate dehydrogenase (H6PDH) and muscle function 
As described in Section 1.4.6, the oxoreductase activity of 11 β-HSD1 is 
determined by nicotinamide adenine dinucleotide phosphate (NADPH) co-factor 
availability produced by the ER specific enzyme hexose-6-phosphate 
dehydrogenase (H6PDH). H6PDH is ubiquitously expressed and utilizes glucose-
6-phosphate (G6P), transported into the ER by the G6P transporter (G6PT), to 
reduce coenzyme NADP+ to NADPH for utilization within an otherwise oxidizing 
environment. In support of this role of H6PDH in determining directionality of 11 β-
HSD1, tissues from H6PDHKO mice have a ‘switch’ in 11β-HSD1 activity, due to 
the change in NADPH/NADP+ ratio, and the enzyme acts as a dehydrogenase 
rather than the native reductase, resulting in local GC inactivation (2). Transgenic 
mice lacking H6PDH have a severe myopathy with a shift in fibre Type from Type 
II to Type I (154).  This may be due to reduced active GCs, a reduction in NADPH 
or effects on ER specific metabolism (154, 155). The myopathy is associated with 
elevated glycogen storage and activation of the unfolded protein response (UPR) 
suggesting that H6PDH is important in the control of SR metabolic function (154).  
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The molecular and biochemical basis for UPR activation is unknown and an 
important aspect to consider within muscle is the activity of 11β-HSD1 in 
H6PDHKO mice, specifically the gain in dehydrogenase activity and the 
subsequent inactivation of GCs. Previous reports have documented 11β-HSD1 
expression and activity in human and rodent skeletal muscle (151, 156-158). 
However, 11β-HSD1KO mice have no reported skeletal muscle phenotype (159). 
In work performed during my thesis, within Professor Stewart and Dr Lavery’s 
group, but not directly related to the subsequent results chapters we 
hypothesised that H6PDH is important in muscle, complementary but 
independent to its role in the regulation of 11β-HSD1 and GC metabolism. To 
further explore the role of 11β-HSD1 in the pathogenesis of myopathy in 
H6PDHKO mice, the 11β-HSD1/ H6PDH double KO (DKO) mice was generated, 
in which 11β-HSD1 dehydrogenase activity is negated. We have shown that the 
DKO is a phenocopy of the major features of myopathy reported in the H6PDHKO 
at both the histological and molecular level.  Using the DKO we have provided 
clear evidence for a role of H6PDH in skeletal muscle integrity that is independent 
of 11β-HSD1 by using the DKO mice. The most striking differences were 
apparent in the TA of DKO and H6PDHKO mice, a muscle abundant in ‘fast-
twitch’ glycolytic Type IIb muscle fibres, in which atrophy and vacuolation of 
distinct fibres was severe. In contrast, no gross histological differences were seen 
in soleus with only the appearance of some atrophied fibres being present. 
Soleus is a muscle rich in ‘slow-twitch’ oxidative Type I fibres, again highlighting 
that this myopathy is Type II fibre specific.  
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1.4.6.2. 11 β-HSD1 substrate specificity, affinity and kinetics 
The main substrate for 11 β-HSD1 in humans is cortisone and in rodents 11-
dehydrocorticosterone (2).  Many mammalian steroid dehydrogenases including 
11 β-HSD1 have been implicated in the detoxification of molecules in addition to 
roles in steroid metabolism (160-162).  11 β-HSD1 also has roles in 
biotransformation of several carbonyl group compounds xenobiotics, drugs, 
insecticides, carcinogens.  Prednisolone and prednisone are also substrates for 
11 β-HSD1 (163, 164).  9a-fluorinated steroids such as dexamethasone are not 
metabolised by 11 β-HSD2 (165) but may also be regenerated by 11 β-HSD1 
(166). 
Homogenous enzyme has a rectilinear Eadie plot and Michaelis Menton (Km) 
constant of 1.83 +/- 0.06mM for corticosterone and 17.3 +/ - 2.24mM for cortisol 
(2).  First-order rate constants are one order of magnitude higher for 
corticosterone than cortisol, but maximal velocities are similar (167). There are 
species and tissue differences in Km values for 11 β-HSD1, for example, in mice 
the Km for liver is 0.7 for A and 1.7 for B (mM) (168) and 0.09mM for pancreas for 
A (169). In comparison in humans the Km in liver is 13.9 (E), 41.3 (F), 19.7 (A), 
42.8 (B) (170) and in omental preadipocytes 2.8 for F and 0.27 for E (2).   
 
1.4.6.3. Molecular Biology of 11 β-HSD1 
The gene for 11 β-HSD1 is on chromosome 1 (1q32.2-41), has 6 exons (182, 
130, 111, 185, 143 and 617bp respectively) and 5 introns (776, 767, 120, 25,300 
and 1,700 bp, respectively) (2).   
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Human 11 β-HSD1 transcription initiates 93bp upstream from the start of 
translation, yielding a 5’ untranslated region similar in length to that of the rat 11 
β-HSD1 mRNA (2).  Recent studies on the rat 11 β-HSD1 promoter showed that it 
is predominantly regulated by the C/EBP family of transcription factors, mainly 
C/EBPα. C/EBPα regulates a series of genes concerned with the metabolism of 
fuels (171).  C/EBPα is regulated by GC in a tissue specific manner (172), for 
example in liver basal C/EBPα levels are high ensuring high levels of 11 β-HSD1 
transcription and hence high intra hepatic GC levels (173).  
 
1.4.6.4. Recombinant models of 11 β-HSD1 
Tomlinson et al have extensively reviewed transgenic models of 11 β-HSD1 (2), 
which have shown that elevated 11 β-HSD1 expression and activity, either 
globally or in a tissue specific manner, is associated with the development of 
cognitive impairment (174), the metabolic syndrome (175) and insulin resistance 
(176), which is due to increased intracellular glucocorticoid action.   
Conversely, knockout animals or pharmacological inhibition of 11 β-HSD1 reveal 
improved insulin sensitivity and resistance to diet induced obesity (177).  Much 
less is known about the role of 11 β-HSD1 in skeletal muscle and the 
consequences of local production of GCs.  Transgenic mice with a null HSD11B1 
gene have previously been generated by Kotelevtsev et al. replacing the genomic 
region containing exons 3 and 4 with a neomycin-resistant cassette via 
homologous recombination in mouse 129 embryonic stem cells (159).  In 
homozygous mutant mice, hepatic 11 β-HSD1 activity was less than 5% that of 
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wild type.  When WT and KO mice were adrenalectomised and implanted with 
pellets of 11-dehydrocorticosterone (A) the WT mice converted 11-
dehydrocorticosterone (A) to corticosterone (B) whereas B levels in the KO mice 
remained undetectable.  This demonstrated that 11 β-HSD1 is the only 11 oxo-
reductase (in the mouse) able to generate active GC from inert 11 keto-steroids. 
11 β-HSD1KO mice have adrenal hyperplasia due to reduced negative feedback 
on the HPA axis causing increased ACTH-stimulated corticosterone secretion 
and zona fasciculata hypertrophy.  There was no compensatory change in 11 β-
HSD2 activity or expression in this model (159).   
A global KO a transgenic mouse over-expressing 11 β-HSD1 specifically within 
adipose tissue has also been developed (178) through fusion of the 5.4kb of the 
aP2 promoter/ enhancer, which is an adipocyte specific promoter and a 1.6kb 
fragment of rat 11 β-HSD1 cDNA followed by an SV40 consensus 
polyadenylation signal.  This led to a 7-fold increase in expression of transgene 
mRNA compared with endogenous mRNA. 11 β-HSD1 enzyme activity was 
increased almost 3 fold in adipose tissue, a level comparable to ob/ob mice or 
that seen in obese humans (179), demonstrating that the extent of transgenic 
amplification of 11 β-HSD1 activity is physiologically relevant (2).  Transgenic 
mice had similar serum concentrations as controls whereas concentrations in 
adipose tissue were elevated 30% higher compared with WT mice secondary to 
local increased activation of glucocorticoid via 11 β-HSD1 (2).   
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1.4.6.5.  Putative Role of 11β-HSD1 in ageing  
Although the effect of ageing on serum levels of cortisol is controversial there is 
evidence that 11β-HSD1 is elevated in a number of tissues.  There is also 
evidence from a recent paper by Weinstein et al., which shows an increase in 
endogenous glucocorticoid concentrations and adrenal weights with increasing 
age in C57BL/6 mice (180). In bone, 11β-HSD1 regulates the effects of 
glucocorticoids upon osteoblasts (181), Cooper et al., within our group has shown 
that enzyme activity in primary cultures of human osteoblasts increases with 
advancing age (5). Tiganescu et al., from our group, has shown that 11β-HSD1 
increases in skin with increasing age (6).  From a functional perspective, there is 
evidence that 11β-HSD1KO mice are resistant to hippocampal changes 
associated with ageing (7).  There is, however, no data to date regarding the 
effect of ageing on skeletal muscle 11β-HSD1.  
 
1.4.6.6. Growth Hormone /IGF-I system interaction with 11 β-HSD1 
GH acting via IGF-I inhibits the autocrine generation of cortisol through inhibition 
of 11β-HSD1 (182). The phenotype of GHD in the context of hypopituitarism may, 
in part be mediated through increased 11β-HSD1 activity (182) as in these GHD 
patients the THF + allo-THF/ THE ratio (indicative of increased 11β-HSD1 
activity) is increased by 50% from baseline and reduces after commencing GH 
therapy (even in elderly patients) without alteration in the UFF/UFE ratio, 
indicative of a resulting decrease in 11β-HSD1 oxoreductase activity (183, 184) 
without any change in 11β-HSD2 activity. Conversely, patients with acromegaly 
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and high IGF-I concentrations have decreased 11β-HSD1 activity; a defect that 
resolves with appropriate treatment of the GH excess (182). These studies are 
endorsed by in vivo studies, which show a decrease in hepatic 11β-HSD1 
expression in rats treated with GH (185-187).  Subsequent in vitro experiments 
have shown that GH has no direct effect on 11β-HSD1 but rather acts via IGF-I 
(i.e. IGF-I inhibits 11β-HSD1 activity) (182, 188). 
 
 
1.5 Glucocorticoid mediated myopathy 
1.5.1. Introduction 
Excess circulating cortisol can be due to either exogenous or endogenous 
sources and if chronic leads to Cushing’s syndrome (CS) (130).  Endogenous CS 
is a rare condition with an incidence of 1.5-3.9 million per year, however CS 
secondary to exogenous glucocorticoid use is far more common (between 0.5-1% 
of the western population is receiving GC therapy at any point in time) (130). 
Proximal muscle weakness is one of the key features of CS (observed in 56-90% 
of cases), along with thin skin, easy bruising and osteoporosis (130).  Harvey 
Cushing noted muscle weakness in his original patients, however, it was Muller 
and Kugelberg, who in the 1950’s first performed systematic studies of myopathy 
in CS (189).  In this study of 6 patients with CS, 5/6 presented with lower limb 
proximal muscle weakness.  On histological examination of the quadriceps 
muscle in these patients there was replacement of muscle fibres with fat and 
connective tissue and degenerated muscle fibres clustered in groups or 
individually among normal fibres.  The degenerated muscle fibres appeared 
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hyalinised with their striations indistinct, and there was no evidence of muscle 
fibre regeneration (189).   
Subsequently, several clinical studies have examined muscle function, histology 
and metabolism in patients with endogenous and exogenous glucocorticoid (GC) 
related myopathy (103, 107, 108, 190, 191).  The effects of GCs on muscle 
appear to be related to dose, duration and type of steroid (192).  Duration of 
exposure to GCs and different sensitivities of skeletal muscle fibre types also play 
an important role in the development of myopathy (193).   
 
1.5.2. Features of Glucocorticoid myopathy 
In vitro (194-199) and in vivo studies of rodent (84, 141, 143, 200-210) and 
human skeletal muscle (96, 101-108, 191) clearly demonstrate a causal 
relationship between GC and muscle atrophy.  Type II fibre atrophy is the 
classically described histological abnormality reported in GC mediated myopathy 
(104, 107, 189, 191).  In the majority of studies Type I fibres generally display 
little, if any, abnormalities despite Type I fibres containing twice as many GR 
binding sites in the cytoplasm (211) and a greater GR binding capacity than Type 
II fibres (212). There are also a number of ultrastructural changes described in 
the muscle of patients with CS including a marked disarray of muscle fibres with 
wide interfibrillar spaces containing large vacuoles representing damaged and 
degenerating mitochondria (129).  Muscle fibres also demonstrate thickening and 
deep invaginations of the sarcolemmal basement membrane and thickening of 
the basement membrane of capillaries (129).  Khaleeli et al. reported a 
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sarcolemmal accumulation of glycogen and mitochondria with small deposits of 
lipofuscin pigment (103).   
 
1.5.3. Molecular mechanisms underpinning glucocorticoid myopathy 
Many molecular pathways have been described as playing an important role in 
the development of GC mediated myopathy including abnormalities in protein 
metabolism, myostatin, atrophy related genes, collagen metabolism, 
mitochondrial function and myosin heavy chain isoform synthesis and 
degradation.  
 
1.5.3.1. Effect of Glucocorticoids on Protein metabolism 
Most studies indicate that GC excess increases the rate of whole body proteolyis, 
even during short term treatment, by inhibiting protein synthesis (213).  In patients 
with CS, plasma leucine concentration, leucine metabolic clearance rate, leucine 
transport into muscle, leucine turnover and leucine incorporation into protein are 
all significantly reduced compared to controls (214).  Leucine oxidation rates were 
similar in both groups and this along with other findings suggest that CS 
associated muscle wasting is associated with a reduction in protein synthesis 
(214).  This may in part be related to the insulin resistance, which occurs in CS 
leads to a blunted anabolic response to insulin and amino acids (213).   
Age may also have an effect on sensitivities of muscle to GC induced myopathy 
as compared with younger rats, ageing rats with GC induced muscle wasting 
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have more rapid wasting and slower recovery of muscle function following 
cessation of GC treatment (215).  The underlying pathogenesis in the older rats 
was depressed protein synthesis compared to increased protein breakdown in the 
younger rats and this was associated with the activation of the ubiquitin-
proteasome proteolytic pathways (215).  This change in protein metabolism may 
be explained by leucine resistance on muscle protein synthesis in older rats as 
the time to recovery of leucine responsiveness following dexamethasone 
withdrawal is significantly slower in older rats (216).  
 
1.5.3.2. Effect of glucocorticoids on myocyte proliferation and differentiation 
There is conflicting data with regard to the effect of GC treatment on myoblast 
proliferation rate.  Some studies have reported an increase in myoblast 
proliferation rate with GC treatment (217, 218) (particularly with low dose), others 
reporting no effect of treatment with glucocorticoids (219) and others reporting a 
dose dependent decrease in myoblast proliferation with glucocorticoid therapy 
(220).  Te Pas et al. reported that GCs are capable of attenuating proliferation 
and differentiation of myocytes in a dose response manner by altering mRNA 
levels of myoD1 and myf-5 and myogenin (220).  When C2C12 myoblasts were 
incubated with dexamethasone or α-methyl-prednisolone for 9 days, the cell 
proliferation rate was reduced in a dose dependent manner despite increasing the 
mRNA expression of MyoD1 and myf-5 (220). The differences reported in the 
above studies may be due to the use of different models, different glucocorticoid 
doses, different glucocorticoid types (e.g. dexamethasone, corticosterone and 
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alpha methylprednisolone), duration of myoblast proliferation assessed and 
method of proliferation assay used.    
 
1.5.3.3. Glucocorticoid regulation of myostatin 
As previously described in section 1.3.5.2 myostatin is a member of the tumour 
growth factor β family and is a potent inhibitor of muscle growth, regulating 
satellite cell activation, myoblast proliferation and terminal differentiation. Cell 
proliferation requires the completion of the G, M and S cell cycle phases and 
myostatin prevents myoblasts from progressing past the G0/G1 and G2 phase 
(68) through the cyclin CDK inhibitor protein 21 (CKIp21), a key component of cell 
cycle arrest during the G and M phase (69).  Thus, fewer cells accumulate in the 
S-phase and proliferation is prevented.  Myostatin also down regulates MyoD1 
expression (70) preventing myoblast differentiation into multinucleated 
myotubules (71, 72).  Disruption of the myostatin gene in mice increased muscle 
mass through muscle hypertrophy and hyperplasia (70).  In rats treated with 
dexamethasone, the resultant muscle atrophy was associated with significantly 
elevated myostatin mRNA expression and protein concentrations (141).  In 
contrast, myostatin knockout mice resisted GC induced muscle atrophy, whilst 
also showing increased muscle IGF-I and II mRNA expression (201), indicating 
that myostatin may play a key role in GC mediated myopathy. 
In rodent studies, Type IIb fibres (which are more sensitive to GC mediated 
myopathy) contain more myostatin than Type I muscle fibres (71, 221, 222), 
although this might not be the case in humans (223).  Transgenic mice over-
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expressing the myostatin gene develop severe atrophy in Type IIb fibres 
compared to Type I fibres (221) with a 20% decrease in gastrocnemius cross 
sectional area (224).  Conversely, the gain in muscle cross sectional area in the 
myostatin null mouse is predominantly due to Type IIb fibre hypertrophy.  
Myostatin null mice are 30% larger than age matched wild type litter mates (225) 
with a 50% increase in gastrocnemius cross sectional area and also increased 
size of tibialis anterior (62% increase) and soleus (41% increase). 
Inhibition of myostatin using a blocking antibody increases mouse quadriceps and 
gastrocnemius muscle mass by 30% and 23%, respectively (226).  This increase 
in muscle mass is secondary to muscle fibre hypertrophy (227), or a combination 
of hyperplasia and hypertrophy depending on the species and methodology 
employed (225, 228).  The first reported human with a mutation in the myostatin 
gene also had gross muscle hypertrophy (229).   
The human myostatin promoter region has several GRE (141) and 
glucocorticoids increase myostatin transcription in a dose dependent fashion in 
C2C12 cells (141, 230). In the short term (5 days), GCs increased myostatin 
mRNA expression and reduced MyHC Type II expression by 43% without a 
change in MyHC Type I expression (141).  In the long term (10 days), myostatin 
expression returned to control values, suggesting a possible down-regulation to 
protect from sustained muscle loss (141).  Gilson et al. (201), reported increased 
mRNA for markers of muscle atrophy such as muscle atrogin-1/ atrophy factor f-
box (MAFbx), muscle ring finger-1 (MURF-1) and cathepsin L, a lysosomal 
protease, in wild type mice after high dose dexamethasone, but these genes were 
unaltered in myostatin KO mice (201).  After 10 days of treatment with 
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dexamethasone, wild type mice developed a ~15% reduction in tibialis anterior 
and gastrocnemius cross sectional area, whereas myostatin KO mice showed no 
signs of atrophy compared with wild type littermates.  In conclusion, GC mediated 
myopathy and its prediliction for Type II fibres, may be caused, in part, by the 
upregulation of myostatin which has a negative impact on myocyte proliferation 
and differentiation. 
 
1.5.3.4. Glucocorticoid regulation of atrophy related genes 
Within each muscle cell there is a fine balance between atrophy and hypertrophy, 
which is regulated by a number of cellular pathways. The atrophy pathways 
include the lysosomal proteases (eg. Cathepsins), the calcium dependent 
protease calpain family and the ATP-dependent ubiquitin-proteasome pathway 
(231).  Blockade of any of these atrophy pathways (by IGF-I for example) reduces 
proteolysis (232-234) and attenuates the loss in muscle mass.  The pathway 
primarily associated with muscle atrophy and the breakdown of myofibrillar 
protein is the ATP-dependent ubiquitin-protease pathway (235).  GC treatment 
increases (~250%) the activity of this pathway (236, 237) with smaller changes 
(60-100%) in the maximal capacity of the lysosomal process, but no change in 
the calcium dependent proteolytic system (236, 237). 
 
1.5.3.5. Effect of Glucocorticoids on FOXO/ MURF-1/ MAFbx 
As discussed in detail in Section 1.3.5.4, proteins scheduled for degradation in 
the proteasome are labelled by conjugation with ubiquitin.  The 26s proteasome 
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enzyme complex can then recognise the ubiquitin and initiate protein degradation 
using at least three classes of proteins.  These include the E1 (ubiquitin activating 
enzymes), E2 (ubiquitin-conjugating enzymes) and E3 (Ubiquitin ligase).  Within 
skeletal muscle, MAFBX and MURF-1 are two important E3 ubiquitin ligases 
clearly associated with many models of muscle atrophy such as sepsis (79, 80) 
and disuse atrophy (81) .  These genes encode E3 ubiquitin ligase proteins that 
bind and mediate ubiquitination of specific proteins for degradation (82), such as 
myosin, actin, troponin and tropomyosin found within skeletal muscle sarcomere 
(83). 
Increased MAFbx and MURF-1 mRNA expression are both associated with 
translocation of the forkhead transcription factor (FOXO-1) into the cell nucleus 
(84).  Phosphorylation of FOXO-1 by Akt sequesters FOXO-1 from the cell 
nucleus to the cytoplasm by 14-3-3 proteins (85) preventing MAFbx and MURF-1 
upregulation.  However, GCs dephosphorylate FOXO-1 allowing subsequent 
translocation to the cell nucleus.  GCs do not activate MAFbx transcription 
directly, since MAFbx does not contain GREs (238). Instead, GCs target MAFbx 
via changes in phosphorylation status of FOXO-1 and FOXO-3, leading to 
increased MAFbx expression (84, 239). 
GCs upregulate MURF-1 expression in vivo and in vitro (84, 86, 239, 240) 
through the co-binding of the GR and FOXO-1 with the GRE and Fbox response 
element (FBE) found on MURF-1’s promoter region.  This combination results in 
a substantial synergistic upregulation of MURF-1 (143).   
When phosphorylated, FOXO-1 is also capable of disrupting mTOR signalling.  In 
vivo , mice over-expressing FOXO-1 demonstrated reduced mTOR 
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phosphorylation and protein abundance with a concomitant reduction in p70S6K 
threonine389 phosphorylation (239).  Reduced p70S6K phosphorylation was 
similarly observed in C2C12 myotubes with a corresponding reduction in [14C] 
phenylalanine incorporation into muscle protein (239).  The authors also 
demonstrated that FOXO-1 increased 4EBP1 mRNA expression, cellular 
abundance, hypophosphorylation status, and binding of 4EBP1 to eIF4E by 
interacting with the 4EBP1 DNA binding domain.  These effects were in spite of 
unchanged total or phosphorylated Akt.  Taken together, the GC induced 
increase in FOXO-1 expression inhibits protein synthesis by targeting mTOR, 
4eBP1 and p70S6K, whilst increased FOXO-1 nuclear abundance targets MAFbx 
and MURF-1 (alone or in combintion with the GR) to initiate proteolysis (239). 
In addition to the above activities the activation of FOXO-1 and FOXO-3a in 
response to GCs can also promote a shift in utilisation from carbohydrate to fat 
metabolism (241, 242), sparing glucose and its precursors (alanine, glycerol) for 
glucose dependent cells during periods of starvation, disease or exercise.  
Constantin et al. (243) showed simultaneous increases in fat metabolism and 
MAFbx and MURF-1 expression after stimulation of FOXO-1, but, crucially, there 
was no evidence of muscle protein breakdown since the 20s proteasome 
transcription was unchanged. 
 
1.5.3.6. Effect of Glucocorticoids on hypertrophy related genes 
Four major signalling pathways regulate protein synthesis and cell growth 
including the energy status of the cell (244); the amino acid sensing pathway 
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(245); mechanotransduction (246, 247) and the insulin/ IGF-I-AI3K-Akt-mTOR 
signalling system (245). 
1.5.3.6.1 Effect of Glucocorticoids on insulin/ IGF-I-AI3K-Akt-mTOR signalling 
The insulin/ IGF-I-AI3K-Akt-mTOR signalling pathway increases protein synthesis 
in the short term (minutes to hours) (240, 248) by activating translational 
machinery such as eukaryotic initiation factors (eIFs) and eukaryotic elongation 
factors (eEFs) (249).  Over the long term (hours to days), increased protein 
synthesis stems from elevated ribosome biogenesis, ribosomal cellular content 
and protein synthesis capacity (249). 
Binding of insulin to its cell surface receptor leads to a conformational change and 
tyrosine autophosphorylation. Consequently, the insulin receptor substrate (IRS) 
family of adaptor proteins are recruited to the intracellular domain of the receptor 
and are phosphorylated at multiple tyrosine residues by the receptor tyrosine 
kinase to permit the docking of phosphatidylinositol-3-kinase (PI3K) and 
subsequent generation of PI(3,4,5)P3. Generation of this second messenger acts 
to recruit the Akt/PKB family of serine/threonine kinases to the plasma membrane 
where they are then activated (250). Further downstream, activated Akt1/protein 
kinase B (PKB) phosphorylates a rab-GAP (GTPase) protein, AS160, which is a 
crucial regulator of the translocation of GLUT4 GLUT storage vesicles to the 
plasma membrane (251). It is this mechanism that permits insulin-stimulated 
glucose entry into target tissues including skeletal muscle (252). The molecular 
mechanisms underpinning insulin resistance are complex and variable. 
Serine/threonine phosphorylation of IRS1 (in particular Ser307 phosphorylation) 
has been shown to negatively regulate insulin signalling through multiple 
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mechanisms including decreased affinity for the insulin receptor and increased 
degradation (253, 254). The interaction of glucocorticoids and the insulin 
signaling cascade has only been examined in a small number of studies that have 
offered variable explanations for the induction of insulin resistance (255-258). 
Importantly, the role of serine phosphorylation and the impact of prereceptor 
glucocorticoid metabolism have not been explored. 
The insulin/ IGF-I-AI3K-Akt-mTOR signalling cascade can also inhibit several 
regulators of muscle atrophy (196). In rats, 5 days of treatment with cortisone 
increased the insulin receptor (IR) protein by 36%, but reduced skeletal muscle 
total IR tyrosine kinase phosphorylation by 69%, which was attributed to a loss in 
the pool of IR undergoing tyrosine phosphorylation. Although muscle IRS-1 
tyrosine phosphorylation was unaffected by GC treatment, GCs were associated 
with a 50% reduction in total IRS-1 protein content (255).   
GC mediated alterations in the expression and cellular abundance of the two 
PI3K regulatory subunits, p85α and p85β may also induce insulin resistance (259, 
260) and impair protein synthesis.  GCs act on p85α via the GR (261), leading to 
a 3-fold increase in p85α mRNA expression and total cellular abundance, 
whereas p85β remains unchanged.  The increased ratio of p85α:p85β can enable 
more p85α (unbound to its catalytic p110 subunit) to competitively associate with 
IRS-1, reducing p110 activity and suppressing PI3K activity by 50% (260).  Thus, 
GC myopathy may stem, in part from a GC mediated decrease in the anabolic IR-
IRS-1-PI3K-Akt signalling pathway. 
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1.5.3.7. Effect of glucocorticoids on muscle ribosome function 
The reduction in overall rates of translation initiation in GC treated muscle is 
associated with a reduction in mRNA translational rates, ribosome biogenesis and 
total cellular RNA abundance (262).  Six days of GC treatment reduced rat Type I 
and Type II muscle fibre RNA synthesis rates by ~29% and 51%, respectively, 
and resulted in a ~19% and 48% reduction in Type I and Type IIb muscle RNA, 
respectively.  The reduced muscle RNA may be due to to impaired ribosomal 
capacity (RNA:protein) for protein synthesis (262) and a reduced number of 
muscle ribosomes (263). 
 
1.5.3.8. Effect of glucocorticoids on muscle collagen 
Basement membranes form the extracellular matrix surrounding tissues and this 
matrix provides the enclosed cells with information, acts as a scaffold and 
maintains cellular integrity through mechanical strength and stress tolerance 
(264).  The extracellular matrix is composed of a number of proteins such as 
laminin, glycoproteins, proteoglycans and collagen (in particular Type IV).  Slow 
twitch muscle fibres contain approximately 50% more collagen than fast twitch 
muscle fibres (265) and GC treatment has been shown to reduce rat Type IV 
collagen expression in slow twitch soleus, and fast twitch muscles of the extensor 
digitorum longus (EDL) and tibialis anterior (TA).  However, the overall amount of 
Type IV collagen remained unchanged suggesting either a reduced turnover of 
Type IV collagen with GC treatment or that the duration of treatment (10 days) 
was insufficient (266).  Another study also showed a GC induced reduction in 
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Type I, II and IV collagen mRNA that was similar between slow and fast twitch rat 
muscle fibres (266). 
 
1.5.3.9. Effect of glucocorticoids on muscle mitochondria 
Mitochondrial function is also altered by GC therapy.  In a micro-array study of 
501 human mitochondrial related genes, a number of genes were altered by GC 
treatment, the most significantly upregulated being monoamine oxidase A (MAO-
A) (267).  MAO-A’s main function is to metabolise cathecholamines and dietary 
amines, and this up regulation in GC treated cells leads to an increase in MAO-A 
mediated hydrogen peroxide production which in turn may lead to muscle cell 
damage (267). 
 
1.5.3.10. Effect of glucocorticoids myosin heavy Chains (MyHCs) 
Myosin is a key structural protein in skeletal muscle that is essential for 
contraction and force generation.  Each myosin protein contains 2 myosin heavy 
chains (MyHC) and 2 myosin light chains (MyLC), the type of MyHC expressed is 
closely associated with the contractile and metabolic characteristics of a particular 
muscle fibre (268). The human soleus is a Type I, slow oxidative muscle fibre and 
expresses 99% Type I MyHC, whereas the gastrocnemius contains a mixture of 
Type I and IIa isoforms.  The quadriceps has a mixture of all 3 fibre Types (95). 
GCs have been shown to have a potent effect on MyHC levels.  Rats treated with 
GC displayed increased degradation of muscle contractile proteins and a 
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decrease in MyHCIIb isoforms and MyHC Type IIa, IIb and IId synthesis rates 
(269).  The resistance of Type I compared to Type II muscle fibres to GC may be 
attributable to the different MyHC isoforms present in each muscle fibre. Seene et 
al. assessed the effect of dexamethasone treatment on rodent MyHC content and 
synthesis rates (269). Dexamethasone treatment had no effect on MyHC Type I 
isoform synthesis rates in the soleus and plantaris muscles whereas significant 
reductions in plantaris MyHC Type IIa, Type IId and Type IIb synthesis rates were 
observed.  In the EDL muscle, MyHC IIa, IIb synthesis rates were also reduced, 
but there was no effect of GC on MyHC IId (269). 
 
Figure 1.7. Schema summarising the effect of GCs on regulators of muscle 
atrophy and hypertrophy. 
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1.5.3.11. Role of glutamine synthase in resistance of Type I fibres to 
glucocorticoids 
The precise mechanisms underpinning the increased sensitivity of fast twitch 
fibres to GC mediated myopathy compared with slow twitch fibres is yet to be fully 
elucidated.  However, the fibre type differences in glutamine synthetase 
concentrations, an enzyme which catalyses the formation of amino acid 
glutamine, may partially be responsible.  Glutamine synthetase is targeted by the 
GR (270) and regulates the export of glutamine from muscle.  During GC 
mediated atrophy, glutamine efflux accounts for between 25-30% of the total 
protein exported from muscle (271).  Basal glutamine synthetase activity and 
expression is lowest in GC resistant rat soleus, intermediate in fast twitch red 
quadriceps and highest in fast twitch white quadriceps (272).  GC treatment 
increased glutamine synthetase activity and mRNA by 2-4 fold in all muscles; 
however, the low levels present in the soleus muscle were not related to atrophy 
(272). Taken together, the fibre type differences in basal glutamine activity and 
expression are consistent with the sensitivity of fibres to GCs. 
 
1.5.3.12. Potential treatments of glucocorticoid mediated myopathy 
Normalisation of GC concentrations in patients treated for CS with pituitary 
surgery (which normalised of GC concentrations), lead to an increase in overall 
muscle and Type II mean fibre area (103).  The findings suggest that the increase 
in muscle mass which may follow cure of CS is due to an increase in individual 
cell size (103).   
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1.5.3.12.1 GH/IGF-I in the treatment of GC mediated myopathy 
Chronic GC excess is associated with a number of changes to growth hormone 
(GH) secretion.  These include a decrease in mean 24hr serum GH 
concentration, peak GH heights and peak GH areas, but normal GH pulse 
frequency (273).  Despite this, patients with CS often have a normal IGF-I 
concentration (which may be explained by changes to other sex steroids or 
increased tissue sensitivity to GH or by a decrease in GH binding protein) (274).  
When administered during a short time period, the deleterious effects of 
pharmacological doses of GC on protein metabolism can be prevented with the 
concomitant administration of GH in normal volunteers (assessed by nitrogen 
balance and isotope dilution techniques) (275).  IGF-I gene transfer into GC 
treated rats also prevented GC induced muscle atrophy (276).  IGF-I has been 
shown to inhibit many proteolytic pathways including lysosomal, protease 
dependent and calpain dependent proteolysis (277) and regulate the ubiquitin 
system (278). 
 
1.5.3.12.2 Exercise in the treatment of GC mediated myopathy 
Endurance training is not typically associated with skeletal muscle hypertrophy, 
but aerobic training can reduce GC induced muscle atrophy in rodents (212, 272, 
279-284), but human data is lacking.  Endurance training (running 28.7m/minute 
for 90 minutes/ day for 11 consecutive days) in GC treated rats decreased 
atrophy by 60% (plantaris) and 25% (gastrocnemius), compared to a control 
group treated with GC but no exercise.  Using the same exercise protocol Falduto 
et al., (280) showed that the endurance training treatment with GC prevented 
Chapter 1  Introduction 
 52 
100% and 50% of the atrophy in the deep and superficial regions, respectively, of 
Type IIa muscle fibres and a 67% and 40% reduction in atrophy of Type IIb deep 
and superficial regions, respectively.   
These findings may be explained by the protective effect of exercise on MyHCs.  
Rats treated with GC who underwent endurance training had a GC induced 
decrease in MyHC synthesis rates but endurance training did reduce the rate of 
MyHC breakdown to ~80% of those receiving GCs (285). 
A further explanation might involve reduction in glutamine synthetase in skeletal 
muscle.  When rats completed a 12 to 16 week endurance training program, 
glutamine synthetase expression was reduced to 60% of the sedentary control 
values with similar findings observed in GC treated, endurance trained rats (286).  
Moreover, endurance training reduced glutamine synthetase activity and 
expression in rat fast twitch red fibres to between 35-70% of sedentary control 
values (287) . Endurance training also reduced glutamine synthetase activity in 
soleus, but did not alter basal or GC mediated expression in fast twitch white 
muscle fibres. 
Resistance training has also been shown to increase muscle mass and strength 
in patients receiving GC treatment after heart transplantation.  Following 
transplantation, 6 months of resistance exercise increased fat free mass by 3.9% 
above pre-transplant levels.  Knee extension, chest press and lumbar extension 
strength improved between 4-6 fold after resistance training compared with 
controls (288).  In a more recent study, transplant recipients presenting with GC 
mediated myopathy underwent 6 months of resistance training following 
transplantation (289). Type I MyHC increased 73% in the training group 
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compared with a 28% reduction in the control group.  A 17% increase in MyHC IIb 
and 33% decrease was observed in the training and control groups.  Taken 
together, these studies demonstrate an inhibitory effect of endurance and 
resistance exercise on GC mediated atrophy, although the underlying molecular 
mechanisms remain unclear. 
 
1.6 Conclusions 
As the population ages, conditions such as sarcopaenia are becoming more 
prevalent.  Sarcopaenia has many similarities with GC mediated myopathy and 
there is evidence from other tissue that glucocorticoids exposure may increase 
with age as a result of upregulation of 11 β-HSD1.  GCs impact on atrophy and 
hypertrophy pathways within muscle. Type I fibres are more resistant to the 
effects of GC compared to Type II fibres, yet the mechanisms underpinning the 
disparity are not fully understood. Our knowledge of the role of 11 β-HSD1 in 
skeletal muscle is starting to emerge, but further research is required in this area.  
Pharmacological inhibition of 11 β-HSD1 may possibly provide a therapeutic 
target to reduce muscle atrophy in ageing and those with GC excess. 
Chapter 1  Introduction 
 54 
1.7 Hypothesis 
a. 11β-HSD1 is abundant and biologically important in skeletal muscle. 
b. 11β-HSD1 activity and expression is increased with glucocorticoid treatment, 
therefore leading to higher tissue glucocorticoid levels. 11β-HSD1 may be a key 
regulator of glucocorticoid mediated myopathy. 
c. 11β-HSD1 increases in muscle with age and may be associated with muscle 
atrophy.   
d. In patients with hypopituitarism and cortisol deficiency, hydrocortisone 
replacement therapy may increase tissue glucococorticoid exposure, which may 
explain some of the adverse phenotype in these patients.  
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1.8 Aims 
a. Characterise the expression and activity of 11β-HSD1 in skeletal muscle. 
 
b. Determine the role of 11β-HSD1 in glucocorticoid-mediated myopathy. 
 
c. Determine the role of ageing on 11β-HSD1 expression and activity in skeletal 
muscle and the impact of changes in 11β-HSD1 during ageing. 
 
d. Determine the effect of exogenous glucocorticoid replacement therapy on 11β-
HSD1 in patients with hypopituitarism. 
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Chapter 2 
Materials and Methods 
The procedures described in this chapter were commonly used in this 
thesis. Methods specific to individual chapters are found in the methods 
section of those particular chapters. Unless otherwise stated, all reagents 
were purchased from Sigma Aldrich, Dorset, UK. 
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2.1 C2C12 cell culture  
The C2C12 cell line is a well-established model of both skeletal muscle 
proliferation and differentiation. The C2C12 cell line was originally generated by 
serial passage of myoblasts cultured from the thigh muscles of C2H mice 70 
hours following a crush injury (290).  A subclone of these myoblasts was selected 
for its ability to differentiate rapidly and express characteristic muscle proteins 
(291).  The C2C12 cell line has been widely used in research with regard to 
muscle atrophy and glucocorticoid induced myopathy (84, 86, 195, 197).   
 
2.2 Proliferation and Differentiation 
 2.2.1 Proliferation 
Cryofrozen C2C12 myoblasts (passage 17) were purchased from ECACC 
(Salisbury, UK), and maintained in 75cm3 TC flasks (Corning, Surrey, UK) in 
15mL of DMEM with high glucose and L-glutamine (PAA, Somerset, UK) 
supplemented with 10% FCS, in incubators at 37°C under a 5% CO2 atmosphere. 
At 60-70% confluence cells were trypsinised and re-seeded into fresh flasks. Prior 
to experiments being performed, cells were trypsinised and subcultured into 24 
well TC plates (Corning, Surrey, UK) and cultured until 60-70% confluent. 
Proliferation media was replaced every 48 hours.  Cells were not proliferated 
beyond passage 25 in order to ensure they retained adequate myoblast/ 
myotubule characteristics. 
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 2.2.2 Differentiation 
Once myoblasts had reached 60-70% confluence, differentiation was initiated by 
replacing proliferation media with DMEM with high glucose and L-glutamine 
(PAA, Somerset, UK) supplemented with 5% horse serum. Differentiation media 
was replaced every 48 hours. After 8 days, myoblasts had fused to form 
multinucleated myotubes (Figure 2.1). 
 
 
Figure 2.1. C2C12 myoblast cells were differentiated in chemically defined media 
for 8 days forming multinucleated myotubes. 
 
 2.2.3. Freezing down cells 
Cells to be frozen were grown in 25cm2 flasks until 70% confluent at which point 
cells were trypsinised and resuspended in 10mls of proliferation media before 
being centrifuged at 1000g for 10 minutes.  Media was aspirated to leave the 
remaining pellet which was resuspended in 3mls of foetal calf serum (FCS) 
supplemented with 10% DMSO.  The cell mixture was then aliquoted into 1.5ml 
cryovials.  Cryovials were frozen at 1oC per minute in a Cryo freezing container 
(Nalgene, Hereford, UK) containing isopropanol.  They were kept at -80oC 
Chapter 2  Materials and Methods 
 59 
overnight following which the cells were transferred to a liquid nitrogen storage 
container for long-term storage. 
 
2.3. RNA extraction 
 2.3.1. Principle 
Total RNA was extracted from monolayer cells using TRIreagent (Sigma-Aldrich, 
Dorset, UK).  The procedure was carried out according to protocol provided with 
the reagent (Sigma-Aldrich, Dorset, UK).   
RNA was extracted from cultured cell monolayers or tissue explants using a 
single step procedure developed by Chomczynski (292). This was achieved by 
homogenizing tissue or lysis of cultured cells in TRI reagent. This solution 
contains phenol and guanidine thiocyanate and immediately and effectively 
inhibits RNase activity.  The addition of chloroform, followed by centrifugation 
results in the formation of three phases. RNA is present exclusively in the 
aqueous phase following centrifugation at 10,000G for 15 minutes, and is 
subsequently precipitated with isopropanol. 
 
 2.3.2. Methods 
Monolayer cells were washed on ice with PBS.  1.0ml of TRIreagent (Sigma-
Aldrich, Dorset, UK) was added per well and cells were incubated at room 
temperature for 5 minutes and then the cell lysates were transferred into 
eppendorfs.  For tissue explants approximately 20mg of tissue was homogenized 
in 1.0mL of TRIreagent, then incubated at room temperature for 5 min.  200ml of 
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chloroform was added to the eppendorf for every 1ml of TRIreagent initially 
added, and the tubes were shaken for 30 seconds at room temperature, following 
which they were allowed to stand at room temperature for 15 minutes.  The 
eppendorf was then transferred to a refrigerated centrifuge and centrifuged at 
10,000g for 15 minutes at 4oC.  After this there were 3 layers an upper aqueous, 
middle protein layer and lower organic layer containing DNA.  The upper aqueous 
phase containing RNA was then transferred to a fresh eppendorf and 0.5mls of 
isopropanol was then added.  Tubes were mixed by inverting and placed at -20oC 
overnight, following which they were centrifuged at 10,000g at 4oC for 15 minutes. 
This resulted in a visible pellet and the supernatant was carefully removed.  The 
pellet was then washed with 75% ethanol, following which the eppendorf was 
vortexed and subsequently centrifuged at 5000g for 10 minutes at 4oC.  Again a 
pellet was found at the bottom of the eppendorf and the ethanol supernatant was 
removed by aspiration.  The RNA pellet was allowed to air dry for 5 minutes and 
then re-suspended in 50ml of RNAase/ Nuclease free H20 and put on a heating 
block at 55oC to aid dissolving of the pellet.  Finally, the RNA was stored in a -
80oC freezer until further use.   
 
 2.3.3. RNA quality and quantification 
The quality of the RNA was assessed by gel electrophoresis on a 1% agarose gel 
with 0.15µg/ml ethidium bromide.  The gel was visualised under a UV light in a 
G:Box gel documentation system (Syngene, Cambridge, UK).  The RNA 
separates down the gel according to its molecular mass and the resultant bands 
werw visualized under UV light.  Intact RNA shows two sharp bands 
corresponding to the highly abundant 28S and 18S rRNA. 
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The quantity of RNA was measured using NanoDrop ND-1000 UV-Vis 
Spectrophotometer (Thermofisher, Surrey, UK). The absorbance of 2μl of RNA at 
260nm and 280nm was determined where 1 OD260 = 40μg/mL of RNA and the 
OD260/OD280 ratio indicates the RNA purity. Only OD260/OD280 ratios in the range 
of 1.8-2 were used. All measurements were made with respect to a blank 
consisting of the nuclease free water in which the RNA was suspended. 
 
2.4. Reverse transcription and polymerase chain reaction of RNA 
 2.4.1. Principles 
Reverse transcription polymerase chain reaction (RT-PCR) is the process of 
converting single strand mRNA into complimentary DNA (cDNA) using RNA-
dependent DNA polymerase.  Initially the extracted RNA is heated to allow 
annealing of random hexamers to the RNA template.  
The reverse transcription process is initiated by increasing the temperature 
further allowing the RNA-bound primers to be extended generating a 
complementary DNA copy of the RNA template. Lastly, the reaction is heated to a 
high temperature to inactivate the enzyme and terminate the reaction. 
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 2.4.2. Method 
All RT reactions were carried out using Applied Biosystems High-Capacity 
Reverse Transcription Kit (Applied Biosystems, Warrington, UK). The reagents 
listed in Table 2.1 were combined in an eppendorf tube to generate a 2x RT 
master mix. 
 
 
 
 
 
 
Table 2.1. Constituents of reverse transcriptase reactions  
1μg of RNA was diluted with nuclease free water to a volume of 10μl before 10μl 
of 2x RT master mix was added giving a final volume of 20μl. Samples were 
loaded onto a thermal cycler (Applied Biosystems, Warrington, UK) and incubated 
at 25°C for 10 minutes followed by 48°C for 30 minutes and finally 95°C for 5 
minutes to terminate the reaction. 
 
 
 
Component Volume (μl) per sample 
10X RT Buffer 2 
25X dNTP mix (100mM) 0.8 
10X Random Hexomers 2 
MultiScribe Reverse 
Transcriptase 
1 
RNase inhibitor 1 
Nuclease-free H2O 3.2 
TOTAL VOLUME 10 
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2.5. Conventional PCR  
 2.5.1. Principles 
Regions of DNA or cDNA can be amplified using oligonucleotide primers that are 
complimentary to the 3’ and 5’ ends of a region of interest DNA or cDNA 
fragments by PCR.  High temperature is used to denature double stranded DNA 
which is then cooled to allow the oligonucleotides primers to anneal. When the 
temperature is increased to the optimal catalytic temperature for taq polymerase, 
these oligonucleotides are extended to generate complementary DNA strands. 
Taq DNA polymerase is then used to extend the oligonucleotide and produce a 
complementary strand.  Both strands act as templates for subsequent cycles.  
Therefore the amount of product increases exponentially until production plateaus 
due to limiting nucleotides and Taq concentrations.  Conventional PCR, was used 
to check the integrity of cDNA prior to RT-PCR and to assess presence of a gene 
sequence in cDNA. 
 
 2.5.2. PCR Methods 
All conventional PCR reactions were carried out using Promega reagents 
(Promega, Southampton, UK).  In a 20ml reaction the following components were 
added: reaction buffer (final conc 1x), MgCl2 (1-2.5nM), deoxy-NTPs (0.5mM), 
Taq polymerase (0.05U/mL), forward and reverse primers (0.6mM) and 100mg 
cDNA taken from RT-PCR reaction).  In a thermal cycler, samples were incubated 
at 95°C for 5 minutes and then cycled 30 times at 95°C for 30 seconds, 60°C, 
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30°C and 72°C for 1 minute.  Samples were then incubated for 7 minutes at 72°C.  
Samples were then stored in a -80°C freezer. 
 
2.6. Relative quantitative (Real Time) PCR reaction 
 2.6.1. Principles 
Real-time PCR or relative quantitative PCR is a technique used to monitor the 
progress of a PCR reaction in real-time.  Taqman Real-Time PCR technology 
uses fluorogenic probe to allow detection of a specific PCR product as it 
accumulates during the PCR reaction.  An oligonucleotide probe is synthesized 
containing a fluorescent reported dye on its 5’ end and a quencher dye on its 3’ 
end.  The proximity of the quencher dye reduces the fluorescence emitted by the 
reporter dye by fluorescence resonance energy transfer (FRET).  The probe 
anneals downstream from one of the primer sites and during the primer extension 
is cleaved by the 5’ nuclease activity of Taq polymerase.  The removal of the 
probe allows primer extension to continue and does not inhibit the PCR process. 
The cleavage of the probe separates the reporter and the quencher dye, 
increasing the reporter dye signal (Figure 2.2).  During each cycle additional 
reporter dye molecules are cleaved, resulting in an increase in fluorescence 
intensity proportional to the amount of PCR product produced.  
Real time PCR allows collection of data through the PCR process and thus 
allowing detection during the amplification cycling.  The method insures one can 
measure when the target is first detected rather than the amount of target 
produced after a fixed number of cycles.  The value at which the product is 
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detected is the Ct value.  The higher the target copy number in a sample the 
lower the cycle number where the fluorescence is first observed (lower Ct value).  
This technique was used for relative quantification, whereby the Ct value for the 
target gene is compared to the Ct value of a housekeeping gene, with a constant 
expression level (such as 18s or GAPDH).  This comparison (Ct of the gene of 
interest – Ct of the house keeping gene) allows calculation of the changes in 
expression due to treatment relative to the housekeeping gene, this is known as 
the delta Ct (ΔCt). For ease of data interpretation and graphical representation 
the ΔCt was converted to arbitrary units (AU = 1000x2-ΔCt) (Figure 2.3). 
 
 
 
 
 
 
 
Figure 2.2. Schematic representation of real-time PCR. Separation of reporter 
dye from the quencher allows detection of fluorescence. Fluorescence is 
proportional to the amount of PCR product produced (FP = forward primer, RP = 
reverse primer, R = reporter and Q = Quencher).  
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Figure 2.3. Representative real time PCR graph showing differences in 
expression between target and housekeeping genes. 
 
 2.6.2. Real-Time PCR Method 
Unless otherwise stated, quantitative PCR was carried out using Applied 
Biosystems Reagents and gene expression assays (AssayonDemand) (Applied 
Biosystems, Warrington, UK).  PCRs for genes of interest and for 18s/ GAPDH 
housekeeping genes were carried out in singleplex.  For the 18s house keeping 
gene, the following components were combined per well: 10μl of 2x MasterMix, 
18s forward and reverse primers and vic labelled probe (final concentration 25nM 
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each), 100ng of cDNA and nuclease free water to a final volume of 20μl. For the 
gene of interest, the following components were combined per well: 10μl of 2x 
MasterMix, 1μl of 20x expression assay, 100ng of cDNA and nuclease free water 
to a total volume of 20μl. Plates were sealed with clear adhesive film (Applied 
Biosystems, Warrington, UK) and run on a 7500 real-time PCR system (Applied 
Biosystems, Warrington, UK).  Target gene expression was normalised against 
the 18s RNA house keeping gene Ct value and these measurements were 
carried out in separate wells from target gene expression measurements 
(singleplex).  All reactions were carried out in duplicate in 96-well plates (Applied 
Biosystems, Warrington, UK).  Data were expressed as Ct values (Ct=cycle 
number at which logarithmic PCR plots cross a calculated threshold line).  And 
used to determine ΔCt values (ΔCt = (Ct of the target gene) – (Ct of the 
housekeeping gene), lower ΔCt values reflecting higher mRNA expression.  Data 
are expressed as arbitrary units using the following transformation [expression in 
arbitrary units = 1000*(2-ΔCt)] or fold changes were calculated using the 
transformation [fold increase = 2-difference in ΔCt]. 
 
2.7. Protein Extraction on monolayer cells 
 2.7.1. Principles 
Monolayer cells were lysed in Radio-Immunoprecipitation (RIPA) buffer 
containing detergent which enables efficient cell lysis and protein solubilisation 
while avoiding protein degradation and interference with protein immunoreactivity 
and biological activity.  The lysate was freeze thawed to further break open cell 
membranes and the insoluble components removed by centrifugation. 
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 2.7.2. Methods 
Monolayer cells were washed on ice with cold phosphate buffered saline (PBS).  
For cells grown in 24-well plates 70μl of RIPA buffer was added to each well.  The 
constituents of RIPA buffer included (1mM EDTA, 150mM NaCl, 0.25% SDS, 1% 
NP40, 50mM Tris pH 7.4, supplemented with protease inhibitor cocktail (Roche, 
Sussex, UK) and phosphatase inhibitor (Thermofisher, Surrey, UK)).  After the 
addition of RIPA buffer the cells were scraped using a 1mL syringe plunger. The 
resultant cell lysate was transferred into an eppendorf and incubated at -80oC for 
20 minutes and thawed on ice.  The lysate was then centrifuged at 14000g for 15 
minutes at 4°C to spin down the insoluble cellular components.  The supernatant, 
containing soluble proteins was measured and samples were stored at -80oC.  
 
 2.7.3. Protein extraction from mouse tissue explants 
Mouse tissue was quickly harvested and snap frozen using liquid nitrogen. 
Samples were then transferred to a -80°C freezer until required. Proteins were 
extracted by homogenising approximately 20mg of tissue in 1.5mL of RIPA buffer 
using a mechanical homogeniser. Cell lysates were then incubated at -80°C for 
20 mins, thawed out on ice, then centrifuged at 14,000 g for 15 mins at 4°C. The 
supernatants containing soluble proteins was transferred to fresh eppendorfs 
tubes and stored at -80°C prior to assessment of protein concentrations (see 
below). 
 
 
Chapter 2  Materials and Methods 
 69 
 2.7.4. Measuring protein concentration 
  2.7.4.1. Principles of measuring protein concentration 
Total soluble protein concentrations of cell extracts and tissue explants were 
measured using BioRad RC DC protein assay (BioRad, Herts, UK).  This is a 
colourmetric assay for protein concentration following detergent solubilisation, the 
RC means the assay is reducing agent compatible and the DC means it is 
detergent compatible.  The assay is based on the Lowry method, that is the 
reaction of protein with an alkaline copper tartrate solution and then reduction of 
Folin reagent.  Folin reagent is reduced by the loss of 1,2 or 3 oxygen atoms, 
primarily due to amino acids tyrosine, tryptophan and to a lesser extent, cystine, 
cysteine and histidine.   
The protein to be quantified initially reacts with the copper in an alkaline copper 
tartrate solution. Folin then reacts with the copper treated protein subsequently 
leading to the generation of various reduced folin species all of which have a 
characteristic blue colour and absorb maximally at 750nM and minimally at 
405nM. 
 
  2.7.4.2. Methods of protein measurement 
Protein assays were carried out according to the protocol provided by 
manufacturer (BioRad, Herts, UK) in a 96 well plate.  5µl of protein sample or 
standard were added per well in duplicate.  The range of standards were 0, 0.25, 
0.5, 1, 2, 4, 8 and 10mg/ mL of Bovine Serum Albumin (BSA) in RIPA buffer.  
25ml of solution A (alkaline copper tartrate) (with 20µl of solution S per ml of 
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solution A) was initially added followed by 200µl of solution B (Folin reagent).  
Once the solutions were added the plate was incubated at room temperature for 
10 minutes and the absorbance read at 690nm on a Victor3 1420 multilabel 
counter (PerkinElmer, Beaconsfield, Bucks, UK).  Protein concentration in the 
sample was then calculated according to the slope of the standards line. 
 
Figure 2.4. Representative BSA protein standard curve for the BioRad RC DC 
protein assay. Protein concentrations can be determined from the equation 
y=mx+c once the absorbance at 690nm is known.  
 
2.8. 11 β-hydroxysteroid dehydrogenase type 1 and 2 enzyme 
activity assay 
 2.8.1. Principles 
This technique allows for the measurement of the inter-conversion between the 
inactive glucocorticoid cortisone (E) in humans [11-dehydrocorticosterone (A) in 
rodents] and active cortisol (F) in humans [corticosterone (B) in rodents] by 
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isozymes of 11β-HSD.  This protocol was carried out on both monolayers of intact 
cells and whole tissue explants. Prior to the assay monolayer cells were left in 
serum free media for 1-2 hours.  Media was then removed from cells and the cells 
were then washed in PBS. 
 
 2.8.2. Method of 11β-HSD assay on monolayers 
Confluent cell monolayers (C2C12 murine skeletal muscle cells) were incubated 
with serum free DMEM media for 2 hours following which they were washed once 
with PBS then and then 1ml of serum free DMEM media containing 100nM of 
either 11-DHC enriched with 20000cpm/reaction 3H-11DHC (for synthesis see 
below) or corticosterone enriched by 20000cpm/reaction of 3H-corticosterone (GE 
Healthcare, Bucks, UK). Incubations were carried out at 37°C under a 5% CO2 
atmosphere for 20minutes to 2 hours depending on the cell or tissue type.  Media 
was then transferred to a glass test tube and 6mL of dichloromethane was added. 
The cells were retained in 100μL of PBS (or 70μl RIPA) and stored at -80°C for 
protein quantification (see Section 2.5). Steroids were extracted from media by 
vortexing the tubes for 20 seconds.  Aqueous and organic phases were 
separated by centrifugation at 1000 g for 10 minutes. The aqueous phase was 
aspirated off and the organic phase containing the steroids was evaporated at 
55°C using an air blowing sample concentrator (Techne, New Jersey, US). 
Steroids were resuspended in 70μl of dichloromethane and spotted onto a silica 
coated thin layer chromatography plate (Thermofisher, Surrey, UK) using a glass 
Pasteur pipette followed by spotting of 2μl of non-radiolabelled 11-
DHC/corticosterone or cortisone/cortisol (10mM in ethanol) as a cold standard. 
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Each spot was separated by at least 1.5cm from adjacent samples and 2cm from 
the bottom of the plate. Steroids were then separated by thin layer 
chromatography using 200mL of cholorform:ethanol (92:8) as the mobile phase 
for 2.5 h.  Radioactivity of the separated 3H-11-DHC/3H-corticosterone or 3H-
cortisone/3H-cortisol was measured using a Bioscan 200 Imaging Scanner 
(LabLogic, Sheffield, UK) for 10 minutes per lane. Finally, to assign the 
radioactivity peaks with the correct steroids the plates were placed under UV light 
to visualise the position of the cold standards.  
Percentage conversion was calculated using region counts for the individual 
peaks. Enzyme activity was expressed in pmoles of steroid converted per mg of 
protein per hour (pmol/mg/h). Calculation for steroid conversion (V): 
Steroid conversion = % conversion/100 x S x (1000/P)/T  
S = substrate concentration in reaction volume; e.g. if 100nM of substrate used in 
0.1ml volume, S=100pmol/reaction, P= protein concentration in well in mg, T = 
time in hours 
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Figure 2.5. Representative Bioscan traces for 11β-HSD1 oxo-reductase activity 
in C2C12 myotubes. 
 
 
 
 
 
 
 
 
Figure 2.6. Representative Bioscan traces for 11β-HSD1 dehydrogenase activity 
in mouse C2C12 myotubes.   
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11-dehydrocorticosterone (A) 
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 2.8.3. Method of 11β-HSD assay on Mouse tissue explants 
Fresh tissue explants were chopped to ~20mg/well and the above protocol was 
followed. Activity expressed as pmoles of steroid converted per mg of tissue per 
hour (pmol/mg/h). Incubations were carried out at 37°C under a 5% CO2 
atmosphere for 20 minutes (liver) to 2 hours (muscle and adipose tissue) 
depending on the tissue type. 
 
 2.8.4. Production of tritiated 11-dehydrocorticosterone (3H-
11DHC) 
Unlike tritiated cortisone (3H-cortisone), cortisol (3H-cortisol) and corticosterone (3H-
corticosterone), tritiated 11-dehydrocorticosterone (3H-11DHC) is not commercially 
available; consequently tritiated corticosterone [3H-corticosterone (GE Healthcare, 
Bucks, UK] was used to generate 3H-11DHC by a dehydrogenase reaction 
employing 11β-HSD2 dehydrogenase activity in placenta.  Initially, mouse placenta 
was homogenised with a few strokes of homogeniser in 2ml of 0.154 M KCl.  This 
tissue homogenate was then centrifuged at 1500rpm for 10 min at 4oC and 
supernatant was aliquoted into eppendorfs and stored at -80oC until required (at 
this stage protein concentration was measured using BioRad method, Section 2.5). 
In glass test tubes, 20μl of 3H-corticosterone (1mCi/mL) was incubated with 
250μg of homogenised mouse placenta in 500μl of 0.1M phosphate buffer 
(pH7.4), with 500μM NAD+.  Conversion was carried out overnight in a shaking 
water bath at 37°C. Steroids were extracted by addition of 6mL of 
dichloromethane and vortexing the tubes for 20 seconds. Aqueous and organic 
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phases were separated by centrifugation at 1000 g for 10 minutes. The aqueous 
phase was aspirated off and the organic phase containing the steroids was 
evaporated at 55°C using an air blowing sample concentrator (Techne, New 
Jersey, US). Steroids were resuspended in 5μl of dichloromethane and spotted 
onto a singly point of a silica coated thin layer chromatography plate 
(Thermofisher, Surrey, UK) using a Pasteur pipette. Cold standards of 
corticosterone and 11-dehydrocorticosterone were spotted onto the plate but at 
least 4cm distant to the spotted hot steroids, to avoid contamination.  Steroids 
were then separated by thin layer chromatography using 200mL of 
cholorform:ethanol (92:8) as the mobile phase for 2.5 hour. To establish the 
position of 3H-11DHC, the silica plates were read using a Bioscan 200 Imaging 
Scanner (LabLogic, Sheffield, UK).  The silica at the corresponding position to 3H-
11DHC was scraped into a glass test tube and eluted in 500mL of ethanol 
overnight at 4°C. The eluted 3H-11DHC and silica were separated by 
centrifugation at 1000 g for 5 minutes. Radioactivity of 3H-11DHC was determined 
by spotting 5μL of stock by thin layer chromatography and number of counts 
determined using the Bioscan 200 Imaging Scanner. Stock was then diluted in 
ethanol to give ~1000 counts/μL. 
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2.9. Immunohistochemistry of 11β-HSD1 
 2.9.1. Principles of Immunohistochemistry 
Immunohistochemistry is based on the binding of antibodies (usually IgG) to a 
specific antigen in tissue sections (293). Fixation of tissues is necessary as it 
adequately preserves the cellular components and proteins, prevents autolysis 
and displacement of cell constituents, stabilizes cellular materials and facilitates 
immunostaining (293).  Fixation modifies the tertiary structure of antigens which 
may make it more difficult for antibodies to detect them (85% of antigens fixed in 
formalin require some type of antigen retrieval to optimize immunoreaction).  
Antigen retrieval reverses some of these changes (293).  Another factor is the 
antibody type as polyclonal antibodies are more likely to detect antigens than 
monoclonal antibodies without antigen retrieval (293). Methods of antigen 
retrieval include protease induced epitope retrieval, heat induced epitope retrieval 
and pretreatment with formic acid (293). 
The antigen-antibody reaction cannot be seen with the light microscope unless it 
is labelled, therefore labels are attached to the primary, secondary or tertiary 
antibodies of a detection system to allow visualisation of the immune reaction 
(293).  Detection systems are either direct or indirect, the direct method is a one 
step process with a primary antibody conjugated with a reporter molecule.  
Indirect methods (two steps) are needed for more sensitive antigen detection.  In 
this method the first antibody added is unlabelled but the second layer, raised 
against the primary antibody is labelled. This is superior and more sensitive to the 
direct method as the primary antibody is not labelled therefore retaining its activity 
and resulting in a strong signal and the number of labels per molecule of primary 
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antibody is higher, therefore increasing the intensity of the reaction. Indirect 
methods include the Avidin-Biotin, Peroxidase-antiperoxidase, polymeric labelling 
two step method, tyramine amplification and immuno-rolling method (293). 
 
 2.9.2. Method of Immunohistochemistry 
Immunohistochemistry was performed on paraffin embedded sections of tissue 
that were collected in 10% formalin.  Slides were dewaxed and rehydrated by 
initially placing in an oven at 60oC for 20 minutes followed by immersion in xylene 
for 2 minutes (x2), then 100% ethanol for 5 minutes (x2) and finally 95% ethanol 
for 5 minutes (x2).   
Following this an antigen retrieval step was performed by placing slides in a 
beaker containing 0.01M citrate buffer (pH 6) which was microwaved on high 
power (2x2mins with 5 minute rest in between) or 8 minutes until boiling.  This 
was then allowed to cool to room temperature and washed thoroughly with tap 
water.  Slides were then incubated for 15 minutes in methanol hydrogen peroxide 
30% (62.5:1 v/v) for 5 minutes followed by a rinse in copious tap water and finally 
a wash in PBS.   
Three different primary antibodies for 11β-HSD1 were used and primary and 
secondary antibody concentrations were as shown in Table 2.2. 
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Table 2.2. Summary of the three different primary antibodies for 11β-HSD1 used 
and primary and secondary antibody concentrations. 
 
Blocking was then performed with 10% normal donkey serum in PBS v/v for 30 
minutes at room temperature to reduce background staining (goat serum for 
Caymen and Abcam), importantly, the blocking agent was not washed off prior to 
placing the primary antibody on the slide. Sections were incubated with 100μl 
primary antibody (final concentration 30µg/ml) in 10% NDS/PBS (NB for Cayman/ 
 
Antibody 
Primary 
antibody 
stock 
Primary antibody 
dilution and final 
concentration 
Secondary antibody 
dilution 
Binding Site 
(polyclonal)?
(294) 
1mg/ml 1:33 
30µg/ml  
anti-sheep/goat 
peroxidase (1:100)  
Abcam 
(polyclonal) 
Ab39364 
0.6mg/ml 1:20 
30µg/ml  
goat/ anti-rabbit 
peroxidase (1:100) 
 
Cayman 
(polyclonal) 
Cayman No: 
10004303 
0.6mg/ml 1:20 
30µg/ml  
goat/ anti-rabbit 
peroxidase (1:100) 
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Abcam 10% NGS/ PBS) for 1.5 hours at room temperature.  Following the 
incubation of primary antibody the slides were washed once in PBS and then 
incubated with 100μl secondary antibody (goat anti-sheep IgG peroxidase 
conjugate for binding site and goat anti-rabbit for Abcam and Cayman) at a 
dilution of 1:100 (in PBS for 30 minutes at room temperature).  The slides were 
then rinsed in PBS prior to visualisation of the secondary antibody. To visualise 
staining one DAB (3,3'-Diaminobenzidine) tablet, Sigma Aldrich, Dorset, UK with 
the H2O2 tablet was dissolved in 15mls of H2O and the solution mixed and 
filtered through Whatman filter paper.  Sufficient DAB solution was added to each 
slide to completely cover the section and left to develop for 5 minutes or until 
brown stain appears.  Following this the slide was submerged in tap water to stop 
the chromagen reaction and washed with copious tap water.  The slide was then 
counterstained by immersing in Meyers haematoxylin for 30 seconds, following 
which it was washed in copious tap water.  The slide was then placed in 100% 
ethanol for 5 minutes (x2), then Xylene for 5 minutes (x2) and mounted using 
dibutyl polystyrene xylene (DPX). 
Negative controls were carried out using anti-11β-HSD1 immunising peptide 
1:100-1:500 (pre-adsorbed), blank or isotype control.  
 
 2.9.3. Methods for Immunoflourescence 
Immunoflourescence was performed in collaboration with Dr Chris Shaw, School 
of Sports and Exercise Science, University of Birmingham.  Muscles to be 
processed for immunoflourescence were handled differently than those for 
standard immunohistochemistry. Briefly, muscle samples were embedded in 
Chapter 2  Materials and Methods 
 80 
Tissue-Tek OCT Compound (Sakura Finetek Europe, The Netherlands) and 
immediately frozen in liquid nitrogen-cooled isopentane. Serial 5 μm sections 
were cut at -30°C and collected onto room temperature, uncoated glass slides. 
Cross-sections were cut and used to stain 11 β-HSD1, and myosin heavy chain I 
and IIa protein. 
Slides were left to air dry for a minimum of 1 h before treatment. Briefly slides 
were fixed in acetone at -20C for 20 minutes, followed by 30 second washes (x3) 
in deionised water. The slides were then permeabilised in 0.5% Triton-X for 5 
minutes followed by 5 minute washes (x3) in PBS. The muscle samples were 
then blocked for 30 minutes with 5% normal donkey serum. Following which they 
were incubated in appropriate primary antibodies for 60 minutes, followed by 5 
minutes washes (x3) in PBS. The 11 β-HSD1 binding site antibody concentration 
was 1:100, whereas the myosin heavy chain I (Developmental Studies Hybridoma 
Bank, University of Iowa, Dr Blau, A4.840) and IIa (Developmental Studies 
Hybridoma Bank, University of Iowa, Dr Blau, N2.261) antibody concentration 
were both 1:25.  The samples were further incubated in appropriately targeted 
secondary fluorescent conjugated antibodies for 30 min [11 β-HSD1, donkey anti-
sheep IgG 568 (red)] and followed by treatment with Alexa Fluor GAMIgM 350 
MyHCI (blue) and Alexa Fluor GAMIgM 488 MyHCIIa (green) (Invitrogen, Paisley, 
UK).  
This was followed by 5 minute washes (x3) in PBS. Coverslips were mounted in a 
glycerol and mowiol 4–88 solution in 0.2 M Tris-buVer (pH 8.5) with the addition 
of 0.1% 1,4-diazobicyclo-[2.2.2]-octane (DABCO) antifade medium. Muscle cross-
sections were illuminated with a mercury lamp and viewed with a Nikon E600 
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microscope with a 40 x 0.75 NA objective. A SPOT RT KE colour 3 shot CCD 
camera (Diagnostic Instruments Inc, MI, USA) was coupled to the microscope for 
digital image capture. In order to visualise the Alexa fluor 350 (blue) and 488 
(green) fluorophores the DAPI UV (340–380 nm) and FITC (465–495) excitation 
filters were used respectively. Sections stained Alexa fluor 568 (red) were 
examined using a Texas red (540–580 nm) excitation filter. Images were 
processed using Image-Pro Plus 5.1 software (Media Cybernetics, MD, USA) 
(295).  
 
 
2.10. Immunoblotting 
 2.10.1. Principles of immunoblotting 
Immunoblotting allows the measurement of relative amounts of a specific protein 
in a mixed protein sample (296). Proteins are boiled in a strong reducing agent 
which removes all secondary and tertiary structures and gives them a uniform 
negative charge. SDS-PAGE electrophoresis is then employed to separate the 
proteins according to molecular mass. Since the proteins are negatively charged 
they are pulled through the gel towards the anode at a speed that is dependent 
on their size (small proteins migrate fast and large proteins migrate slowly). The 
separated proteins are then transferred to a membrane, usually polyvinylidene 
diflorise (PVDF) or nitrocellulose using electrical current. Since these membranes 
strongly bind proteins they will also bind to any antibodies that it is exposed to. To 
prevent this non-specific binding the membrane is incubated in a blocking solution 
containing a generic protein such as milk or BSA. The next step involves probing 
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the membrane with a primary antibody that specifically recognises the protein of 
interest, followed by incubation with a secondary antibody that is directed against 
the primary antibody. The secondary antibody is conjugated to horseradish 
peroxidase (HRP), which, in the presence of hydrogen peroxide, catalyses a 
reaction involving the oxidation of luminol. Upon oxidation of luminol, an 
iridescent blue light is produced which is proportional to the amount of protein on 
the membrane. The reaction is captured on photographic film. 
 
 2.10.2. Method of Immunoblotting 
20μg of protein was mixed with an appropriate amount to 5 x loading buffer and 
boiled for 5 minutes. Samples were loaded into a 4-20% gradient SDS-PAGE gel 
(BioRad, Herts, UK) and run at 200V for 1 h - 1 h 30 minutes. Transfer of proteins 
to nitrocellulose membrane (GE Healthcare, Bucks, UK) was conducted at 
140mA for 1-2 h depending on the size of the protein of interest. Efficient transfer 
was assessed by incubating the membrane in ponceau stain with agitation for 60 
seconds, and then rinsed with water to allow visualisation of the protein bands. 
Electrophoresis and protein transfer was carried out in BioRad mini protein 3 
apparatus (BioRad, Herts, UK). Membranes were blocked in 10mL of blocking 
buffer for 1 hour at room temperature with constant agitation, then incubated with 
primary antibody overnight at 4°C on an orbital shaker. Membranes were washed 
with 100mL of washing buffer 3 times for 15 minutes. Secondary antibody 
incubation was conducted at room temperature with constant agitation. The 
membrane was then washed with 100mL of washing buffer 3 times for 15 
minutes. Bound antibody was detected using Enhanced Chemiluminescence 
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(ECL, GE Healthcare, Bucks, UK). The reaction mixture was set up by combining 
substrate A with substrate B at a 50:50 ratio (final volume: 1mL per membrane). 
Following equilibration for 5 minutes, 1mL was added per membrane and left to 
incubate for 2 minutes before the membrane was placed between two plastic 
sheets in a photo cassette. Photographic film (PerkinElmer, Surrey, UK) was 
placed over the membrane in the dark and exposed for 30 seconds to 3 h, then 
developed on Compact X4 automatic film processor (Xograph Imaging Systems, 
Gloustershire, UK). Membranes were routinely stripped to remove bound 
primary/secondary antibodies by incubating the membrane in stripping buffer (2% 
SDS, 100mM β-mercaptoethanol, 50mM Tris, pH 6.8) at 50°C for 1 h with gentle 
agitation. Membranes were then washed with 100mL of washing buffer 3 times 
for 15 minutes before being re-probed with a different primary antibody. 
Immunoblots were evaluated by integrating densitometry using GeneSnap and 
GeneTool (Chemigenius Gel Documenting System, Syngene, Cambridge, UK). 
Equal loading was confirmed by reprobing membrane with anti-β-actin antibody 
conjugated to HRP and visualized as described above. 
 
2.11. Proliferation assays 
 2.11.1. Principles of Proliferation assay using Promega Cell 
Titre 96 ® Aqueous Non-Radioactive Cell Proliferation Assay (MTS) 
The Cell Titre 96 ® AQueous Non-Radioactive Cell proliferation assay is a 
homogenous, colorimetric method for determining the number of viable cells in 
proliferation, cytotoxicity or chemosensitive assays.  The Cell Titre 96 ® AQueous 
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assay is composed of solutions of a novel tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-“H-
tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine 
methosulfate) PMS.  MTS is bioreduced by cells into a formazan product that is 
soluble in tissue culture medium.  The absorbance of the formazan product at 
490nm can be measured directly from 96-well assay plates without additional 
processing.  The conversion of MTS into the aqueous soluble formazan product is 
accomplished by dehydrogenase enzymes found in metabolically active cells.  
The quantity of formazan product is measured by the amount of 490nm 
absorbance is directly proportional to the number of living cells in culture.  Data 
from proliferation bioassays comparing the Cell Titre 96 ® AQueous Non-
Radioactive Cell proliferation assay and the [3H]-thymidine incorporation show 
similar results, however the Promega assay was more flexible and reproducible.  
 
 2.11.2. Procedure of MTS assay 
The assay was performed according to the manufacturers protocol.  C2C12 cells 
were trypsinised and counted, they were then seeded at a concentration of 
approximately 1000 per well on 96 well plate (in a volume of 100 µl) and left for 
24 hrs.  After 24 hours treatments were added to cells (e.g. glucocorticoids, IGF-I) 
and the cells were incubated in treatment for another 24 hours at 37°C.   
The CellTiter 96® AQueous One Solution Reagent was thawed and 20µl of CellTiter 
96® AQueous One Solution Reagent (a mix of 2mls of reagent MTS and100 μl of 
reagent PMS) was pipetted into each well of the 96-well assay plate containing 
the samples in 100µl of culture medium. The plate was then incubated for 1 hour 
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at 37°C in a humidified, 5% CO2 atmosphere. The absorbance at 490nm was 
recorded using a 96-well spectrophotometer Victor3 1420 multilabel counter 
(PerkinElmer, Beaconsfield, Bucks, UK).  The plate can was returned to the 
incubator for another 24 hours and the procedure repeated on cells which have 
not been previously assayed (results shown are from 24 and 48 hour proliferation 
studies). IGF-I was used as a positive control in all experiments as it is well 
described as leading to myoblast proliferation in C2C12 cells (297). 
 
Figure 2.7.  Plate set up for The CellTiter 96® AQueous plate as per 
manufacturers guidance. 
(http://www.promega.com/resources/protocols/technical-bulletins/0/celltiter-96-
aqueous-nonradioactive-cell-proliferation-assay-protocol). 
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2.12. 11 β-HSD1 inhibitors and Glucocorticoid receptor 
anatagonists used in this thesis 
 2.12.1. LJ2 (PF-877423) 
LJ2 (PF-877423, Pfizer Global R&D, La Jolla, CA, USA) is a selective 11 β-HSD1 
inhibitor.  The potency of this inhibitor is strongly affected by the presence of 
substrate in the assay buffer, Kiapp values increased at high concentrations of 
cortisone suggesting that the inhibitor behaved as a reversible and competitive 
inhibitor against cortisone, inhibition constant Ki 0.2 + 0.04 and Michaelis Menten 
constant Km 333.4 + 109.2 nM (298).  
 
 2.12.1.1. Specificity of LJ2 (PF-877423) 
LJ2 (PF-877423, Pfizer Global R&D, La Jolla, CA, USA) is a selective 11 β-HSD1 
inhibitor.  This group have previously published the efficacy of LJ2 in assays on 
HEK293T1 and HEK293T2 cells showing total abolition of oxoreductase activity 
(34.7 + 0.6 vs. 0.4 + 0.1, % cortisone to cortisol conversion, mean + SD) activities 
of 11 β-HSD1 following incubation with 100nM PF-877423 for 24 hours but no 
effect on 11 β-HSD2 activity.  No toxic effects of PF-877423 were observed up to 
10μM concentrations using a commercially available assay kit (CellTitre 96 
Aqueous, Promega) (298).  The dose of LJ2 used in all experiments was 100nM. 
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 2.12.2. Glycyrrhetinic Acid 
Glycyrrhizic acid, a glycosylated saponin and a major constituent of licorice and 
glycyrrhetinic acid (its aglycone) (299) are non-specific inhibitors of 11 β-HSD 
isozymes. In addition to its established role as a competitive inhibitor of 11 β-HSD 
isozymes, liquorice results in pretranslational inhibition of 11 β-HSD both in vitro 
and in vivo (300). In addition glycyrrhetinic acid inhibits 11 β-HSD2 with an 
inhibition constant (Ki) of 5-10nM (301, 302).   
 
 2.12.3. Glucocorticoid receptor blockade – RU486 
The bulky dimethyl-aminophenyl residue in RU486 fits snugly into the 
hydrophobic pocket of the glucocorticoid receptor (GR) and the progesterone 
receptor and explains its bifunctional antagonism at the level of these receptors 
(303).  RU486 has a prolonged metabolic half-life of about 20 hours, thus it 
effectively excludes cortisol from receptor binding by binding to the receptor itself 
(304).  After RU486 binds to the cytosolic GR, the interaction of the GR with HSP 
90 and 59 is strengthened, therefore, not allowing it to enter the nucleus and bind 
to GREs (304). 
 
2.13. Rodent Models used in this thesis 
All mice were group housed under controlled temperature (21-23oC) and light 
(12:12 light-dark cycle; lights on at 0700h) with ad libitum access to standard 
rodent chow and water.  Body weights were monitored weekly.  Animal 
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procedures were approved under the British Home Office Animals (Scientific 
Procedures) Act 1986. 
In the ageing mouse experiments, the colony of aged mice were between 22 and 
26 months, this time frame was determined from published data regarding age 
related myopathy which describes ‘old mice’ as being aged from 19 to 28 months 
(305-308). In the initial ageing mouse experiments the colony of young mice were 
approximately 12 weeks old and aged mice were between 22 and 26 months (all 
mice C57Bl\6). In our 11β-HSD1 KO model the mice strain was of mixed 
background C57Bl6/129SVJ.  
 
 2.13.1. Generation of targeted 11β-HSD1 knock out mouse 
The 11β-HSD1 knock out mouse was developed within our group by Dr Gareth 
Lavery. The murine HSD11B1 gene contains 6 exons and a targeted vector to 
flank exon 5 (containing the catalytic domain of the enzyme) with LoxP sites.  
Genomic DNA from 129SvJ embryonic stem cells was used to amplify 6kb 5’ and 
2kb 3’ homology arms, which were subsequently cloned into pBluescript SK(+) 
containing a thymidine kinase cassette. A loxP flanked Neomycin cassette was 
subcloned into a Xhol site 5’ of exon 5 and an additional loxP site subcloned into 
a PmlI site 3’ of exon 5.  Following verification by DNA sequencing, the construct 
was linearized with BamHI and electroporated into E14TG2a mouse embryonic 
stem cells. Southern hybridization of Spe1 and NcoI digested genomic DNA 
probed with 500-bp H6PD fragments located at the 5' and 3' ends of the targeting 
vector respectively identified cells positive for a recombined HSD11B1 tri-loxed 
allele after selection in G418 and gancyclovir (see Figure 2.8). Three targeted 
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embryonic stem cell clones were expanded, screened, and karyotyped to ensure 
correct recombination and chromosomal integrity. Two clones were injected into 
C57BL/6 blastocysts and chimeric mice derived from embryonic stem cell clone 
were mated with C57BL/6 females to achieve germ line transmission of the 
recombined allele. Mice heterozygous for a tri-loxed allele were crossed with the 
ZP3-Cre expressing strain (309) which is a powerful deleter expressing early in 
development and will recombine between the most distant LoxP sites with high 
efficiency, thus rendering the allele null which can be passed into the next 
generation. Germline transmission of a disrupted allele was detected by PCR 
(depicted schematically in Figure 2.8). For genotyping HSD11B1 alleles the 
following primers were multiplexed in a standard PCR reaction: P1 5’-
GGGAGCTTGCTTACAGCATC-3’; P2 5’-CATTCTCAAGGTAGATTGAACTCTG-
3’; P3 5’-TCCATGCAATCAACTTCTCG-3’. PCR genotyping confirmed germline 
transmission of the disrupted allele, which was subsequently bred to 
homozygosity generating a 11β-HSD1KO. The validity of the model was 
assessed by demonstrating no 11β-HSD1 gene expression or enzyme activity in 
a number of tissues.   
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Figure 2.8. Targeted disruption of murine HSD11B1 using the Cre-LoxP system. 
A. schematic representation of the 6 exons of the HSD11B1 gene, the targeting 
vector, tri-floxed recombined allele and the KO allele upon ZP3-Cre mediated 
recombination. The location of the 5' and 3' external probes used for Southern 
hybridization and PCR primers P1, P2, and P3 used for genotyping are indicated. 
NEO, neomycin resistance cassette; TK, thymidine kinase cassette. B. 
Successful targeting of HSD11B1 in 3 independent lines (1, 14 and 15. c-control 
non targeted cells) of embryonic stem cells confirmed by Southern hybridization 
of SpeI and NcoI digested genomic DNA. SpeI digests produced a WT fragment 
of 10.8kb which in the presence of the tri-floxed recombined allele produced a 
fragment to 9.7kb. For the NcoI digest the WT fragment is 8.1Kb and the 
recombined allele is5.4kb.  C. PCR detection of knockout alleles (see material 
and methods for primer details). Primers P2 and P3 produce a band of 139bp 
representing the presence of a WT allele. Amplicons representing amplification 
between P1 and P3 are not detected due to the distance between these primers. 
In the KO allele a P2 binding site is removed and P1 and P3 are brought in to 
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proximity generating a product of 242bp allowing us to detect WT, heterozygote 
and homozygote animals (310). 
 
2.14. Mouse Muscle Strength Testing 
 2.14.1. Procedure 
In experimental animals, the Linton Grip-Strength meter (Linton Instrumentation, 
Norfolk, UK) was used to assess muscle performance (4).  The Linton Grip-
Strength meter reproducibly measures peak grip strength (4;5).  This is a non-
invasive method whereby the peak grip strength is routinely measured by holding 
the animal by the base of the tail and gently and gradually assessing grip strength 
following the animal holding onto a grasp grid which assesses force via sensors 
in the machine while the animal is being gently pulled in the opposite direction. 
Mice will naturally reach and grasp an object if an object is brought in front of their 
forepaws. On each assessment, the mouse will be removed from their housing 
and lowered into the apparatus so that it grasps the grip grid, one with each paw, 
with its back legs standing on the smooth floor of the apparatus. The mouse will 
then be held by the base of the tail and pulled gently in a rearward direction. The 
applied force at which the mouse releases the cage with each paw was measured 
by the strain gauges. 
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2.15. Gas Chromatography/ Mass spectrometry for corticosteroid 
metabolites in human and mouse urine 
 2.15.1. Principles 
GC/MS urinary steroid analysis was carried out by Beverley Hughes at the 
Institute for Biomedical Research, Centre for Endocrinology, Diabetes and 
Metabolism (CEDAM), University of Birmingham.  The GC/MS was based on the 
method described by Palermo et al. (311). The methods of sample work-up for 
GC/MS analysis (conjugate hydrolysis, extraction and derivatization) and their 
methodologies have been published in detail in several manuscripts (149, 312) 
and in depth description is beyond the scope of this thesis. 
GC/MS was used to analyse the metabolites of steroid hormones and their 
precursors.  In the CEDAM at the University of Birmingham, approximately 40 
steroids are targeted for selected-ion-monitoring analysis, which cover all 
disorders of steroid synthesis and metabolism. A recent review by Krone et al. 
from this Department has highlighted several key features of urinary steroid 
metabolite analysis including the major shortcoming of data presentation in 
clinical GC/MS urine steroid profiling (313). Tabulating only the quantified 
amounts of steroid metabolites can be confusing and difficult to interpret, 
therefore improvement in the visual presentation of data has been made within 
the department (313). 
The pathway to steroid hormone production is commonly divided into the 
synthesis of mineralocorticoid, glucocorticoids and sex steroids (Figure 2.9). We 
have added two groups to this classification; ‘androgen precursors’ includes the 
Δ5-steroids pregnenolone, 17OHpregenenolone, DHEA and the Δ4-steroids 
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androstenedione and their metabolites as this represents the main pathway to 
active androgens. The second additional group is ‘glucocorticoid precursors’, 
which consists of the Δ4-steroids progesterone, 17OHprogesterone and 21-
deoxycortisol and their metabolites (313). Within CEDAM, normal ranges have 
been developed from a large number of healthy controls. The GC/MS profile of an 
individual patient is plotted for each determined parameter against the normal 
reference population (Figure 2.10). Such profiles allow for an immediate overview 
of the complete set of metabolites (313). In this thesis ratios of glucocorticoid 
metabolites are used to determine the relative activity of 11 β-HSD1. 
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Figure 2.9 - Synthesis and metabolism of hormonal steroids. This figure 
illustrates the formation of the major hormone classes from cholesterol. Steroid 
names in conventional script are steroid hormones and precursors; those in italics 
are urinary metabolites of the aforementioned. The major transformative enzymes 
are in rectangular boxes, the cofactor (“facilitator”) enzymes in ovals. 
Mitochondrial CYP type I enzymes requiring electron transfer via adrenodoxin 
reductase (ADR) and adrenodoxin (Adx) CYP11A1, CYP11B1, CYP11B2, are 
marked with a labelled box ADR/Adx. Microsomal CYP type II enzymes receive 
electrons from P450 oxidoreductase (POR), CYP17A1, CYP21A2, CYP19A1, are 
marked by circled POR. The 17,20-lyase reaction catalyzed by CYP17A1 
requires in addition to POR also cytochrome b5 indicated by a circled b5. 
Similarly, hexose-6-phosphate dehydrogenase (H6PDH) is the cofactor-
generating enzyme for 11β-HSD1. The asterisk (*) indicates the 11 hydroxylation 
of 17OHP to 21-deoxycortisol in 21-hydroxylase deficiency. The conversion of 
androstenedione to testosterone is catalyzed by HSD17B3 in the gonad and 
AKR1C3 (HSD17B5) in the adrenal. StAR, steroidogenic acute regulatory protein; 
CYP11A1, P450 side-chain cleavage enzyme; HSD3B2, 3β-hydroxysteroid 
dehydrogenase type 2; CYP17A1,17α-hydroxylase; CYP21A2, 21-hydroxylase; 
CYP11B1, 11β-hydroxylase; CYP11B2, aldosterone synthase; HSD17B, 17β-
hydroxysteroid dehydrogenase; CYP19A1, P450 aromatase; SRD5A2, 5α-
reductase type 2; SULT2A1 from Krone et al (313).  Figure based on a diagram 
courtesy of Dr Nils Krone. 
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Figure 2.10. Graphical representation of the normal range of urinary steroid 
metabolites (quantity reported in μg/24 h). The groups are the same as described 
in Figure 2.9. Box and whisker plots represent mean values, 5th and 95th 
percentile and given (courtesy of Professor Wiebke Arlt). 
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 2.15.2. Gas Chromatography/ Mass Spectrometry Methods 
Quantitative data on excretion of individual steroids requires accurate 24 hour 
sampling and 1ml of a 24-hour collection for analysis.  For murine studies 
individual mouse urine was collected on filter paper and processed. 
The following isotope labelled internal standards were used; (9,11,12,12-2H) 
cortisol and (9,12,12-2H) cortisone.  The standards were calibrated by high 
performance liquid chromatography (HPLC) analysis of solubilised, non-labelled 
standard on known weight.  Free steroid was extracted using Sep-pak C18 
cartridges (314).  Labelled steroid d4-cortisol (0.18μg), and d3-cortisone (0.12μg), 
as well as internal standards (stigmasterol and cholesteryl butyrate), 200μg were 
then added.  The samples were then derived using 100μl of 2% methoxyamine 
hydrochloride in pyridine and 50μl of trimethylsilylimidzole.  Lipidex 
chromatography was then used to purify the steroid derivative. 
GC/MS was carried out using a Hewlett Packard 5970 mass spectometer and 
15m fused-silica capillary column, 0.25mmID, 0.25μm film thickness (J&B 
Scientific, Folsom CA, USA) using 2μl of sample.  Steroids were quantified by 
comparing individual peak area to the peak area of the internal standards, for 
cortisol fragment 605m/z compared to 609 m/z and for cortisone fragment 531 
m/z compared to 534 m/z.  The relative peak area was calculated and the 
metabolite concentration expressed as μg/24hr.  A quality control (QC) was 
analysed with each batch.  The intra and inter-assay co-efficient of variance was 
<10%.   
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2.16.  Assays and DEXA scan methods for clinical study 
These will be discussed in detail in Chapter 6. 
2.17. Statistical methods 
Statistical analysis was performed using Prism for Windows version 5.0 
(GraphPad Software Inc, San Diego, CA, USA) software packages.  Continuous 
data were summarised using means and standard deviations (or standard error of 
mean) if parametrically distributed or medians and inter-quartile ranges if non-
parametrically distributed.  Parametric data was compared using a paired t-test 
and non-parametric data was analysed using a Mann-Whitney test.  Multiple 
comparisons were assessed using one-way analysis of variance (ANOVA), with 
Kruskal-Wallis for non-parametric data.  Associations between variables were 
analysed using Pearson correlation for parametric data and Spearman rank 
correlation for non-parametric data.  The level for statistical significance 
throughout the thesis is p<0.05. 
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Chapter 3 
Characterising 11 β-HSD1 in skeletal muscle 
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3.1. Introduction 
Within tissues, GC levels are regulated at the pre-receptor level by the isozymes 
of 11 β-hydroxysteroid dehydrogenase (11 β-HSD), which are located in the 
endoplasmic reticulum (ER). 11 β-HSD2 acts as a dehydrogenase converting 
active cortisol (corticosterone in rodents) to inactive cortisone (11-
dehydrocorticosterone in rodents) to protect the mineralocorticoid receptor from 
illicit occupancy by cortisol (150).   In contrast, 11 β-HSD1 in vivo acts 
predominantly as an oxoreductase converting inactive cortisone (11-
dehydrocorticosterone in rodents) into active cortisol (corticosterone in rodents) 
(2).  This oxoreductase activity is determined by nicotinamide adenine 
dinucleotide phosphate (NADPH) co-factor availability produced by the ER 
specific enzyme hexose-6-phosphate dehydrogenase (H6PDH).   
The biological activity of glucocorticoids is dependent on their binding to the 
glucocorticoid receptor (GR) which is a ligand regulated nuclear receptor that in 
the absence of its GC ligand remains bound to other proteins within the 
cytoplasm such as the 90 kDA and 70 kDA heat shock proteins (HSP90, HSP70).  
GC binding to the GR leads to dissociation of the HSPs and translocation of the 
GR-ligand complex into the cell nucleus where it binds to specific DNA 
sequences known as glucocorticoid response elements (GREs) in the promoter 
region of the target gene (131).   
The role of 11 β-HSD1 in adipose tissue, liver and brain has been extensively 
studied (2), however the role of 11 β-HSD1 in skeletal muscle is less well-defined. 
Expression of 11 β-HSD1 in human skeletal muscle has been reported to be only 
~5% that reported in liver (151) with conflicting evidence as to whether 11 β-
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HSD2 is present in muscle or not (151, 152).  In muscle cells extracted from the 
vastus lateralis of patients with type 2 diabetes, baseline 11 β-HSD1 mRNA 
expression was elevated compared to controls.  This increase in 11 β-HSD1 
mRNA expression was associated with impaired glucose transport in response to 
acute insulin and cortisone stimulation (152).  In human myocytes, Whorwood et 
al. (153) demonstrated elevated 11 β-HSD1 activity with increasing GC 
concentration and 11 β-HSD1 activity decreased with insulin and IGF-I 
administration, independently.   
Glucocorticoids are known to have profound effects on skeletal muscle biology 
and in excess can lead to myopathy as clearly demonstrated through in vitro 
(194-199) and in vivo studies of rodent (84, 141, 143, 200-210) and human 
skeletal muscle (96, 101-108, 191).  The effect of glucocorticoids on muscle, liver 
and fat are also associated with a number of metabolic derangements including 
hyperglycaemia, insulin resistance and hyperlipidaemia (130).  Thus, both in 
health and disease 11 β-HSD1 may play a fundamental role in skeletal muscle 
biology by altering intracellular glucocorticoid concentrations.  
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3.2. Aims 
The aim of this chapter is to characterise 11 β-HSD1 in murine skeletal muscle 
and the murine skeletal muscle cell line (C2C12), which will be the models used 
for the remainder of the thesis. 
 
3.3 Strategy of Research 
Using cultured C2C12 myocytes as a skeletal muscle model and skeletal muscle 
tissue from C57BL\6 mice we assessed 11 β-HSD1 activity, mRNA expression 
and protein content (with immunohistochemistry). 
 
3.4. Methods 
 3.4.1. C2C12 cell culture 
The C2C12 cell line is a well-established model of both skeletal muscle 
proliferation and differentiation which has been widely used in research with 
regard to muscle atrophy and glucocorticoid induced myopathy (84, 86, 195, 
197). This cell line was derived as a subclone of a myoblast line established from 
normal adult C3H mouse leg muscle. They differentiate rapidly; produces 
extensive contracting myotubes and express characteristic muscle proteins. They 
provide an excellent model to study in vitro myogenesis and muscle cell 
differentiation, which until recently have been difficult to primary culture.  The use 
of C2C12 in muscle molecular biology research has been reported in many high 
impact citations.? ? Cryofrozen C2C12 myoblasts (passage 17) were purchased 
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from ECACC (Salisbury, UK), Once myoblasts had reached 60-70% confluence, 
differentiation was initiated by replacing proliferation media with DMEM with high 
glucose and L-glutamine (PAA, Somerset, UK) supplemented with 5% horse 
serum. Differentiation media was replaced every 48 hours. After 8 days, 
myoblasts had fused to form multinucleated myotubes (Figure 3.1). 
 
Figure 3.1. C2C12 myoblast cells were differentiated in chemically defined media 
for 8 days to form multinucleated myotubes. 
 
 
 3.4.2. RNA extraction and cDNA synthesis 
Total RNA was extracted from monolayer cells using TRIreagent (Sigma-Aldrich, 
Dorset, UK).  The procedure was carried out according to protocol provided with 
the reagent (Sigma-Aldrich, Dorset, UK).  The quantity of RNA was measured 
using NanoDrop ND-1000 UV-Vis Spectrophotometer (Thermofisher, Surrey, 
UK). The reverse transcription process was carried out using Applied Biosystems 
High-Capacity Reverse Transcription Kit (Applied Biosystems, Warrington, UK) 
For a full description of methods used see Section 2.4. 
 
8 days Differentiation 
MYOBLASTS MYOTUBULES 
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 3.4.3. Quantitative or Real Time PCR 
Quantitative PCR was carried out using Applied Biosystems Reagents and gene 
mRNA expression assays (AssayonDemand) (Applied Biosystems, Warrington, 
UK).  PCRs for genes of interest and for 18s housekeeping genes were carried 
out in singleplex. Data were expressed as Ct values (Ct=cycle number at which 
logarithmic PCR plots cross a calculated threshold line).  And used to determine 
ΔCt values (ΔCt = (Ct of the target gene) – (Ct of the housekeeping gene), lower 
ΔCt values reflecting higher mRNA mRNA expression.  Data are expressed as 
arbitrary units using the following transformation [mRNA expression in arbitrary 
units = 1000*(2-ΔCt)]. For a full description of methods used see Section 2.6. 
 
3.4.4. Protein Extraction and concentration measurement on 
monolayer cells 
Monolayer cells were lysed in Radio-Immunoprecipitation (RIPA) buffer 
containing detergent.  The lysate was freeze-thawed to further break open cell 
membranes and the insoluble components removed by centrifugation. The 
supernatant, containing soluble proteins was measured using BioRad RC DC 
protein assay (BioRad, Herts, UK). 5µl of protein sample or standard were added 
per well in duplicate.  The ranges of protein standards were 0, 0.25, 0.5, 1, 2, 4, 8 
and 10mg/mL of Bovine Serum Albumin (BSA) in RIPA buffer.  25ml of solution A 
(alkaline copper tartrate) (with 20µl of solution S per ml of solution A) was initially 
added followed by 200ml of solution B (Folin reagent).  Once the solutions were 
added the plate was incubated at room temperature for 10 minutes and the 
absorbance read at 690nm on a Victor3 1420 multilabel counter (PerkinElmer, 
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Beaconsfield, Bucks, UK).  Protein concentration in the sample was then 
calculated according to the slope of the standards line. For a full description of 
methods used see Section 2.7. 
 
 
3.4.5. 11 β-hydroxysteroid dehydrogenase type 1 and 2 enzyme 
activity assay on monolayer and tissue explants 
11 β-hydroxysteroid dehydrogenase type 1 and 2 enzyme activity assay was 
carried out on both monolayers and whole tissue explants. Incubations were 
carried out at 37°C under a 5% CO2 atmosphere for 20 minutes to 2 hours 
depending on the cell/tissue type. Enzyme activity was expressed in pmols of 
steroid converted per mg of protein per hour (pmol/mg/h) for monolayers or 
steroid converted per mg tissue per hour (explants). For a full description of 
methods used see Section 2.8. 
 
3.4.6. Inhibition of 11 β-HSD1 and glucocorticoid receptor 
antagonism 
The most commonly used inhibitors of 11 β-HSD1 for in vitro studies are the 
liquorice derivatives glycyrrhizic acid, its hydrolytic product glycyrrhetinic acid and 
its hemisuccinate derivative carbenoxolone (CBX).  Glycyrrhetinic acid (GE) is a 
potent inhibitor of 11 β-HSD1 (both competitive and inhibiting 11 β-HSD1 mRNA 
levels) (300, 315).  The dose of GE used in all experiments was 2μM.   
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LJ2 (PF-877423, Pfizer Global R&D, La Jolla, CA, USA) is a selective 11 β-HSD1 
inhibitor.  This group has previously published the efficacy of LJ2 in assays on 
HEK293T1 and HEK293T2 cells showing total abolition of oxoreductase activity 
(34.7 + 0.6 vs. 0.4 + 0.1, % cortisone to cortisol conversion, mean + SD) activities 
of 11 β-HSD1 following incubation with 100nM PF-877423 for 24 hours but no 
effect on 11 β-HSD2 activity (298).  The dose of LJ2 used in all experiments was 
100nM. 
RU486 is a potent glucocorticoid receptor (GR) antagonist receptors (303). After 
RU486 binds to the cytosolic GR, the interaction of the GR with HSP 90 and 59 is 
strengthened thus not allowing it to enter the nucleus and bind to GREs (304).  
The dose of RU486 used in all experiments was 10μM. 
 
3.4.7. Immunohistochemistry of 11β-HSD1 
Immunohistochemistry was performed on paraffin embedded sections of tissue 
that were collected in 10% formalin. An antigen retrieval step was performed 
following which three different primary antibodies for 11β-HSD1 were used and 
primary and secondary antibody concentrations were as shown in Table 3.1. 
Blocking was then performed with 10% normal donkey serum in PBS v/v for 30 
minutes at room temperature to reduce background staining (goat serum for 
Caymen and Abcam antibodies). Importantly, the blocking agent was not washed 
off prior to placing the primary antibody on the slide.   
Sections were incubated with 100μl primary antibody (final concentration 
30µg/ml) in 10% NDS/PBS (NB for Cayman/ Abcam 10% NGS/ PBS) for 1.5 
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hours at room temperature.  Following the incubation of primary antibody the 
slides were washed once in PBS and then incubated with 100μl secondary 
antibody (goat anti-sheep IgG peroxidase conjugate for binding site and goat anti-
rabbit for Abcam and Cayman) at a dilution of 1:100 (in PBS for 30 minutes at 
room temperature). To visualise staining one DAB (3,3'-Diaminobenzidine) tablet, 
Sigma Aldrich, Dorset, UK with the H2O2 tablet was dissolved in 15mls of H2O  
and applied to completely cover the section and left to develop for 5 minutes The 
slide was then counterstained by immersing in Meyers haematoxylin for 30 
seconds, following which it was washed in copious tap water.  
Negative controls were carried out using anti-11β-HSD1 immunising peptide 
1:100-1:500 (pre-adsorbed), blank or isotype control. For a full description of 
methods used see Section 2.9.  
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Table 3.1. Summary of the three different primary antibodies for 11β-HSD1 used 
and primary and secondary antibody concentrations. 
 
 
3.4.8. Methods for Immunoflourescence 
Immunoflourescence was performed in collaboration with Dr Chris Shaw, School 
of Sports and Exercise Science, University of Birmingham.  Muscles to be 
processed for immunoflourescence were handled differently than those for 
standard immunohistochemistry. Briefly, muscle samples were embedded in 
Tissue-Tek OCT Compound (Sakura Finetek Europe, The Netherlands) and 
immediately frozen in liquid nitrogen-cooled isopentane. Serial 5 μm sections 
were cut at -30°C and collected onto room temperature, uncoated glass slides. 
Binding Site 
(polyclonal)?
(294) 
1mg/ml 1:33 
30µg/ml  
anti-sheep/goat 
peroxidase (1:100)  
Abcam 
(polyclonal) 
Ab39364 
0.6mg/ml 1:20 
30µg/ml  
goat/ anti-rabbit 
peroxidase (1:100) 
 
Cayman 
(polyclonal) 
Cayman No: 
10004303 
0.6mg/ml 1:20 
30µg/ml  
goat/ anti-rabbit 
peroxidase (1:100) 
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Cross-sections were cut and used to stain 11 β-HSD1, and myosin heavy chain I 
and IIa. 
Slides were left to air dry for a minimum of 1 h before treatment. Briefly slides 
were fixed in acetone at -20C for 20 minutes, followed by 3 x 30 s washes in 
deionised water. The slides were then permeabilised in 0.5% Triton-X for 5 min 
followed by three 5 min washes in PBS. The muscle samples were then blocked 
for 30 minutes with 5% normal donkey serum. Following which they were 
incubated in appropriate primary antibodies for 60 min, followed by three 5 min 
washes in PBS. The 11 β-HSD1 binding site antibody concentration was 1:100, 
whereas the myosin heavy chain I (Developmental Studies Hybridoma Bank, 
University of Iowa, Dr Blau, A4.840) and IIa (Developmental Studies Hybridoma 
Bank, University of Iowa, Dr Blau, N2.261) antibody concentration were both 
1:25.  The samples were further incubated in appropriately targeted secondary 
fluorescent conjugated antibodies for 30 min [11 β-HSD1, donkey anti-sheep IgG 
568 (red)] and followed by treatment with Alexa Fluor GAMIgM 350 MyHCI (blue) 
and Alexa Fluor GAMIgM 488 MyHCIIa (green) (Invitrogen, Paisley, UK).  
This was followed by three 5 min washes in PBS. Coverslips were mounted in a 
glycerol and mowiol 4–88 solution in 0.2 M Tris-buVer (pH 8.5) with the addition 
of 0.1% 1,4-diazobicyclo-[2.2.2]-octane (DABCO) antifade medium. Muscle cross-
sections were illuminated with a mercury lamp and viewed with a Nikon E600 
microscope with a 40 x 0.75 NA objective. A SPOT RT KE colour 3 shot CCD 
camera (Diagnostic Instruments Inc, MI, USA) was coupled to the microscope for 
digital image capture. In order to visualise the Alexa fluor 350 (blue) and 488 
(green) fluorophores the DAPI UV (340–380 nm) and FITC (465–495) excitation 
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filters were used respectively. Sections stained Alexa fluor 568 (red) were 
examined using a Texas red (540–580 nm) excitation filter. Images were 
processed using Image-Pro Plus 5.1 software (Media Cybernetics, MD, USA) 
(295).  
 
 
 3.4.9. Rodent Models used in this chapter 
C57BL\6 mice were group housed under controlled temperature (21-23oC) and 
light (12:12 light-dark cycle; lights on at 0700h) with ad libitum access to standard 
rodent chow and water.  Body weights were monitored weekly.  Animal 
procedures were approved under the British Home Office Animals (Scientific 
Procedures) Act 1986. 
 
3.5. Statistical methods 
Statistical analysis was performed using Prism for Windows version 5.0 
(GraphPad Software Inc, San Diego, CA, USA) software packages.  Continuous 
data were summarised using means and standard deviations (or standard error of 
mean) if parametrically distributed or medians and inter-quartile ranges if non-
parametrically distributed.  Parametric data was compared using a paired t-test 
and non-parametric data was analysed using a Mann-Whitney test.  Multiple 
comparisons were assessed using one-way analysis of variance (ANOVA), with 
Kruskal-Wallis for non-parametric data. The level for statistical significance was 
p<0.05.  
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3.6. Results 
3.6.1. 11 β-HSD1 activity and mRNA expression in C2C12 myocytes 
Both oxoreductase and dehydrogenase activity of 11 β-HSD1/2 was assessed in 
C2C12 myoblasts and compared to myotubules.  There was minimal 
dehydrogenase activity, indicating that 11 β-HSD2 was not biologically relevant in 
C2C12 myoblasts or myotubules (not shown).  There was a significant increase in 
11 β-HSD1 oxoreductase activity and mRNA expression during myocyte 
differentiation (Figure 3.2).  To ensure myocyte differentiation at a molecular 
level, actin and myogenin mRNA expression was measured which increased 10-
fold and 3-fold, respectively, between myoblast and day 8 myotubules.  These 
changes in the molecular markers of differentiation characterised day 8 
myotubules as having undergone terminal differentiation (see Section 1.2).  The 
mRNA expression of other key genes in glucocorticoid regulation in day 8 C2C12 
myotubules was assessed GRα [0.259 + 0.02 arbitrary units (AU)] and H6PDH 
(2.49 + 0.4 AU). 
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Figure 3.2. 11 β-HSD1 activity (a) and mRNA expression (b) increases during 
differentiation from C2C12 myoblasts to Day 8 myotubules C2C12 (Data shown 
are the mean+SE, n = 5, p** <0.001, p*** = <0.0001). 
 
 
3.6.1.1. The inhibition of oxoreductase activity in C2C12 myotubules   
To ensure the oxoreductase activity documented in Figure 3.2 was secondary to 
11 β-HSD1, Day 8 C2C12 cells were treated with the specific (LJ2) and non-
specific (GE) 11 β-HSD1 inhibitors.  11 β-HSD1 oxoreductase activity in Day 8 
C2C12 myotubules was inhibited by 24 hour treatment with non-specific (GE) and 
specific (LJ2) inhibition of 11 β-HSD1.  Additionally, it was noted that the GRα 
antagonist RU486 had no effect on oxoreductase activity (Figure 3.3).  
 
 
 
 
????
????
???
????
????
???
a b 
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Figure 3.3. 11 β-HSD1 activity in C2C12 myoblast compared to day 8 
myotubules and the effect of treatment with a non-specific11 β-HSD1 inhibitor 
(GE) and specific 11 β-HSD1 inhibitor (LJ2) and the GRα antagonist RU486 (Data 
shown are the mean+SE, n = 4, p NS = non statistically significant, p*** = 
<0.0001). 
 
In the initial phases of the PhD preliminary data assessed the effect of GR 
antagonism and inhibition of 11 β-HSD1 following 8 day continuous treatment (i.e. 
treatments from time of commencement of differentiation to Day 8 differentiation).  
The cell photographs below show that 8 days treatment with RU486 and LJ2 an 
11 β-HSD1 inhibitor lead to significant abnormalities in myotubule formation (from 
myoblast to myotubule).  
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Figure 3.4. The effect of 8 days treatment (initiated at change of media from 
proliferation to differentiation) with the glucocorticoid receptor antagonist RU486 
and the specific 11 β-HSD1 inhibitor LJ2. 
 
Rather than assessing the effect of these treatments over 8 days which had 
significant alterations in myotubule formation in Chapter 4 we decided to focus on 
the short term modulation of 11 β-HSD1 and the GR on myoblasts proliferation 
rate and the effect of short term treatment (24 hours) on fully differentiated Day 8 
myotubules on atrophy/ hypertrophy markers rather than prolonged treatment. 
 
 3.6.2. 11 β-HSD1 activity and mRNA expression in murine 
tissues 
The activity and mRNA expression of 11 β-HSD1 and other key genes for tissue 
specific regulation of glucocorticoid action (GRα and H6PDH) were assessed in 
different muscle groups and compared to that of murine liver and omental fat.  
Liver had the highest 11 β-HSD1 oxoreductase activity when compared to 
quadriceps and tibialis anterior.  However, there was no difference in activity 
between liver and gonadal fat and soleus (Figure 3.5.a).  The high level of 11 β-
HSD1 oxoreductase activity in the soleus may either be due to increased 11 β-
???????? ?????? ????
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HSD1 activity or due to the small weight of tissue which would impact on the 
calculation of activity per mg/tissue (Section 2.8). 11 β-HSD1 mRNA expression 
was higher in liver than in all other tissues (including gonadal fat and soleus), 
Figure 3.5.b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. 11 β-HSD1 activity (a) and mRNA expression (b) in murine liver, 
quadriceps (Quad), tibialis anterior (TA), soleus (SOL) and omental/ gonadal fat 
(OM) (Data shown are the mean+SE, n = 6).  
 
To ensure that the oxoreductase activity measured in tissue was secondary to 11 
β-HSD1, tissues were incubated with GE during the course of the 11 β-HSD1 
????
????
a 
b 
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activity assay.  This led to a significant decrease in oxoreductase activity in both 
liver and quadriceps. 
 
 
 
 
 
 
 
 
Figure 3.6. 11 β-HSD1 oxoreductase activity is reduced in liver and quadriceps 
(Quad) when co-incubated with the non-specific 11 β-HSD1 inhibitor 
glycyrrhetinic acid (GE) during activity assay. n=3, * p<0.05, *** p<0.0001.  
 
3.6.3. mRNA expression of hexose 6 phosphate dehydrogenase and 
the glucocorticoid receptor alpha in murine tissue 
The expression of H6PDH and GRα were assessed in liver, quadriceps, tibialis 
anterior, soleus and gonadal fat.  There were no differences in mRNA expression 
of GRα between tissues.  There was a lower level of mRNA expression of 
H6PDH in quadriceps and soleus when compared with liver (Table 3.2). 
 
 
??
????
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Table 3.2. GRα and H6PDH mRNA expression in murine liver, quadriceps, tibialis 
anterior, soleus and gonadal fat (Data shown are the mean+SE, n = 5). ** 
p<0.001. *** p<0.0001 compared to liver. AU = arbitrary units.  
 
3.6.4. 11 β-HSD1 immunohistochemistry 
In order to assess the localisation of 11 β-HSD1 within skeletal muscle 
immunohistochemistry was performed on young (12 weeks) murine liver (positive 
control) and quadriceps muscle.  Initially the in-house designed binding site 
antibody (294) was used and a fibre specific pattern of staining was observed 
(Figure 3.6.d).  To further evaluate this finding and clarify whether fibre specificity, 
immunohistochemistry was performed using two further 11 β-HSD1 polyclonal 
antibodies [Abcam (Ab39364) and Cayman (10004303)], Figures 3.8 and 3.9, 
respectively.  The fibre specific staining was also present in the quadriceps 
muscle using the Abcam and Cayman polyclonal antibodies.  The staining of 11 
β-HSD1 appeared to be predominantly in the smaller diameter fibres which would 
be characteristic of Type I fibres (slow twitch fibres).  Type I fibres are the most 
resistant to glucocorticoid induced myopathy.  In contrast to other muscle fibres 
(Type II a/b) whose main fuel is glycogen, Type I fibres use fatty acids and 
triglycerides as their major source of fuel (the increase in tissue specific cortisol 
concentrations could play a key role in the activity of hormone sensitive lipase 
which converts diacylglycerol to a fatty acid and diacylglycerol). 
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Figure 3.7. Immunohistochemistry of 11 β-HSD1 using the binding site 11 β-
HSD1 primary antibody (294) (a = negative control liver with isotype control and 
secondary antibody, b = positive control liver with primary 11 β-HSD1 and 
secondary binding site antibody, c = negative control quadriceps with isotype 
control and secondary antibody and d = quadriceps with primary 11 β-HSD1 and 
secondary binding site antibody).   
 
????????????????????????????????????
??????
?????????????????????????????
????????????????????????????????????
???????????
??????????????????????????????????
a b 
c d 
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Figure 3.8. Immunohistochemistry of 11 β-HSD1 using the Abcam (Ab39364) 11 
β-HSD1 primary antibody (a = negative control liver with isotype control and 
secondary antibody, b = positive control liver with primary 11 β-HSD1 and 
secondary Abcam antibody, c = negative control quadriceps with isotype control 
and secondary Abcam antibody and d = quadriceps with primary 11 β-HSD1 and 
secondary Abcam antibody). 
 
 
 
???????????????????????????????????????? ???????????????????????????
??????????????????????????????????? ??????????????????????
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Figure 3.9. Immunohistochemistry of 11 β-HSD1 using the Cayman (10004303) 
11 β-HSD1 primary antibody (a = negative control liver with isotype control and 
secondary antibody, b = positive control liver with primary 11 β-HSD1 and 
secondary Cayman antibody, c = negative control quadriceps with isotype control 
and secondary Cayman antibody and d = quadriceps with primary 11 β-HSD1 
and secondary Cayman antibody). 
 
 
 
 
???????????????????????????????????? ???????????????????????
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3.6.5. Immunoflourescence of 11 β-HSD1 and fibre type specificity in 
skeletal muscle. 
To further assess the apparent fibre specificity seen with immunohistochemistry, 
immunoflourescence was performed on serial sections of isopentane frozen 
skeletal muscle (soleus).  Serial sections were stained for 11 β-HSD1 (Figure 
3.10.a) and fibre type (Figure 3.10.b).  There was no obvious fibre type specificity 
on immunoflourescence and in particular no evidence of specific co-localisation 
with Type I fibres. 
 
 
 
Figure 3.10.  Immunofluorescence of 11 β-HSD1 (red, Figure a) and fibre type 
specificity with antibody for Type I MyHC (Blue, 1) and Type IIa MyHC (green, 2a) 
in soleus muscle (Figure b).  Images are matched and there is no fibre type 
specific localisation of 11 β-HSD1.  
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3.7. Discussion 
11 β-HSD1 is expressed and is biologically active in murine skeletal muscle and 
the C2C12 murine muscle cell line in significant amounts as evident by the 11 β-
HSD1 oxoreductase in all muscle groups tested.  Importantly, the oxoreductase 
activity of 11 β-HSD1 in muscle groups ranged from 40% to 100% that of liver, 
whereas mRNA expression in liver was orders of magnitude greater than that 
seen in muscles.  This highlights the fact that murine 11 β-HSD1 is a very efficient 
enzyme (2) and low levels of mRNA expression may be sufficient to deliver 
significant oxoreductase activity. To ensure that this oxoreductase activity was 
secondary to 11 β-HSD1 in both C2C12 cells and murine tissue, both specific 
(LJ2) and non-specific (GE) inhibitors of 11 β-HSD1 were used, which lead to 
significant decreases in conversion of inactive 11-dehydrocorticosterone to 
biologically active corticosterone.  
We observed significant increases in the activity and mRNA expression of 11 β-
HSD1 during differentiation in the C2C12 murine skeletal muscle cell line, as 
observed previously (157).  There is conflicting evidence for the role of 
glucocorticoids in muscle differentiation.  Nishimura et al. treated C2C12 cells 
with the synthetic glucocorticoid, dexamethasone for 24 hours, which significantly 
increased mRNA expression of several key myogenic differentiation genes 
including myogenin, MyoD1, Myf5 and MRF4 (316).  Aubrey et al. did not, 
however, report any changes on C2C12 differentiation despite retinoic acid 
leading to a downregulation of 11 β-HSD1 (157).   
This tissue specific regulation of glucocorticoid action in skeletal muscle may 
have important implications for the biological effects of glucocorticoids in skeletal 
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muscle.  Within skeletal muscle glucocorticoid excess is associated with 
significant changes in atrophy (upregulation) and hypertrophy (downregulation) 
pathways which lead to glucocorticoid mediated myopathy.   
The effect of exposure of skeletal muscle to supraphysiological active 
glucocorticoid concentration in serum (in endogenous and exogenous Cushing’s 
syndrome) may be further affected by 11 β-HSD1 activity within muscles.  Muscle 
specific activation of the inactive glucocortoid cortisone (11-
dehydrocorticosterone in rodents) which is produced from cortisol (corticosterone) 
by the dehydrogenase activity of 11 β-HSD2 in the kidney (which is known to be 
significantly elevated in Cushing’s syndrome) (317) may lead to a more significant 
phenotype. 
Levels of 11 β-HSD1 oxoreductase activity were particularly elevated in soleus 
muscle which is a Type I fibre rich muscle.  This could either be due to elevated 
levels of 11 β-HSD1 in type I fibres or a product of the method of calculation of 
oxoreductase activity which may exaggerate the oxoreductase activity of small 
amounts of tissue due to increased surface area to weight ratios (Section 2.8). 
Immunohistochemistry revealed evidence of a specific subset of fibres staining 
greater for 11 β-HSD1 than others and following review with our Sports and 
Exercise physiology colleagues, we attempted to co-stain 11 β-HSD1 and Myosin 
heavy chains to further assess this.  Muscle fibres can be divided into a number 
of subgroups including slow twitch oxidative (Type I fibres), fast twitch oxidative 
(Type IIa fibres) and fast twitch glycolytic (Type IIx or IIb) (Table 1.1).  Type I 
fibres contain high levels of slow isoform contractile proteins, high volumes of 
mitochondria, high levels of myoglobin and capillary densities and a high 
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oxidative enzyme capacity (14).  Type IIa fibres are characterised by fast 
contraction with high oxidative capacity.  Type IIb fibres are characterised by low 
volumes of mitochondria, high glycolytic enzyme activity, high myosin ATPase 
activity, increased rate of contraction and low fatigue resistance (14) (Table 1.1). 
To assess if the fibres which stained preferentially for 11β-HSD1 were indeed 
Type I fibres, we performed immunoflourescence and co-localisation using Type I 
MyHC (i.e. Type I fibres).  There was no obvious pattern of co-staining in these 
studies, however, it should be highlighted that we had difficulties with auto-
flourescence using the Binding site 11 β-HSD1 antibody and future studies are 
going to further examine this fibre specificity using alternative 11 β-HSD1 
antibodies. 
Chapters 4 and 5 of this thesis will examine the role of 11 β-HSD1 in skeletal 
muscle related to glucocorticoid mediated myopathy and age related 
sarcopaenia.  
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Chapter 4 
The role of 11 β-HSD1 in glucocorticoid mediated 
myopathy 
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4.1. Introduction 
Glucocorticoids affect every organ system with the main physiological and 
pathophysiological effects being on energy metabolism, bone, connective tissue 
(including muscle) and cardiovascular, immune, central nervous, gastrointestinal 
and endocrine systems (130).   
Excess circulating cortisol either secondary to exogenous or endogenous sources  
[Cushing’s syndrome (CS)] is associated with proximal muscle weakness (130). 
Several clinical studies have examined muscle function, histology and 
metabolism in patients with endogenous and exogenous glucocorticoid (GC) 
related myopathy (103, 107, 108, 190, 191).  The effects of GCs on muscle 
appear to be related to dose, duration and type of steroid (192). Different 
sensitivities of skeletal muscle fibre types also play an important role in the 
development of myopathy (193).  Muscle atrophy has been widely associated 
with glucocorticoids treatment in multiple experimental models, in vitro (194-199) 
and in vivo studies of rodent (84, 141, 143, 200-210) and human skeletal muscle 
(96, 101-108, 191).  Type II fibre atrophy is the classically described histological 
abnormality reported in GC mediated myopathy (104, 107, 189, 191).  In the 
majority of studies Type I fibres generally display little, if any, abnormalities.    
 
4.1.1. Molecular pathways associated with glucocorticoid myopathy 
Many molecular pathways have been described as playing an important role in 
the development of GC mediated myopathy including abnormalities in protein 
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metabolism, myostatin, atrophy related genes, collagen metabolism, 
mitochondrial function and myosin heavy chain isoform synthesis and 
degradation which are covered in detail in Section 1.5.  Areas of glucocorticoid 
mediated myopathy which will be assessed further in this chapter, and 
summarised below, include atrophy related genes (particularly the ATP-ubiquitin-
protease pathway), hypertrophy pathways (insulin/ IGF-I-AI3K-Akt-mTOR, 
particularly the role of IRS-1 and its phosphorylation) and the effects of GC on 
myocyte proliferation rates.  
 
4.1.1.1. Atrophy pathways in glucocorticoid mediated myopathy 
The atrophy pathways include the lysosomal proteases (eg. Cathepsins), the 
calcium dependent protease calpain family and the ATP-dependent ubiquitin-
proteasome pathway (231) (described in detail in Section 1.5.3.4). The pathway 
primarily associated with muscle atrophy and the breakdown of myofibrillar 
protein is the ATP-dependent ubiquitin-protease pathway (235) which include the 
E1 (ubiquitin activating enzymes), E2 (ubiquitin-conjugating enzymes) and E3 
(Ubiquitin ligase).  Within skeletal muscle, MAFBX and MURF-1 are two important 
E3 ubiquitin ligases clearly associated with many models of muscle atrophy such 
as sepsis (79, 80) and disuse atrophy (81). Translocation of the forkhead 
transcription factor (FOXO-1) into the cell nucleus increases MAFbx and MURF-1 
mRNA expression (84).  Phosphorylation of FOXO-1 by Akt sequesters FOXO-1 
from the cell nucleus to the cytoplasm by 14-3-3 proteins (85) preventing MAFbx 
and MURF-1 upregulation.  However, GCs dephosphorylate FOXO-1 allowing 
subsequent translocation to the cell nucleus.  
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4.1.1.2. Apoptotic pathways in glucocorticoid mediated myopathy 
Caspase-3 is an important regulator of glucocorticoid regulated myocyte 
apoptosis, Orzechowski et al. have shown a relationship between caspase-3 and 
apoptosis in skeletal muscle following longer periods of glucocorticoid exposure 
(for example 8 days rather than 24 hours) (318).  There is no evidence of GC 
regulating the effect of short term treatment on caspase-3 mRNA expression but 
this may not be surprising as Caspase-3 is an effector caspase (319).  An effector 
caspase depends on upstream initiator caspases (caspase 8, 9, 12) to be cleaved 
and activated which then carries out the proteolytic events that result in cellular 
breakdown and demise (319) which may take a number of days of GC exposure 
to modify expression (caspase 8 was increased after 8 days GC treatment in rats) 
(320).   
 
4.1.1.3. Hypertrophy pathways in glucocorticoid mediated myopathy 
Four major signalling pathways regulate protein synthesis and cell growth 
including the energy status of the cell (244); the amino acid sensing pathway 
(245); mechanotransduction (246, 247) and the insulin/ insulin-like growth factor I 
(IGF-I) system (245).  
The insulin/ IGF-I-AI3K-Akt-mTOR signalling pathway has been described in 
detail in Section 1.5.3.6.1.  Briefly, binding of insulin to its cell surface receptor 
leads to a conformational change and tyrosine autophosphorylation. 
Consequently, the insulin receptor substrate (IRS) family of adaptor proteins are 
recruited to the intracellular domain of the receptor and are phosphorylated at 
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multiple tyrosine residues by the receptor tyrosine kinase to permit the docking of 
phosphatidylinositol-3-kinase (PI3K) and subsequent generation of PI(3,4,5)P3. 
Generation of this second messenger acts to recruit the Akt/PKB family of 
serine/threonine kinases to the plasma membrane where they are then activated 
(250). The molecular mechanisms underpinning insulin resistance are complex 
and variable. Serine/threonine phosphorylation of IRS1 (in particular Ser307 
phosphorylation) has been shown to negatively regulate insulin signalling through 
multiple mechanisms including decreased affinity for the insulin receptor and 
increased degradation (253, 254). The interaction of glucocorticoids and the 
insulin signalling cascade has only been examined in a small number of studies 
that have offered variable explanations for the induction of insulin resistance 
(255-258). The role of serine phosphorylation and the impact of prereceptor 
glucocorticoid metabolism have not been explored. 
The insulin/ IGF-I-AI3K-Akt-mTOR signalling cascade can also inhibit several 
regulators of muscle atrophy (196). In rats, 5 days of treatment with cortisone 
increased the insulin receptor (IR) protein by 36%, but reduced skeletal muscle 
total IR tyrosine kinase phosphorylation by 69%, which was attributed to a loss in 
the pool of IR undergoing tyrosine phosphorylation. Although muscle IRS-1 
tyrosine phosphorylation was unaffected by GC treatment, GCs were associated 
with a 50% reduction in total IRS-1 protein content (255).  Thus, GC myopathy 
may stem, in part from a GC mediated decrease in the anabolic IR-IRS-1-PI3K-
Akt signalling pathway. 
 
Chapter 4   Glucocorticoid myopathy 
 129 
4.1.1.4. Myocyte proliferation in glucocorticoid mediated myopathy 
There are conflicting data with regard to the effect of GC treatment on myoblast 
proliferation rate.  Some studies have reported an increase in myoblast 
proliferation rate with GC treatment (217, 218) (particularly with low dose GC 
treatment), others reporting no effect of treatment with glucocorticoids (219) or a 
dose dependent decrease in myoblast proliferation (220).  Te Pas et al. reported 
that GCs are capable of attenuating proliferation and differentiation of myocytes in 
a dose response manner by altering mRNA levels of myoD1, myf-5 and myogenin 
(220).  When C2C12 myoblasts were incubated with dexamethasone or α-methyl-
prednisolone for 9 days, the cell proliferation rate was reduced in a dose 
dependent manner despite increasing the mRNA expression of MyoD1 and myf-5 
(220).  Evidence suggests that GCs have an impact on myoblast proliferation; 
however data are conflicting and precise mechanisms underpinning the GC 
manipulation of myogenic growth factors remain to be determined.  The reported 
differences may be due to a number of factors including the use of different 
experimental models, variable glucocorticoid doses and ligands (e.g. 
dexamethasone, corticosterone and alpha methylprednisolone), duration of 
myoblast proliferation assessed and proliferation assay used.    
 
4.1.2. 11 β-HSD1 within muscle 
Within tissues, GC levels are regulated at the pre-receptor level by the isozymes 
of 11 β-hydroxysteroid dehydrogenase (11 β-HSD), which are located in the 
endoplasmic reticulum (ER). 11 β-HSD1 in vivo acts predominantly as an 
oxoreductase converting inactive cortisone into active cortisol (2). The role of 11 
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β-HSD1 in skeletal muscle is less well-defined and has only been investigated in 
a small number of studies over recent years, which are discussed in Section 
1.4.6. 
 
4.2. Hypothesis 
In myocytes, 11 β-HSD1 is increased with glucocorticoid exposure and this is 
associated with alterations of genes associated with glucocorticoid mediated 
myopathy.  Glucocorticoids have effects on myoblast proliferation and modulation 
of 11 β-HSD1 may alter this. 
 
4.3. Strategy of Research and Aims 
C2C12 myoblasts and Day 8 myotubules were used to assess the role of 11 β-
HSD1 in glucocorticoid mediated myopathy, which included: 
a. Assessment of 11 β-HSD1 activity and mRNA expression following treatment 
with the active glucocorticoid [corticosterone, (B)] and the inactive glucocorticoid 
[11-dehydrocorticosterone (A)], which requires 11 β-HSD1 activation for biological 
activity. 
b. Assessment of the mRNA expression of key glucocorticoid regulated markers 
of atrophy following treatment with the active glucocorticoid (corticosterone, B) 
and the inactive glucocorticoid (11-dehydrocorticosterone, A). 
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c. Assessment of the effect of glucocorticoid treatment and modulation of 11 β-
HSD1 on the insulin/ IGF-I-AI3K-Akt-mTOR signalling pathway (in particular IRS1 
and Ser307 phosphorylation of IRS1). 
d. The effect of glucocorticoids and the modulation of 11 β-HSD1 on C2C12 
myoblast proliferation. 
 
4.4. Methods 
4.4.1. C2C12 cell culture 
The C2C12 cell line is a well-established model of both skeletal muscle 
proliferation and differentiation which has been widely used in research with 
regard to muscle atrophy and glucocorticoid induced myopathy (84, 86, 195, 
197).  Cryofrozen C2C12 myoblasts (passage 17) were purchased from ECACC 
(Salisbury, UK), Once myoblasts had reached 60-70% confluence, differentiation 
was initiated by replacing proliferation media with DMEM with high glucose and L-
glutamine (PAA, Somerset, UK) supplemented with 5% horse serum. 
Differentiation media was replaced every 48 hours. After 8 days, myoblasts had 
fused to form multinucleated myotubes. 
 
4.4.1. RNA extraction and cDNA synthesis 
Total RNA was extracted from monolayer cells using TRIreagent (Sigma-Aldrich, 
Dorset, UK).  The procedure was carried out according to protocol provided with 
the reagent (Sigma-Aldrich, Dorset, UK).  The quantity of RNA was measured 
using NanoDrop ND-1000 UV-Vis Spectrophotometer (Thermofisher, Surrey, 
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UK). The reverse transcription process was carried out using Applied Biosystems 
High-Capacity Reverse Transcription Kit (Applied Biosystems, Warrington, UK) 
For a full description of methods used see Section 2.2 and 2.3. 
 
4.4.2. Quantitative or Real Time PCR 
Quantitative PCR was carried out using Applied Biosystems Reagents and gene 
mRNA expression assays (AssayonDemand) (Applied Biosystems, Warrington, 
UK).  PCRs for genes of interest and for 18s housekeeping genes were carried 
out in singleplex. Data were expressed as Ct values (Ct=cycle number at which 
logarithmic PCR plots cross a calculated threshold line).  And used to determine 
ΔCt values (ΔCt = (Ct of the target gene) – (Ct of the housekeeping gene), lower 
ΔCt values reflecting higher mRNA mRNA expression.  Data are expressed as 
arbitrary units using the following transformation [mRNA expression in arbitrary 
units = 1000*(2-ΔCt)]. For a full description of methods used see Section 2.6. 
 
4.4.3. Protein Extraction and concentration measurement on 
monolayer cells and explants 
Monolayer cells were lysed in Radio-Immunoprecipitation (RIPA) buffer 
containing detergent.  The lysate was freeze-thawed to further break open cell 
membranes and the insoluble components removed by centrifugation.  
Mouse tissue was quickly harvested and snap frozen using liquid nitrogen. 
Samples were then transferred to a -80°C freezer until required. Proteins were 
extracted by homogenising approximately 20mg of tissue in 1.5mL of RIPA buffer 
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using a mechanical homogeniser. Cell lysates were then incubated at -80°C for 
20 mins, thawed out on ice, then centrifuged at 14,000 g for 15 mins at 4°C.  
The supernatant, from both monolayers and tissue explants, containing soluble 
proteins was measured using BioRad RC DC protein assay (BioRad, Herts, UK). 
5µl of protein sample or standard were added per well in duplicate.  The ranges of 
protein standards were 0, 0.25, 0.5, 1, 2, 4, 8 and 10mg/mL of Bovine Serum 
Albumin (BSA) in RIPA buffer.  25ml of solution A (alkaline copper tartrate) (with 
20µl of solution S per ml of solution A) was initially added followed by 200ml of 
solution B (Folin reagent).  Once the solutions were added the plate was 
incubated at room temperature for 10 minutes and the absorbance read at 690nm 
on a Victor3 1420 multilabel counter (PerkinElmer, Beaconsfield, Bucks, UK).  
Protein concentration in the sample was then calculated according to the slope of 
the standards line. For a full description of methods used see Section 2.7. 
 
4.4.4. 11 β-hydroxysteroid dehydrogenase type 1 and 2 enzyme 
activity assay 
11 β-hydroxysteroid dehydrogenase type 1 and 2 enzyme activity assay was 
carried out on both monolayers and whole tissue explants. Incubations were 
carried out at 37°C under a 5% CO2 atmosphere for 20 minutes to 2 hours 
depending on the cell/tissue type. Enzyme activity was expressed in pmols of 
steroid converted per mg of protein per hour (pmol/mg/h) for monolayers or 
steroid converted per mg tissue per hour (explants). For a full description of 
methods used see Section 2.8. 
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4.4.5. Proliferation assays 
The Cell Titre 96 ® AQueous Non-Radioactive Cell proliferation assay is a 
homogenous, colorimetric method for determining the number of viable cells in 
proliferation, cytotoxicity or chemosensitive assays.  The Cell Titre 96 ® AQueous 
Assay is composed of solutions of a tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-“H-
tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine 
methosulfate) PMS. The assay was performed according to the manufacturers 
protocol.  C2C12 cells were trypsinised and counted, they were then seeded at a 
concentration of approximately 1000 per well on 96 well plate (in a volume of 100 
µl) and left for 24 hrs.  After 24 hours treatments were added to cells (e.g. 
glucocorticoids, IGF-I) and the cells were incubated in treatment for another 24 
hours at 37°C. For a full description of methods used see Section 2.11.  IGF-I 
was used as a positive control in all experiments as it is well described as leading 
to myoblast proliferation in C2C12 cells (297). 
 
 4.4.6 Immunoblotting 
Immunoblotting allows the measurement of relative amounts of a specific protein 
in a mixed protein sample (296). The theory and procedure is covered in detail in 
Section 2.10. Briefly, 20μg of protein was mixed with an appropriate amount to 5 
x loading buffer and boiled for 5 minutes. Samples were loaded into a 4-20% 
gradient SDS-PAGE gel (BioRad, Herts, UK) and run at 200V for 1 h - 1 h 30 
minutes. Transfer of proteins to nitrocellulose membrane (GE Healthcare, Bucks, 
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UK) was conducted at 140mA for 1-2 h depending on the size of the protein of 
interest. Efficient transfer was assessed by incubating the membrane in ponceau 
stain with agitation for 60 seconds, and then rinsed with water to allow 
visualisation of the protein bands. Electrophoresis and protein transfer was 
carried out in BioRad mini protein 3 apparatus (BioRadert, UK). Membranes were 
blocked in 10mL of blocking buffer for 1 hour at room temperature with constant 
agitation, then incubated with primary antibody overnight at 4°C on an orbital 
shaker. Membranes were washed with 100mL of washing buffer 3 times for 15 
minutes. Secondary antibody incubation was conducted at room temperature with 
constant agitation. The membrane was then washed with 100mL of washing 
buffer 3 times for 15 minutes. Bound antibody was detected using Enhanced 
Chemiluminescence (ECL, GE Healthcare, Bucks, UK). The reaction mixture was 
set up by combining substrate A with substrate B at a 50:50 ratio (final volume: 
1mL per membrane). Following equilibration for 5 minutes, 1mL was added per 
membrane and left to incubate for 2 minutes before the membrane was placed 
between two plastic sheets in a photo cassette. Photographic film (PerkinElmer, Surrey, UK) was placed 
over the membrane in the dark and exposed for 30 seconds to 3 h, then 
developed on Compact X4 automatic film processor (Xograph Imaging Systems, 
Gloustershire, UK). Membranes were routinely stripped to remove bound 
primary/secondary antibodies by incubating the membrane in stripping buffer (2% 
SDS, 100mM β-mercaptoethanol, 50mM Tris, pH 6.8) at 50°C for 1 h with gentle 
agitation. Membranes were then washed with 100mL of washing buffer 3 times 
for 15 minutes before being re-probed with a different primary antibody. 
Immunoblots were evaluated by integrating densitometry using GeneSnap and 
GeneTool (Chemigenius Gel Documenting System, Syngene, Cambridge, UK). 
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Equal loading was confirmed by reprobing membrane with anti-β-actin antibody 
conjugated to HRP and visualized as described above. 
Antibodies used included Primary antiIRS1, anti-p-ser307IRS1 antibodies 
(Upstate, Dundee, UK), secondary Ab (Dako, Glostrop, UK) used at a dilution of 
1/5,000.  Membranes were reprobed for β-Actin primary and secondary Ab 
(Abcam plc, Cambridge, UK) at a dilution of 1/5,000.  
 
4.4.7. Statistical Methods 
Statistical analysis was performed using Prism for Windows version 5.0 
(GraphPad Software Inc, San Diego, CA, USA) software packages.  Continuous 
data were summarised using means and standard deviations (or standard error of 
mean) if parametrically distributed or medians and inter-quartile ranges if non-
parametrically distributed.  Parametric data was compared using a paired t-test 
and non-parametric data was analysed using a Mann-Whitney test.  Multiple 
comparisons were assessed using one-way analysis of variance (ANOVA), with 
Kruskal-Wallis for non-parametric data and Dunn’s multiple comparison test. The 
level for statistical significance was p<0.05. 
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4.5. Results 
4.5.1. 11 β-HSD1 activity and mRNA expression following treatment 
with the active glucocorticoid [corticosterone, (B)] 
Day 8 C2C12 myotubules were treated for 24 hours with increasing doses of 
corticosterone (B).  Following this 11 β-HSD1 mRNA expression was determined 
and a 20 minute 11 β-HSD1 oxoreductase activity assay was performed.  There 
was a dose dependent increase in both 11 β-HSD1 oxoreductase activity (Figure 
4.1.a) and mRNA expression (Figure 4.1.b) with increasing doses of B.  
Therefore, treatment with B leads to increased generation of intracellular active 
glucocorticoid via increased activity of 11 β-HSD1 in myotubules.  
 
 
 
Figure 4.1. 11 β-HSD1 activity (a) and mRNA expression (b) with increasing 
doses of corticosterone (B). * p<0.05, ** p<0.001, *** P<0.0001, n=4 experiments. 
Data shown are the mean+SE. p trend for increasing dose of B effect on activity 
and mRNA expression = p<0.001.  
  
4.5.2. The effect of increasing doses of the active glucocorticoid 
(corticosterone) on atrophy related genes 
?? ??
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To show that the increased GC exposure with increased 11 β-HSD1 expression 
was associated with upregulation of classic markers of glucocorticoid mediated 
myopathy, the mRNA expression of MAFbx and MURF-1 (GC regulated atrophy 
genes) and Caspase 3 (a key regulator of GC mediated apoptosis which is 
upregulated with chronic treatment, but may not be changed with short-term 
treatment), was analysed.  
Day 8 C2C12 myotubules were treated for 24 hours with increasing doses of 
corticosterone (B).  Following this 11 β-HSD1 (Figure 4.2.a), MAFbx (Figure 
4.2.b) and MURF-1 (Figure 4.2.c) and Caspase 3 (Figure 4.2.d) mRNA 
expression were assessed.  There was an upregulation in both MAFbx and 
MURF-1 with GC treatment but no change in Caspase 3. 
 
 
?? ??
?? ??
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Figure 4.2. The effect of increasing doses of corticosterone (B) on mRNA 
expression of 11 β-HSD1 (a), MAFbx (b) and MURF-1 (c) (both of which are key 
glucocorticoid response atrophy genes). Figure (d) shows the response of 
Caspase 3 (a key regulator of GC mediated apoptosis in chronic treatment). NS 
non significant, ** p<0.001, *** P<0.0001, n=3-4 experiments. Data shown are the 
mean+SE. 
 
4.5.3. 11 β-HSD1 activity and mRNA expression following treatment 
with the inactive glucocorticoid 11-dehydrocorticosterone (A). 
However, as the previous results could be interpreted solely as the effect of the 
active GC (B) treatment rather than the effect of tissue specific regulation by 11 β-
HSD1 of GC exposure we repeated the previous experiments with 11-
dehydrocorticosterone (A) instead of B.  11-dehydrocorticosterone (A) requires 11 
β-HSD1 oxoreductase activity to produce active corticosterone (B) in order to 
exert its biological effects as a glucocorticoid at the level of GRα. Day 8 C2C12 
myotubules were treated for 24 hours with increasing doses of 11-
dehydrocorticoserone (A).  Following this 11 β-HSD1 mRNA expression was 
determined and a 20 minute 11 β-HSD1 oxoreductase activity assay was 
performed.  There was an increase in both 11 β-HSD1 oxoreductase activity 
(Figure 4.3.a) and mRNA expression (Figure 4.3.a) with higher concentrations of 
A.  Therefore, following treatment with A 10-6 and 10-5 there is a significant 
increase in the generation of B, which in turn leads to increased generation of 
intracellular active glucocorticoid via 11 β-HSD1.  
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Figure 4.3. 11 β-HSD1 activity (a) and mRNA expression (b) increases with 
increasing doses of the inactive glucocorticoid A. NS non significant, ** p<0.001, 
n=3 experiments. Data shown are the mean+SE. p trend for increasing dose of A 
effect on activity (p<0.0001)and mRNA expression (p<0.001).  
 
4.5.4.  The effect of increasing doses of the inactive glucocorticoid 
[11-dehydrocorticosterone (A)] on atrophy related genes. 
To show that the increased GC via the oxoreductase activity of 11 β-HSD1 was 
associated with upregulation of classic markers of glucocorticoid mediated 
myopathy, MAFbx, MURF-1 and Caspase 3 mRNA expression were analysed.   
Day 8 C2C12 myotubules were treated for 24 hours with increasing doses of A.  
Following this the mRNA expression of 11 β-HSD1 (Figure 4.4.a), MAFbx (Figure 
4.4.b) and MURF-1 (Figure 4.4.c) and Caspase 3 (Figure 4.4.d) were assessed.  
At doses of A 10-6 and 10-5 there was an increase in glucocorticoid mediated 
atrophy genes.  This can be interpreted as the treatment with 11-
dehydrocorticosterone (A) leading to generation of corticosterone (B) via 11 β-
HSD1, which leads to activation of GC mediated atrophy genes.  Therefore, 11 β-
HSD1 may play an important role in glucocorticoid mediated myopathy. 
???
???
???
?? ??
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Figure 4.4. The effect of increasing doses of 11-dehydrocorticosterone on mRNA 
expression of 11 β-HSD1 (a), MAFbx (b) and MURF-1 (c) (both of which are key 
glucocorticoid response atrophy genes).  Figure (d) shows the response of 
Caspase 3 (a key regulator of GC mediated apoptosis in chronic treatment). NS 
non significant, * p<0.05, ** p<0.001, *** P<0.0001, n=3-4 experiments. Data 
shown are the mean+SE. 
 
 
 
 
 
?? ??
?? ??
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4.5.5. Effect of treatment with glucocorticoids and modulation of 11 
β-HSD1 on total IRS1 and pSer307IRS1 
The insulin/ IGF-I-AI3K-Akt-mTOR signalling pathway increases protein synthesis 
(240, 248, 249) and is the key regulator of muscle insulin sensitivity. The insulin/ 
IGF-I-AI3K-Akt-mTOR signalling pathway can also inhibit several regulators of 
muscle atrophy (196).  In collaboration with members of our group (Dr Stuart 
Morgan and Dr Jeremy Tomlinson) who were assessing the role of 
glucocorticoids and 11 β-HSD1 in insulin resistance in skeletal muscle (in 
particular the effect on IRS1 and its phosphorylation status), the effect of 
glucocorticoids and modulation of 11 β-HSD1 on the insulin/ IGF-I-AI3K-Akt-
mTOR signalling hypertrophy pathway was assessed.   Using Day 8 C2C12 
myotubules, treated with increasing doses of corticosterone (B) for 24 hours, total 
IRS1 and pser307 IRS1 protein content was assessed.  
The role of the insulin/ IGF-I-AI3K-Akt-mTOR signalling pathway in insulin 
sensitivity has been discussed in detail in Section 1.5.3.6.1. Importantly, 
Serine/threonine phosphorylation of IRS1 (in particular Ser307 phosphorylation) 
has been shown to negatively regulate insulin signalling through multiple 
mechanisms including decreased affinity for the insulin receptor and increased 
degradation (253, 254). There was a dose dependent decrease in total IRS1 and 
a dose dependent increase in pser307 IRS1 content (which is a known to 
negatively regulate insulin signalling, therefore decreasing downstream 
hypertrophy signals) (Figure 4.5). 
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Figure 4.5. The effect of increasing doses of corticosterone (B) on total IRS1 and 
p-ser307 IRS1 protein content on Day 8 C2C12 myotubules. * p<0.05, ** p<0.00, 
B = corticosterone, nM = nanomolar.  N=4-6 experiments  
 
 
To further assess the role of tissue specific regulation of glucocorticoid activity by 
11 β-HSD1 on the insulin signalling cascade Day 8 C2C12 cells were treated with 
corticosterone (B), 11–dehydrocorticosterone (A) (an inactive GC unless 
converted to B via 11 β-HSD1) and A co-incubated with a non-specific 11 β-HSD1 
inhibitor (glycyrrhetinic acid, GE). Total IRS1 and p-ser307 IRS1 protein content 
was then assessed. There was a decrease in total IRS1 and increase in pser307 
IRS1 content (which is a known to negatively regulate insulin signalling, therefore 
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decreasing downstream hypertrophy signals) in cells treated with A and B, which 
was reversed on treatment with the 11 β-HSD1 inhibitor GE (Figure 4.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. The effect of corticosterone (B, 250nM), 11 dehydrocorticosterone 
(A,250nM) and co-incubation of A and the non-specific 11 β-HSD1 inhibitor (GE, 
2.5μM) on total IRS1 and p-ser307 IRS1 protein content on Day 8 C2C12 
myotubules. * p<0.01 compared to control, † p<0.01 compared to A/ and B 
treatment, N=4-6 experiments.  
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4.5.6. The effect of treatment with the active glucocorticoid 
(corticosterone) on myoblast proliferation rate. 
To assess the impact of glucocorticoids on myoblast proliferation C2C12 
myoblasts were treated with increasing doses of B and IGF-1 100ng/ml (as a 
positive control) for 48 hours to assess the impact on myoblast proliferation rates 
(assessed using the Cell Titre 96 ® AQueous Non-Radioactive Cell proliferation 
assay). B10-5 lead to decreased proliferation rates.  Treatment with IGF-I 
100ng/ml was associated with increased proliferation rates (positive control).  Co-
incubation of cells with IGF-I 100ng/ml (IGF100) and B10-5 leads to a significant 
decrease in the proliferation rate of C2C12 myoblasts compared with IGF-I 
treatment. Therefore, B can inhibit the proliferative effect of IGF-I. 
 
 
 
Figure 4.7. Effect of 48-hour treatment with increasing doses of corticosterone 
(B) on C2C12 myoblast proliferation rate.  Relative proliferation rate compared to 
controls at 48 hours (a) and trend in raw proliferation counts over 2 days (b) are 
represented. *** p<0.0001, n=5 experiments. Data shown are the mean+SE. 
 
????
????
?? ??
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4.5.7. Effect of treatment with the inactive glucocorticoid 11-
dehydrocorticosterone (A) on C2C12 myoblast proliferation rate. 
The effect of 48-hour co-treatment with the inactive glucocorticoid 11-
dehydrocorticosterone (A) (which requires 11 β-HSD1 to activate to 
corticosterone) on C2C12 myoblast proliferation rate was assessed. There was 
no effect of treatment with A on proliferation rates which may be explained by the 
low levels of 11 β-HSD1 mRNA expression and oxoreductase activity in C2C12 
myoblasts, therefore not generating significant levels of active intracellular 
glucocorticoid (see Figure 3.2, Section 3.5.1). 
 
 
 
 
 
 
 
 
 
Figure 4.8. Effect of 48-hour treatment with the inactive glucocorticoid 11-
dehydrocorticosterone (A) (which requires 11 β-HSD1 to activate to 
corticosterone) on C2C12 myoblast proliferation rate.  Relative proliferation rate 
compared to controls at 48 hours. There was no effect of treatment with A on 
proliferation rates. NS = p non significant compared to controls, *** p<0.0001 (n=5 
experiments). Data shown are the mean+SE.  IGF100 = IGF-I 100ng/ml, positive 
control. 
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4.5.8. The effect of modulation of 11 β-HSD1 and glucocorticoid 
receptor antagonism on myoblast proliferation rate. 
C2C12 myoblasts were treated with the glucocorticoid receptor antagonist 
RU486, selective and non-selective 11 β-HSD1 inhibitors (LJ2 and glycyrrhetinic 
acid, respectively) and IGF-I 100ng/ml (as a positive control) for 48 hours to 
assess the impact on myoblast proliferation rates.  
 
 
 
Figure 4.9. Effect of 48-hour treatment with the glucocorticoid receptor antagonist 
RU486 and specific and non-specific 11 β-HSD1 inhibitors (LJ2 and glycerrhetinic 
acid, respectively) on C2C12 myoblast proliferation rate.  Relative proliferation 
rate compared to controls at 48 hours (a) and trend in raw proliferation counts (b) 
over 2 days are represented. Glucocorticoid receptor antagonism leads to 
decreased proliferation rates and specific and non-specific 11 β-HSD1 inhibition 
leads to an increase in the proliferation rates of C2C12 myoblasts similar to that 
seen in the positive control group (IGF-I 100ng/ml, IGF100). p NS = non 
significant, ** p<0.001, *** p<0.0001, n=5 experiments. Data shown are the 
mean+SE. 
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4.5.9. Effect of 48-hour co-treatment with corticosterone (B) and 
glucocorticoid receptor antagonist and 11 β-HSD1 inhibition on 
C2C12 myoblast proliferation rate. 
The effect of co-incubation of corticosterone with 11 β-HSD1 inhibitors (GE and 
LJ2) and GRα antagonism (RU486) on myoblast proliferation was assessed.  As 
treatment with B10-5 was associated with a decrease in proliferation rate we 
assessed the effect of B10-5 co-incubation with GE, LJ2 and RU486. 
 
 
 
 
Figure 4.10. Effect of 48-hour co-incubation with corticosterone (B) and 
glucocorticoid receptor antagonist RU486, and specific and non-specific 11 β-
HSD1 inhibitors (LJ2 and glycerrhetinic acid, respectively) on C2C12 myoblast 
proliferation rate (a).  Relative proliferation rate compared to controls at 48 hours. 
High dose corticosterone (B10-5) treatment leads to decreased proliferation rates 
when combined with glucocorticoid receptor antagonism and specific and non-
specific 11 β-HSD1 inhibition (a). Figure (b) represents the effect of 48-hour co-
treatment with increasing doses of corticosterone (B10-7/-6/-5) and specific 11 β-
HSD1 inhibitor (LJ2) on C2C12 myoblast proliferation rate. There is a dose 
dependent decrease in proliferation rates with increasing doses of corticosterone 
(B) treatment (b), indicating that treatment with B can reverse the positive effects 
???
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on proliferation of 11 β-HSD1 inhibition. *p<0.05, ** p<0.001, *** p<0.0001, n= 5 
experiments. Data shown are the mean+SE.  
 
 
4.6. Discussion 
Our data show that 11 β-HSD1 activity and mRNA expression is increased with 
glucocorticoid exposure in C2C12 cells and that this increase in 11 β-HSD1 is 
associated with upregulation of classical GC related atrophy genes (MAFbx and 
MURF-1).  Importantly, to highlight that these changes were not solely related to 
treatment with the active GC corticosterone and that 11 β-HSD1 had an important 
role to play in GC mediated myopathy C2C12 cells were also treated with the 
inactive GC 11-dehydrocorticosterone (A) which is dependent on conversion by 
11 β-HSD1 to corticosterone for its biological activity.  Treatment with A was also 
associated with increased 11 β-HSD1 mRNA expression and activity and also the 
upregulation of genes associated with glucocorticoid mediated atrophy (which 
one can assume were upregulated via the intracellular conversion of A to B by 11 
β-HSD1). This upregulation of 11 β-HSD1 in muscle following exposure to GCs 
may be important as in clinical practice the effect of exposure of skeletal muscle 
to supraphysiological glucocorticoid concentrations in serum (in endogenous and 
exogenous Cushing’s syndrome) may be further affected by 11 β-HSD1 activity 
within muscles.  Muscle specific activation of the inactive glucocorticoid cortisone 
(11-dehydrocorticosterone in rodents) which is produced from cortisol 
(corticosterone) by the dehydrogenase activity of 11 β-HSD2 in the kidney (which 
is known to be significantly elevated in Cushing’s syndrome) (317) may lead to a 
more severe muscle phenotype. 
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MAFBX and MURF-1 are increased in the C2C12 murine skeletal muscle cell line 
by treatment with A and B. As discussed in Section 1.5.3.4, MAFbx and MURF-1 
are two important E3 ubiquitin ligases clearly associated with many models of 
muscle atrophy such as sepsis (79, 80) and disuse atrophy (81) . Translocation of 
the forkhead transcription factor (FOXO-1) into the cell nucleus increases MAFbx 
and MURF-1 mRNA expression (84).    Phosphorylation of FOXO-1 by Akt 
sequesters FOXO-1 from the cell nucleus to the cytoplasm by 14-3-3 proteins 
(85) preventing MAFbx and MURF-1 upregulation.  However, GCs 
dephosphorylate FOXO-1 allowing subsequent translocation to the cell nucleus. 
GCs target MAFbx via FOXO-1 and FOXO-3, leading to increased MAFbx 
expression (84, 239). GCs upregulate MURF-1 expression in vivo and in vitro (84, 
86, 239, 240) through the co-binding of the GR and FOXO-1 with the GRE and 
Fbox response element (FBE) found on MURF-1’s promoter region. The results 
of the above molecular pathways are to increase the atrophy process within 
myocytes. 
The caspase system is an important regulator of apoptosis. In contrast to the 
rapid effects of GC on the atrophy related genes MAFbx and MURF-1, 24 hour 
treatment with A or B was not associated with changes in mRNA expression of 
Caspase-3 which is an important regulator of glucocorticoid regulated myocyte 
apoptosis.  Studies which have shown a relationship between caspase-3 and 
apoptosis in skeletal muscle have involved longer periods of glucocorticoid 
exposure (for example 8 days rather than 24 hours) (318).  As discussed in the 
introduction, this lack of effect of short term GC treatment on caspase-3 mRNA 
expression may be secondary to Caspase-3’s role as an effector caspase (319) 
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rather than an upstream initiator caspase (caspase 8, 9, 12).  Following activation 
and cleavage effector caspases then carry out the proteolytic events that result in 
cellular breakdown and demise (319), which may take a number of days of GC 
exposure to modify expression (caspase 8 was has been described as being 
increased after 8 days GC treatment in rats) (320).  Further work is required to 
explore the role and timing of changes of initiator and effector caspases in GC 
mediated myopathy (321). 
 
The insulin/ IGF-I-AI3K-Akt-mTOR signalling pathway increases protein synthesis 
(Section 1.5.3.6.1).  Binding of insulin to its cell surface receptor leads to a 
conformational change and tyrosine autophosphorylation. Consequently, the 
insulin receptor substrate (IRS) family of adaptor proteins are recruited.  
Serine/threonine phosphorylation of IRS1 (in particular Ser307 phosphorylation) 
has been shown to negatively regulate insulin signalling through multiple 
mechanisms including decreased affinity for the insulin receptor and increased 
degradation (253, 254). The interaction of glucocorticoids and the insulin-
signalling cascade has only been examined in a small number of studies that 
have offered variable explanations for the induction of insulin resistance (255-
258). We have shown that total IRS1 protein content decreases in a dose 
dependent manner with increasing doses of active glucocorticoid.  Furthermore, 
pser307IRS1 was increased by corticosterone in a dose dependent manner.  The 
combination of a decrease in IRS1 (which is known to increase muscle 
hypertrophy pathways and inhibit muscle atrophy pathways) and the increase in 
pser307IRS1 (which is known to decrease insulin signalling) as well as having 
effects on insulin sensitivity (322) would lead to a net decrease in muscle 
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hypertrophy and increase in atrophy pathways.  To assess the role of pre-
receptor metabolism of GC by 11 β-HSD1 on the insulin/ IGF-I-AI3K-Akt-mTOR 
signalling pathway, day 8 C2C12 cells were treated with A, B and a combination 
of A and GE (a non-specific 11 β-HSD1 inhibitor). Results showed that inhibition 
of 11 β-HSD1 by GE lead to normalisation of IRS1 and pser307IRS1 to that seen 
in control experiments.  This shows that 11 β-HSD1 is a crucial regulator of the 
insulin signalling cascade which as well as controlling insulin sensitivity in skeletal 
muscle is a regulator of skeletal muscle hypertrophy.  The alterations in the 
insulin signalling cascade with GC treatment and 11 β-HSD1 inhibition, in 
combination with the upregulation of 11 β-HSD1 in C2C12 cells with GC therapy 
highlight 11 β-HSD1 as a key regulator of both atrophy and hypertrophy pathways 
in skeletal muscle.   
There are conflicting data with regard to the effect of GC treatment on myoblast 
proliferation rate.  Some studies have reported an increase in myoblast 
proliferation rate with GC treatment (217, 218) (particularly with low dose GC 
treatment), others reporting no effect of treatment with glucocorticoids (219) and 
others reporting a dose dependent decrease in myoblast proliferation with 
glucocorticoid therapy (220).  We have shown that both high dose glucocorticoid 
treatment (B10-5 but not B10-6/7) and antagonism of GRα is associated with a 
decrease in C2C12 proliferation rates.  Therefore there seems to be a threshold 
effect whereby too much or too little glucocorticoid exposure is associated with 
decreased proliferation rates. To strengthen this argument, treatment with the 
inactive glucocorticoid (11-dehydrocorticosterone), did not lead to any changes in 
proliferation rates. 
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Te Pas et al. reported that GCs are capable of attenuating proliferation and 
differentiation of myocytes in a dose response manner by altering mRNA levels of 
myoD1, myf-5 and myogenin (220).  When C2C12 myoblasts were incubated with 
dexamethasone or α-methyl-prednisolone for 9 days, the cell proliferation rate 
was reduced in a dose dependent manner despite increasing the mRNA 
expression of MyoD1 and myf-5 (220).  There are some differences in the 
methodology of this study and our study, as in our experiments the proliferation 
rate of C2C12 cells was so rapid that cells need to be split every 2nd and 
proliferation rates were assessed only for 48 hours in order to ensure that 
proliferation was in the linear range [Figure 4.7(b) and 4.9 (b)].  
A surprising finding was the increase proliferation rate in cells treated with the 11 
β-HSD1 selective (LJ2) and non-selective (GE) inhibitors. 11 β-HSD1 is active 
and expressed in myoblasts, however, at significantly lower levels when 
compared to day 8 myotubules.  The activity assays which show low levels of 11 
β-HSD1 oxoreductase activity performed in Figure 3.2, Section 3.5.1 were only 20 
minutes long.  However, when myoblasts were incubated with radiolabelled A for 
24 hours there was approximately 5% conversion to B (data not shown).  
Therefore, although levels are lower than in myotubules there is still some 
biologically activity present during prolonged incubations. H6PDH is the main 
regulator of NADPH levels in the endoplasmic reticulum, although there are other 
sources of NADPH within the ER (323). H6PDH is expressed in C2C12 
myoblasts and therefore there is significant NADPH generation in the 
endoplasmic reticulum (ER) or sarcoplasmic reticulum (SR) in muscle.  Inhibition 
of 11 β-HSD1 by LJ2 or GE leads to an increase of NADPH within the 
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endoplasmic reticulum by decreasing the use of NADPH as co-factor for 11 β-
HSD1 enzyme oxoreductase activity.   
Dr Gareth Lavery, from Professor Stewarts group, has previously shown that a 
decrease in H6PDH and NADPH generation within the sarcoplasmic reticulum in 
the H6PDHKO mouse is associated with a severe vacuolating myopathy and an 
upregulation of unfolded protein response pathway (154).  Further studies, which 
I was involved in during my thesis, have further characterised the role of H6PDH 
and NADPH in the SR independent of the effects of 11 β-HSD1.  The H6PDH/11 
β-HSD1 double KO mouse is a phenocopy of the H6PDHKO, therefore the 
myopathy reported in H6PDHKO is independent of 11 β-HSD1 and 
glucocorticoids and is rather related to alterations in H6PDH and NADPH levels 
within the SR.  
The potential increase in NADPH availability following inhibition of 11 β-HSD1 
during proliferation may be used for other key intracellular and intra ER/SR 
processes.  The ER has many functions including the synthesis of proteins, lipids 
and phospholipids that are required for the synthesis of cell membranes and a 
key regulator of protein folding and the unfolded protein response, all of which 
require a normal Redox environment.  We do not have a mechanism to explain 
the increased proliferation with inhibition of 11 β-HSD1; one speculation is that 
the NADPH which is in normal circumstances used for the oxoreductase activity 
of 11 β-HSD1 is used in other ER/SR specific metabolism which increases 
proliferation rate.   
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In conclusion, the data presented demonstrate that increased activity and 
expression of 11 β-HSD1 may be involved in glucocorticoid mediated myopathy.  
However, this impact on atrophy markers with increasing doses of corticosterone 
is not due solely to the effect of corticosterone increasing 11 β-HSD1 activity and 
expression but also the direct effect of corticosterone itself on the GR. To clarify 
the potential importance of 11 β-HSD1 in glucocorticoid mediated myopathy we 
have also shown that when C2C12 cells are treated with the inactive steroid 11 
dehydrocorticosterone (which is solely dependent on 11 β-HSD1 to activate it to 
corticosterone and thus have its effect on the GR) there is also a dose dependent 
increase in atrophy markers. 11 β-HSD1 is a crucial regulator of the insulin-
signalling cascade which as well as controlling insulin sensitivity in skeletal 
muscle is a regulator of skeletal muscle hypertrophy.  Both high dose 
glucocorticoid treatment and antagonism of GRα is associated with a decrease in 
C2C12 proliferation rates and surprisingly 11 β-HSD1 inhibition increased 
proliferation rate. 
The above results are interesting as selective 11 β-HSD1 inhibitors are currently 
in development. In rodents and primates they limit local glucocorticoid availability 
and improve glucose tolerance, lipid profiles and insulin sensitivity (324, 325).  It 
is interesting to speculate that 11 β-HSD1 inhibitors, particularly if they can be 
targeted to muscle, may also limit the severity of glucocorticoid induced 
myopathy, however these studies have not yet been performed. 
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Figure 4.11. Summary of mechanisms of GC mediated myopathy studied in this 
chapter and role of 11 β-HSD1 in glucocorticoid mediated myopathy via effects on 
atrophy, hypertrophy and proliferation.  The upregulation of 11 β-HSD1 by 
glucocorticoids within muscle may lead to a vicious cycle whereby tissue specific 
increases in GC lead to further muscle atrophy. 
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5.1.  Introduction 
5.1.1. Sarcopaenia 
The population of the UK is increasing in age and currently people over the age of 
60 consume 38% of NHS total expenditure (326). There are a number of 
conditions that increase in prevalence in an ageing population including 
cardiovascular disease, metabolic syndrome (and Type 2 diabetes mellitus), 
osteoporosis and sarcopaenia. Sarcopaenia is the loss of skeletal muscle mass 
that occurs with increasing and is associated age with a significant decrease in 
muscle strength. Muscle strength peaks between the 2nd and 3rd decade of life 
and remains the same until approximately 45-50 years.  After this, strength 
decreases at the rate of 12-15% per decade until the 8th decade (4). Up to 24% of 
people aged <65 years and 50% of people aged >80 years would fulfil the criteria 
for sarcopaenia [an appendicular skeletal mass (muscle mass/ height2) more than 
2 standard deviations (SD) below the mean of a young reference group (18)]  The 
functional consequences of sarcopaenia include falls, functional decline, 
osteoporosis, impaired thermoregulation and glucose intolerance (21-24).  Falls 
increase with increasing age and often lead to institutional and nursing home care 
(327). 
There are many physiological changes which occur within muscle with ageing 
including a decrease in muscle mass and cross-sectional area (26-28) and a 
decrease in Type I and II fibre number (particularly in Type II fibres) (29-31).  
There is also an infiltration of fat and connective tissue (32-36). 
Whole muscle and individual muscle fibre atrophy is heavily implicated in the 
reduction in cross-sectional area with age, especially Type IIb fibres (29, 39, 56, 
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94, 97-99) whereas the cross-sectional area of Type I fibres, although undergoing 
mild atrophy, generally appears well conserved with age (29). Ageing Type I 
fibres are 25% smaller than that of younger individuals, but Type II fibres are 
typically 43% smaller than their younger counterparts (100).  The reason for the 
sensitivity of ageing Type II fibres to atrophy compared with Type I fibres remains 
to be elucidated. However, there are similarities with studies reporting muscle 
fibre atrophy, especially Type II muscle fibres, in individuals with excess 
endogenous or exogenous glucocorticoid exposure (101-108). 
 
5.1.2. Molecular mechanisms underpinning sarcopaenia 
The maintenance of muscle mass depends on the balance between muscle 
protein synthesis via anabolic stimuli (feeding, muscle contraction, anabolic 
hormones) and muscle protein breakdown via catabolic stimuli (fasting, 
glucocorticoids, inflammatory cytokines). Where muscle protein synthesis 
exceeds protein breakdown, hypertrophy occurs, whereas the reverse is true for 
muscle atrophy. It is clear; therefore, that sarcopaenia might be associated with a 
decrease in anabolic stimuli, an increase in catabolic stimuli, or a combination of 
the two.  These pathways have been discussed in detail in Section 1.3.5 and will 
be briefly summarised below. 
One possible mechanism underpinning sarcopaenia is the decline in regenerative 
capacity, possibly as a consequence of a decreased number or impaired function 
of skeletal muscle satellite cells (57). There are conflicting data regarding satellite 
cell number and function in sarcopaenic muscle with some authors describing a 
decrease (58-60), some reporting no change, and others reporting an increase in 
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satellite cell number with age (61, 62). There is also some evidence to suggest 
that there is fibre Type specificity to the decrease in satellite cells with Type II 
fibres having lower satellite cell number than Type I fibres (63).    
Myostatin is a member of the tumour growth factor β family and is a potent 
inhibitor of muscle growth, regulating satellite cell activation, myoblast 
proliferation and terminal differentiation. Data are conflicting data with regard to 
the role of myostatin in sarcopaenic muscle.  Some rodent studies have shown no 
change in myostatin expression in young vs. old mice (73), whereas other studies 
have shown increased expression (74). Therefore, further work is needed to 
clarify the role of myostatin in sarcopaenic muscle.  The calpain system has also 
been reported to be activated in sarcopaenic muscle suggesting an increase in 
calcium dependent proteolysis (57).  
Elderly individuals do not demonstrate a decrease in basal muscle protein 
synthesis despite a reduction in muscle mass with age (77), but do show impaired 
muscle protein synthesis in response to amino acids, in the presence of insulin, 
despite demonstrating normal glucose tolerance and insulin concentrations 
comparable to the younger cohort (78).  
Proteins scheduled for degradation in the proteasome are labelled by conjugation 
with ubiquitin.  The 26s proteasome enzyme complex can then recognise the 
ubiquitin and initiate protein degradation using at least three classes of proteins.  
These include the E1 (ubiquitin activating enzymes), E2 (ubiquitin-conjugating 
enzymes) and E3 (Ubiquitin ligase).  Within skeletal muscle, MAFBX and MURF-
1 are two important E3 ubiquitin ligases clearly associated with many models of 
muscle atrophy such as sepsis (79, 80) and disuse atrophy (81). Increased 
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Translocation of the forkhead transcription factor (FOXO-1) into the cell nucleus 
increases MAFbx and MURF-1 mRNA expression (84). In ageing, MURF-1 and 
MAFbx-1 mRNA and protein expression in human vastus lateralis muscle is 
unchanged (88, 89), whilst in rodent muscle MURF-1 and MAFbx-1 mRNA 
expression is reported to be increased 2 to 2.5 fold (90), decreased (91), or 
MURF-1 expression decreases whilst MAFbx-1 expression remains unchanged 
(92) compared with younger control groups. The disagreement between studies is 
likely due to several confounding factors including the species sampled, the 
strains of animals, the genders and the types of muscles biopsied. Further work is 
required to elucidate the exact role of these above processes in muscle atrophy. 
The role of ubiquitin ligases in sarcopaenia have been discussed in detail in 
Section 1.3.5.4. 
 
5.1.3. Endocrinology of ageing and putative role in sarcopaenia 
There are a number of hormonal changes, which occur with ageing which have 
been implicated (by association and correlation) in the development of 
sarcopaenia, including a decrease in testosterone, DHEA and GH/IGF-I levels 
(discussed in detail in Section 1.3.6).  The data regarding increased muscle 
strength following testosterone replacement in this cohort is conflicting (110-113). 
DHEAS levels also decrease with increasing age and studies replacing DHEA in 
an elderly cohort have not shown an increase in muscle strength (116).  GH 
secretion declines by approximately 14% per decade (87), IGF-I is produced 
predominantly in the liver and in tissues such as bone under the direct influence 
of GH and serum IGF-I levels also fall with increasing age (119). The GH/IGF-I 
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axis has been implicated in sarcopaenia following a number of studies which 
have shown a correlation between IGF-I levels and sarcopaenia (42) and GH 
replacement has been associated with an increase in lean body and muscle mass 
(120-123). However, GH treatment in the elderly is associated with a significant 
side effect profile and potential morbidity; currently it is recommended not to treat 
or replace the GH decline of ageing (somatopause) (125).  
There are contradictory data regarding the changes in plasma cortisol which 
occur with ageing, with a number of groups believing there are no changes (126) 
while others believing that plasma cortisol levels increase with ageing and in a 
sex specific manner (127). Van Cauter et al. have reported an increase in mean 
plasma cortisol levels of 20-50% between 20-80 years, an increase in the 
nocturnal nadir of cortisol and age related dampening of diurnal rhythm with an 
advancement of the timing of the circadian elevation (127).  
 
5.1.4. 11β-HSD1 in muscle and ageing 
Within tissues, GC levels are regulated at the pre-receptor level by isozymes of 
11 β-hydroxysteroid dehydrogenase (11 β-HSD), which are located in the 
endoplasmic reticulum (ER). 11 β-HSD1 in vivo acts predominantly as an 
oxoreductase converting inactive cortisone (11-dehydrocorticosterone in rodents) 
into active cortisol (corticosterone in rodents) (2). The biological activity of 
glucocorticoids is dependent on their binding to the glucocorticoid receptor (GR) 
which is a ligand regulated nuclear receptor which binds to specific DNA 
sequences known as glucocorticoid response elements (GREs) in the promoter 
region of the target gene (131).   
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The role of 11 β-HSD1 in adipose tissue, liver and brain has been extensively 
studied (2), however the role of 11 β-HSD1 in skeletal muscle is less well-defined.  
Although the effect of ageing on serum levels of cortisol is controversial there is 
evidence that 11β-HSD1 is elevated in a number of tissues.  There is also 
evidence from a recent paper by Weinstein et al. which shows an increase in 
endogenous glucocorticoid concentrations and adrenal weights with increasing 
age in C57BL/6 mice (180). In bone, 11β-HSD1 regulates the effects of 
glucocorticoids upon osteoblasts (181), Cooper et al., within our group has shown 
that enzyme expression in primary cultures of human osteoblasts increases with 
advancing age (5). Tiganescu et al., from our group, has shown that 11β-HSD1 
increases in skin with increasing age (6).  From a functional perspective, there is 
evidence that 11β-HSD1KO mice are resistant to hippocampal changes 
associated with ageing (7).  There is, however, no data to date regarding the 
effect of ageing on skeletal muscle 11β-HSD1.  
 
5.2. Hypothesis 
11 β-HSD1 is increased in skeletal muscle with increasing age and this is 
associated with sarcopaenia due elevated expression of glucocorticoid regulated 
atrophy genes. 
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5.3. Strategy of Research and Aims 
3 month (young) versus 22-25 month (old) C57BL/6 mice were investigated to 
assess the following factors in ageing: 
a. The effect on muscle strength and muscle mass. 
b. The expression and activity of 11β-HSD1 in liver fat and muscle  
c. Global glucocorticoid metabolism, using urinary corticosteroid GC/MS 
assessments. 
d. Further clarification of the expression of atrophy related genes in different 
muscle groups (quadriceps, tibialis anterior and soleus). 
 
Following the generation of a global 11β-HSD1 knockout (KO) mouse. 3 month 
(young) versus 22-25 month (old) WT and KO mice were investigated to assess 
the following factors: 
e. The effect of 11β-HSD1 KO on muscle strength and muscle mass  
f. Changes in global glucocorticoid metabolism between 11β-HSD1 KO and WT 
mice with increasing age using GC/MS. 
g. The expression of atrophy related genes in different muscle groups 
(quadriceps, tibialis anterior and soleus) in the 11β-HSD1 KO compared to WT 
littermates. 
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5.4. Methods?
5.4.1. RNA extraction and cDNA synthesis 
Total RNA was extracted from murine tissue explants following homogenisation 
using TRIreagent (Sigma-Aldrich, Dorset, UK).  The procedure was carried out 
according to protocol provided with the reagent (Sigma-Aldrich, Dorset, UK).  The 
quantity of RNA was measured using NanoDrop ND-1000 UV-Vis 
Spectrophotometer (Thermofisher, Surrey, UK). The reverse transcription process 
was carried out using Applied Biosystems High-Capacity Reverse Transcription 
Kit (Applied Biosystems, Warrington, UK) For a full description of methods used 
see Section 2.3 and 2.4. 
 
5.4.2. Quantitative or Real Time PCR 
Quantitative PCR was carried out using Applied Biosystems Reagents and gene 
expression assays (AssayonDemand) (Applied Biosystems, Warrington, UK).  
PCRs for genes of interest and for 18s housekeeping genes were carried out in 
singleplex. Data are expressed as Ct values (Ct=cycle number at which 
logarithmic PCR plots cross a calculated threshold line) and used to determine 
ΔCt values (ΔCt = (Ct of the target gene) – (Ct of the housekeeping gene), lower 
ΔCt values reflecting higher mRNA expression.  Data are expressed as arbitrary 
units using the following transformation [expression in arbitrary units = 1000*(2-
ΔCt)]. For a full description of methods used see Section 2.6. 
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5.4.3. 11 β-hydroxysteroid dehydrogenase type 1 and 2 enzyme 
activity assay 
11 β-hydroxysteroid dehydrogenase type 1 and 2 enzyme activity assay was 
carried out on whole tissue explants. Fresh tissue explants were chopped to 
~20mg/well and the above protocol was followed. Activity expressed as pmols of 
steroid converted per mg of tissue per hour (pmol/mg/h). Incubations were carried 
out at 37°C under a 5% CO2 atmosphere for 20 minutes (liver) to 2 hours (muscle 
and adipose tissue) depending on the tissue type. For a full description of 
methods used see Section 2.8. 
 
5.4.4. Rodent Models used in this chapter 
All mice were group housed under controlled temperature (21-23 oC) and light 
(12:12 light-dark cycle; lights on at 0700h) with ad libitum access to standard 
rodent chow and water.  Body weights were monitored weekly.  Animal 
procedures were approved under the British Home Office Animals (Scientific 
Procedures) Act 1986.   
 
5.4.4.1. Ageing mouse model 
In the initial ageing mouse experiments the colony of young mice were 
approximately 12 weeks old and aged mice were between 22 and 26 months (all 
mice C57Bl\6).  The time frame for old mice was determined from published data 
regarding age related myopathy which describes ‘old mice’ as being aged from 19 
to 28 months (305-308). In our 11β-HSD1 KO model the mice strain was of mixed 
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background C57Bl6/129SVJ. Dr Nina Semjonous was key in the management of 
this colony. 
 
5.4.4.2. Generation of targeted 11β-HSD1 knock out mouse 
The 11β-HSD1 knock out mouse was developed within our group by Dr Gareth 
Lavery. The murine HSD11B1 gene contains 6 exons and a targeted vector to 
flank exon 5 (containing the catalytic domain of the enzyme) with LoxP sites.  
Genomic DNA from 129SvJ embryonic stem cells was used to amplify 6kb 5’ and 
2kb 3’ homology arms, which were subsequently cloned into pBluescript SK(+) 
containing a thymidine kinase cassette. A loxP flanked Neomycin cassette was 
subcloned into a Xhol site 5’ of exon 5 and an additional loxP site subcloned into 
a PmlI site 3’ of exon 5.  Following verification by DNA sequencing, the construct 
was linearized with BamHI and electroporated into E14TG2a mouse embryonic 
stem cells. Southern hybridization of Spe1 and NcoI digested genomic DNA 
probed with 500-bp H6PD fragments located at the 5' and 3' ends of the targeting 
vector respectively identified cells positive for a recombined HSD11B1 tri-loxed 
allele after selection in G418 and gancyclovir (see Figure 5.1.A). Three targeted 
embryonic stem cell clones were expanded, screened, and karyotyped to ensure 
correct recombination and chromosomal integrity. Two clones were injected into 
C57BL/6 blastocysts and chimeric mice derived from embryonic stem cell clone 
were mated with C57BL/6 females to achieve germ line transmission of the 
recombined allele. Mice heterozygous for a tri-loxed allele were crossed with the 
ZP3-Cre expressing strain (309) which is a powerful deleter expressing early in 
development and will recombine between the most distant LoxP sites with high 
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efficiency, thus rendering the allele null which can be passed into the next 
generation. Germline transmission of a disrupted allele was detected by PCR 
(depicted schematically in Figure 5.1). For genotyping HSD11B1 alleles the 
following primers were multiplexed in a standard PCR reaction: P1 5’-
GGGAGCTTGCTTACAGCATC-3’; P2 5’-CATTCTCAAGGTAGATTGAACTCTG-
3’; P3 5’-TCCATGCAATCAACTTCTCG-3’. PCR genotyping confirmed germline 
transmission of the disrupted allele, which was subsequently bred to 
homozygosity generating a 11β-HSD1KO. The validity of the model was 
assessed by demonstrating no 11β-HSD1 gene expression or enzyme activity in 
a number of tissues.   
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Figure 5.1. Targeted disruption of murine HSD11B1 using the Cre-LoxP system. 
A. schematic representation of the 6 exons of the HSD11B1 gene, the targeting 
vector, tri-floxed recombined allele and the KO allele upon ZP3-Cre mediated 
recombination. The location of the 5' and 3' external probes used for Southern 
hybridization and PCR primers P1, P2, and P3 used for genotyping are indicated. 
NEO, neomycin resistance cassette; TK, thymidine kinase cassette. B. 
Successful targeting of HSD11B1 in 3 independent lines (1, 14 and 15. c-control 
non targeted cells) of embryonic stem cells confirmed by Southern hybridization 
of SpeI and NcoI digested genomic DNA. SpeI digests produced a WT fragment 
of 10.8kb which in the presence of the tri-floxed recombined allele produced a 
fragment to 9.7kb. For the NcoI digest the WT fragment is 8.1Kb and the 
recombined allele is5.4kb.  C. PCR detection of knockout alleles (see material 
and methods for primer details). Primers P2 and P3 produce a band of 139bp 
representing the presence of a WT allele. Amplicons representing amplification 
between P1 and P3 are not detected due to the distance between these primers. 
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In the KO allele a P2 binding site is removed and P1 and P3 are brought in to 
proximity generating a product of 242bp allowing us to detect WT, heterozygote 
and homozygote animals (310).  
 
 
5.4.5. Mouse Muscle Strength Testing 
In collaboration with Dr Nina Semjonous the Linton Grip-Strength meter (Linton 
Instrumentation, Norfolk, UK) was used to assess muscle performance in 
experimental animals (4).  The Linton Grip-Strength meter reproducibly measures 
peak grip strength (4;5).  This is a non-invasive method whereby the peak grip 
strength is routinely measured by holding the animal by the base of the tail and 
gently and gradually assessing grip strength following the animal holding onto a 
grasp grid which assesses force via sensors in the machine while the animal is 
being gently pulled in the opposite direction. 
Mice will naturally reach and grasp an object if an object is brought in front of their 
forepaws. On each assessment, the mouse will be removed from their housing 
and lowered into the apparatus so that it grasps the grip grid, one with each paw, 
with its back legs standing on the smooth floor of the apparatus. The mouse will 
then be held by the base of the tail and pulled gently in a rearward direction. The 
applied force at which the mouse releases the cage with each paw was measured 
by the strain gauges.  To measure combined strength in all four limbs, the mouse 
was allowed to grasp the grid with fore and hind limbs and then held by the base 
of the tail and pulled gently in a rearward direction. 
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5.4.6. Gas Chromatography/ Mass spectrometry for corticosteroid 
metabolites in mouse urine 
GC/MS urinary steroid analysis was carried out by Beverley Hughes at the 
Institute for Biomedical Research, Centre for Endocrinology, Diabetes and 
Metabolism (CEDAM), University of Birmingham.  The GC/MS was based on the 
method described by Palermo et al. (311) and Shackleton et al. (328). 
Quantitative data on excretion of individual steroids for murine studies individual 
mouse urine was collected on filter paper and processed. 
GC/MS was carried out using a Hewlett Packard 5970 mass spectometer and 
15m fused-silica capillary column, 0.25mmID, 0.25μm film thickness (J&B 
Scientific, Folsom CA, USA) using 2μl of sample.  Steroids were quantified by 
comparing individual peak area to the peak area of the internal standards, for 
cortisol fragment 605m/z compared to 609 m/z and for cortisone fragment 531 
m/z compared to 534 m/z.  The relative peak area was calculated and the 
metabolite concentration expressed as μg/24hr.  A quality control (QC) was 
analysed with each batch.  The intra and inter-assay co-efficient of variance was 
<10%. For full description of principles of GC/MS and methods see Section 2.15.   
 
5.4.7. Statistical methods 
Statistical analysis was performed using Prism for Windows version 5.0 
(GraphPad Software Inc, San Diego, CA, USA) software packages.  Continuous 
data were summarised using means and standard deviations (or standard error of 
mean) if parametrically distributed or medians and inter-quartile ranges if non-
parametrically distributed.  Parametric data was compared using a paired t-test 
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and non-parametric data was analysed using a Mann-Whitney test.  Multiple 
comparisons were assessed using one-way analysis of variance (ANOVA), with 
Kruskal-Wallis for non-parametric data and Dunn’s multiple comparison test. The 
level for statistical significance was p<0.05. 
  
5.5. Results 
5.5.1. Body weight increases with age in wild type C57Bl\6 mice 
The total body weight of WT mice was measured on a weekly basis while on 
normal chow diet.  There was a gradual increase in weight during ageing. 
 
 
 
 
 
 
 
 
 
Figure 5.2. The total body weight of WT mice was measured on a weekly basis 
while on normal chow diet (n=8-10). 
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5.5.2. Muscle strength in young vs. old (wild type) C57BL6 muscle 
Muscle strength was assessed in young and old C5&BL/6 mice using a Linton 
Grip-Strength meter (Linton Instrumentation, Norfolk, UK).  Young mice had 
significantly greater strength (gram grip/ gram body weight) than older mice 
indicating that the model used did induce functional muscle weakness (Figure 
5.3).   
 
 
 
Figure 5.3. Measurement of mouse forelimb (a) and combined forelimb and 
hindlimb (b) muscle strength using Linton Grip-Strength meter (Linton 
Instrumentation, Norfolk, UK). p ***<0.0001, n = 8-10 in each group.  WT = wild 
type. Data shown are the mean+SE.  Old mice had significantly lower muscle 
strength indicating a functional muscle decline with ageing.  
 
5.5.3. Tissue weights in young versus old wild type mice 
The weight of individual muscle groups was assessed to examine differences in 
tissue weights with increasing age.  Despite this significant decrease in strength 
with increasing age there was no decrease in total muscle mass with age (Figure 
5.4 a+b).  This may be due to the increased accumulation and infiltration of 
intramuscular adipose or connective tissue reported previously (32-36).  There 
was increased liver and adipose tissue weight with increasing age. However, 
???? ????
a b 
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when tissue weights were adjusted for individual animal total body weight, there 
was a decrease in quadriceps, tibialis anterior, soleus and adrenal gland, an 
increase in weight of gonadal adipose tissue but no change in adjusted liver 
weight.  Therefore the increase in total body weight with age (Figure 5.4 c) is 
predominantly secondary to increased adipose tissue depot weight. 
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Figure 5.4. The weight (grams) of key tissues in young versus old mice (and b) 
(n= 8-10 in each group). Tissues included quadriceps (Q), tibialis anterior (TA), 
soleus (Sol), adrenal (Ad), liver and gonadal fat (OM).  Tissue weights were then 
normalised to individual total body weights (c).  p *<0.05, p ** <0.001, p ** 
<0.0001, p NS = non significant. Data shown are the mean+SE. 
 
5.5.4. Urinary GC/MS of corticosteroid metabolites in young vs. old 
C57BL6 wild type 
The overall glucocorticoid exposure in mice was assessed via measurement of 
GC/MS of urinary corticosteroid metabolites.  There was no difference between 
the % A (11-dehydrocorticosterone) metabolites in mouse urine with ageing.  As 
corticosterone (B) is metabolised by 11 β-HSD2 to 11-dehydrocorticosterone (A) 
in the kidney, % A metabolites were used as a surrogate for overall circulating B 
concentrations. The reason for using % A metabolites rather than serum 
corticosterone is due to the large variation in ELISA based measurements of 
corticosterone and the relatively low numbers of animals available for analysis 
due to our breeding scheme.  
 
 
 
 
 
 
Figure 5.5.  Urinary steroid metabolite assessment with % A metabolites 
revealed no difference between young and old mice), (n=8). Data shown are the 
mean+SE. 
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5.5.5. 11 β-HSD 1 mRNA expression in young vs. old C57BL6 WT 
muscle 
11 β-HSD 1 mRNA expression was assessed in explants of young (12 weeks) 
and old (90-112 weeks) C57BL/6 mice quadriceps, tibialis anterior and soleus, 
liver and gonadal fat.  Increased 11 β-HSD 1 expression was seen in quadriceps, 
tibialis anterior, soleus and adipose tissue but not liver (Figure 5.6).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Measurement of 11 β-HSD1 mRNA expression in explants of young 
compared to old tissue (n=4-5, young 12 weeks, old 90-112 weeks).  Tissues 
included quadriceps (quad) (a), tibialis anterior (TA) (b), soleus (Sol) (c), liver (d) 
and gonadal fat (OM) (e).  p *<0.05, p ***<0.0001, p NS = non significant. Data 
shown are the mean+SE. 
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5.5.6. 11 β-HSD 1 oxoreductase activity in young vs. old C57BL6 WT 
muscle 
11 β-HSD 1 oxoreductase activity assays were performed on explants of young 
(12 weeks) and old (90-112 weeks) C57BL/6 mice quadriceps, tibialis anterior, 
soleus, liver and gonadal fat.  Results revealed increased 11 β-HSD 1 activity in 
quadriceps, soleus, liver and gonadal fat but not tibialis anterior (Figure 5.7). This 
would suggest that there is increased tissue specific activation of glucocorticoids 
[11-dehydrocorticosterone (A) to corticosterone (B)] within certain tissues with 
ageing. 
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Figure 5.7. Measurement of 11 β-HSD1 oxoreductase activity in explants of 
young compared to old tissue (n=4-5, young 12 weeks, old 90-112 weeks).  
Tissues included quadriceps (quad)(a), tibialis anterior (TA)(b), soleus (Sol)(c), 
liver (d) and gonadal fat (adipose)(e).  p *<0.05, p ** <0.001, p NS = non 
significant. Data shown are the mean+SE. 
 
 
 
5.5.7. mRNA expression of atrophy genes in young vs. old C57BL6 
wild type muscle 
The mRNA expression of key glucocorticoid regulated atrophy genes were 
determined in young compared to old WT mice. Three different muscle groups 
(quadriceps, tibialis anterior and soleus) were used to assess the mRNA 
expression of atrophy genes in mixed fibre muscle, type II fibre rich muscle and 
type I fibre rich, respectively.   
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5.5.7.1. mRNA expression of MURF-1 and MAFbx in 3 different skeletal 
muscle depots in young compared to old animals 
There was an increase in MURF-1 and MAFbx mRNA expression (key 
glucocorticoid regulated genes) in quadriceps and tibialis anterior but no change 
in the Type I fibre rich soleus (the most glucocorticoid resistant muscle type) 
(Figure 5.8).  These results highlight the importance of assessing different muscle 
groups when assessing the role of specific genes associated with sarcopaenia 
and glucocorticoid mediated myopathy.   
 
 
 
Figure 5.8. mRNA expression of MURF-1 (a) and MAFbx (b) in 3 different 
skeletal muscle depots [quadriceps (Quad) representing a mixture of fibre types, 
tibialis anterior (TA) representing Type II fibres and soleus (Sol) representing 
Type I fibres]. p *<0.05, p ** <0.001, p ***<0.0001, p NS = non significant, n=4-5. 
Data shown are the mean+SE.   
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5.5.7.2. mRNA expression of FOXO1 and FOXO3 in 3 different skeletal 
muscle depots in young compared to old animals 
There was no change in mRNA expression of FOXO1 (a) and FOXO3 (b) in 3 
different skeletal muscle depots with increasing age (Figure 5.9). This is not 
surprising as both FOXO 1 and 3 are heavily dependent on changes in 
phosphorylation for activity. Increased MAFbx and MURF-1 mRNA expression 
are both associated with translocation of the forkhead transcription factor (FOXO-
1) into the cell nucleus (84).  Phosphorylation of FOXO-1 by Akt sequesters 
FOXO-1 from the cell nucleus to the cytoplasm by 14-3-3 proteins (85) preventing 
MAFbx and MURF-1 upregulation.  However, GCs dephosphorylate FOXO-1 
allowing subsequent translocation to the cell nucleus. 
 
 
Figure 5.9. mRNA expression of FOXO1 (a) and FOXO 3 (b) in 3 different 
skeletal muscle depots [quadriceps (Quad) representing a mixture of fibre types, 
tibialis anterior (TA) representing Type II fibres and soleus (Sol) representing 
Type I fibres]. p NS = non significant, n=4-5. Data shown are the mean+SE. 
 
Chapter 5   11 β-HSD1 and Ageing  
 181 
5.5.7.3. mRNA expression of myogenic factor V and myostatin in 3 different 
skeletal muscle depots in young compared to old animals 
Myogenic factor V (myf5) is a key regulator of myocyte differentiation (Section 
1.2.1) and myostatin is a potent inhibitor of muscle myocyte proliferation and 
differentiation (Section 1.3.5.2).  There was an age related decrease in myogenic 
factor V mRNA expression in all 3 muscle groups (Figure 5.10).  There was an 
age related decrease in myostatin mRNA expression in tibialis anterior and 
soleus but no significant decrease in quadriceps (Figure 5.10).  This decrease in 
myostatin may be a compensatory mechanism in ageing muscle. 
 
 
Figure 5.10. mRNA expression of myogenic factor V (a) and myostatin (a) in 3 
different skeletal muscle depots [quadriceps (Quad) representing a mixture of 
fibre types, tibialis anterior (TA) representing Type II fibres and soleus (Sol) 
representing Type I fibres]. p *<0.05, p ** <0.001, p ***<0.0001, p NS = non 
significant, n=4-5. Data shown are the mean+SE. 
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5.5.7.4. mRNA expression of PPAR δ and MAO in 3 different skeletal 
muscle depots in young compared to old animals 
Activation of PPARδ has been previously shown to induce a switch to increased 
formation of Type I fibres (329). Monoamine oxidase is a key mitochondrial 
enzyme which metabolises catecholamines and has been reported to be elevated 
in GC mediated myopathy (Section 1.5.3.9). There was a decrease in PPARδ 
mRNA expression in quadriceps muscle but not in tibialis anterior or soleus 
(Figure 5.11).  There was an age related increase in monoamine oxidase mRNA 
expression in all 3 muscle groups (Figure 5.11). 
 
 
 
 
Figure 5.11. mRNA expression of PPAR δ (a) and MAO (b) in 3 different skeletal 
muscle depots [quadriceps (Quad) representing a mixture of fibre types, tibialis 
anterior (TA) representing Type II fibres and soleus (Sol) representing Type I 
fibres]. p *<0.05, p ** <0.001, p ***<0.0001, p NS = non significant, n=4-5. Data 
shown are the mean+SE. 
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5.5.7.5. mRNA expression of calpain, cathepsin 1 and D in 3 different 
skeletal muscle depots in young compared to old animals 
The atrophy pathways include the lysosomal proteases (eg. Cathepsins), the 
calcium dependent proteases (Calpain family). There was an age related 
decrease in calpain mRNA expression in the quadriceps muscle and increase in 
the soleus muscle, but no change in the tibialis anterior (Figure 5.12).  There was 
an age related increase in cathepsin 1 mRNA expression in the quadriceps and 
soleus muscles, but no change in the tibialis anterior (Figure 5.12).  There was no 
change in mRNA expression of cathepsin D in any muscle groups with increasing 
age (Figure 5.12). 
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Figure 5.12. mRNA expression of calpain (a) and cathepsin I (b) and D (c) in 3 
different skeletal muscle depots [quadriceps (Quad) representing a mixture of 
fibre types, tibialis anterior (TA) representing Type II fibres and soleus (Sol) 
representing Type I fibres]. p *<0.05, p ** <0.001, p ***<0.0001, p NS = non 
significant, n=4-5. Data shown are the mean+SE. 
 
 
 
Table 5.1. Summary of changes in expression of atrophy and hypertrophy related 
genes in different muscle groups of young compared with old muscle revealing 
different patterns of mRNA expression changes depending on fibre type 
preponderance.   
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5.6. Studies on the global 11 β-HSD1 KO mouse 
Through the use of transgenic rodent models it has been shown that elevated 11 
β-HSD1 expression and activity, either globally or in a tissue specific manner, is 
associated with the development of cognitive impairment (174), the metabolic 
syndrome (175) and insulin resistance (176), which is due to increased 
intracellular glucocorticoid action.   
Conversely, knockout animals or pharmacological inhibition of 11 β-HSD1 reveal 
improved insulin sensitivity and resistance to diet induced obesity (177).  Much 
less is known about the role of 11 β-HSD1 in skeletal muscle and the 
consequences of local production of GCs.  Transgenic mice with a null HSD11B1 
gene have previously been generated by Kotelevtsev et al. (159).  In homozygous 
mutant mice, hepatic 11 β-HSD1 activity was less than 5% that of wild type.  
When WT and KO mice were adrenalectomised and implanted with pellets of 11 
dehydrocorticosterone (A) the WT mice converted A to B whereas B levels in the 
KO mice remained undetectable.  This demonstrated that 11 β-HSD1 is the only 
11 oxo-reductase (in the mouse) able to generate active GC from inert 11 keto-
steroids.  11 β-HSD1KO mice have adrenal hyperplasia due to reduced negative 
feedback on the HPA axis causing increased ACTH-stimulated corticosterone 
secretion and zona fasciculata hypertrophy (159).  There was no reported change 
in 11 β-HSD2 activity or expression in this model (159).   
There have not been any studies to date assessing the effect of 11 β-HSD1KO on 
muscle function or ageing.  Of particularly interest, is whether a lifetime of 
decreased intra-muscular glucocorticoid generation in 11 β-HSD1 KO mice would 
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impact on the muscle function in a cohort of old C57BL6/129CVJ 11 β-HSD1KO 
mice when compared to WT littermates. 
 
5.6.1. 11 β-HSD 1 activity in C57BL6 Wild type vs 11 β-HSD 1 KO 
muscle 
11 β-HSD1 oxoreductase activity was assessed in a number of tissues and was 
abolished in 11 β-HSDKO mice (Figure 5.13). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13. 11 β-HSD1 oxoreductase activity was assessed in liver, quadriceps 
(QUAD), tibialis anterior (TA), soleus (Sol) and gonadal fat (GF) and was 
abolished in 11 β-HSDKO mice, compared to WT. (WT = wild type, KO = knock 
out). Data shown are the mean+SE. 
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5.6.2. Effect of global 11 β-HSD1 knockout on total body weight with 
increasing age on normal chow diet. 
The total body weight of WT and 11 β-HSD1 KO mice was measured on a weekly 
basis while on normal chow diet.  There was no difference in body weight 
between WT and 11 β-HSD1 KO mice (Figure 5.14). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14.  Total body weights during ageing of WT compared to 11 β-HSD1 
KO mice (n = 8-10 in each group). There was no difference in body weight 
between WT and 11 β-HSD1 KO mice with increasing age, fed with ad libitum 
normal chow diet. Data shown are the mean+SE. 
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5.6.3. Effect of global 11 β-HSD1KO on tissue weights with 
increasing age. 
The weight of individual muscle groups and liver, fat and adrenals were assessed 
to examine differences in tissue weights between young and old WT and 11 β-
HSD1KO. There was an increase in quadriceps and adrenal weight (in grams) in 
the old 11 β-HSD1KO compared to WT(Figure 5.15.a).  However, when this was 
adjusted for body weight there was only an increase in the adrenal weight in the 
old 11 β-HSD1KO which would be in keeping with the hypothalamic-pituitary-
adrenal axis activation previously reported in 11 β-HSD1KO mice (159, 330) 
(Figure 5.15.b). There was a 45.5% increase in adrenal size between young KO 
and WT and 52.4% between old KO and WT. 
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Figure 5.15. The weight of key tissues in WT compared to 11 β-HSD1KO 
littermates and the effect of increasing age (n-8-10 in each group). Tissues 
included quadriceps (Quad), tibialis anterior (TA), soleus (Sol), adrenal (Ad), liver 
and gonadal fat (GF).  p *<0.05, p ** <0.001, p ***<0.0001, p NS = non significant, 
n=8-9 per group. Data shown are the mean+SE. There was an increase in 
quadriceps and adrenal weight in the 11 β-HSD1KO mice with increasing age 
compared to wild type but no difference in TA or soleus (Figure 5.16.a).  
However, when tissue weights were adjusted for total body weight, only the 
adrenal weight was heavier (Figyre 5.15.b).  This significant increase in adrenal 
size in keeping with adrenal hypertrophy/ hyperplasia secondary to stimulation of 
the hypothalamic pituitary axis in the 11 β-HSD1KO mice.   
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5.6.4. Muscle strength in young vs. old C57BL6 wild type muscle WT 
compared to 11 β-HSD1KO 
Muscle strength in young compared to old mice in both the WT and 11 β-
HSD1KO mice was assessed using a Linton Grip-Strength meter (Linton 
Instrumentation, Norfolk, UK).  Young mice had significantly greater strength 
(gram grip/ gram body weight) than older mice in both WT and 11 β-HSD1KO 
mice indicating that the ageing model used did induce functional muscle 
weakness but there was no difference between WT and 11 β-HSD1KO mice 
(Figure 5.16).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16. Measurement of mouse forelimb (a) and combined forelimb and 
hindlimb (b) muscle strength using Linton Grip-Strength meter (Linton 
Instrumentation, Norfolk, UK). p ***<0.0001, n = 8-10 in each group.  WT = wild 
type. Data shown are the mean+SE.  Old mice had significantly lower muscle 
strength than younger mice indicating a functional muscle decline with ageing. 
However, there was no difference in muscle strength in old WT vs 11 β-HSD1KO.   
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5.6.5. Urinary GC/MS of corticosteroid metabolites in young vs. 
old C57BL6 wild type compared to 11 β-HSD1KO 
The overall glucocorticoid exposure in mice was assessed via measurement of 
GC/MS of urinary corticosteroid metabolites.  There was no difference between 
the % A (11-dehydrocorticosterone) metabolites in WT mouse urine with ageing.  
There was, however, a significant increase in % A metabolites in young 11 β-
HSD1KO compared to WT (Figure 5.17).  This increase was also present in old 
11 β-HSD1KO compared to WT, and the % A metabolites increased significantly 
in young compared to old 11 β-HSD1KO which could be explained by increased 
11 β-HSD2 conversion of B to A from increased levels of B produced by 
activation of the HPA axis (in keeping with increased adrenal size in 11 β-
HSD1KO). 
 
 
 
 
 
 
?
Figure 5.17.  Urinary steroid metabolite assessment with % A metabolites.  Data 
shown are the mean+SE. 
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5.6.6. Markers of glucocorticoid mediated myopathy in the muscle of 
old 11 β-HSD1KO compared to WT littermates. 
In order to assess the effect of 11 β-HSD1KO on key regulators of glucocorticoid 
mediated myopathy, we compared the tibialis anterior (Type IIb fibre rich) and 
soleus (Type I fibre rich) muscles in old 11 β-HSD1KO compared to WT 
littermates.  These muscles groups were chosen as we have shown in Table 5.1 
that different muscle groups have different patterns of gene response to ageing, 
in particular we wanted to see if there was a difference in the markers of atrophy 
in tibialis anterior, which is predominantly a Type IIb fibre rich muscle which are 
known to be sensitive to glucocorticoid mediated myopathy and soleus, which is a 
Type I fibre rich muscle which is resistant to GC mediated myopathy. 
The reduction in 11 β-HSD1 within tissues lead to a different pattern of response 
in TA compared to soleus for MAFbx, myogenic factor V (Myf5) and monoamine 
oxidase (Figure 5.18), however no difference was found in calpain-2 and caspase 
3 (Figure 5.19).  
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Figure 5.18.  mRNA expression of MAFbx, myogenic factor V and monoamine 
oxidase in old WT compared to 11 β-HSD1KO, tibialis anterior (TA) representing 
Type IIb fibres and soleus (Sol) representing Type I fibres. (n=5) Data shown are 
the mean+SE. 
 
 
 
 
 
p=0.1 p=0.03 p=0.03 NS 
p=0.03 p=0.04 
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Figure 5.19. mRNA expression of caspase 3 and calpain in old WT compared to 
11 β-HSD1KO, tibialis anterior (TA) representing Type IIb fibres and soleus (Sol) 
representing Type I fibres. (n=5) Data shown are the mean+SE. 
 
There is evidence in the 11 β-HSD1KO mouse of improvement in atrophy related 
markers in the tibialis anterior with decreased levels of expression of MAO and a 
trend to decrease in MAFbx.  There is evidence in the soleus muscle of the 11 β-
HSD1KO of increased atrophy related genes including MAFbx, MAO and a trend 
to an increase in calpain.  There is also some evidence of increased markers of 
myogenesis with increased expression of myogenic factor V.  
 
 
 
 
 
 
 
 
 
 
 
NS NS p=0.07 NS 
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5.7. Discussion 
We have shown in a murine model of sarcopaenia (characterised by decreased 
muscle strength and individual muscle weight) that 11 β-HSD1 activity and mRNA 
expression increases in some, but not all, tissues with ageing.  This increase in 
11 β-HSD1 oxoreductase activity is associated with an increase in active 
glucocorticoid at a cellular level.  In ageing muscle there are several structural, 
histological and molecular changes that are similar to those reported in GC 
mediated myopathy and the increased intracellular GC availability secondary to 
11 β-HSD1 may play a role in the phenotype of ageing muscle.   
In all rodent models of ageing and in particular those related to sarcopaenia there 
are a number of confounders.  The mice were fed normal chow diet and weight 
increased equally between WT and KO animals with ageing thus allowing us to 
see any effects specifically of 11 β-HSD1 KO.  To ensure weight was not a factor 
when measuring strength and tissue weights the values were reported as a factor 
of total body weight.  We had not considered subnormal chow diets and due to 
technical constraints with regard to feeding this may not have been possible.  The 
ideal study to ensure that weight was not a factor in changes reported in atrophy 
genes with ageing would be to ensure that there was no weight gain during aging 
however this was not possible in our studies due to technical constraints such as 
lack of ability to regulate food intake and measurement of energy homeostasis.  
There are several variables, which could not be controlled in our cohort due to 
technical limitations [particularly at a metabolic level, for example activity levels 
(key in sarcopaenia as inactivity increases the severity of sarcopaenia), dietary 
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intake, differing insulin sensitivity within individual animals with increasing age]. 
Therefore, these results must be interpreted with full appreciation of these 
limitations. 
The results in this chapter show that sarcopaenic changes in a murine model of 
ageing are associated with the upregulation of key glucocorticoid mediated 
atrophy genes, but importantly, the changes reported depend on the muscle 
group sampled (Table 5.1). Muscle fibres can be divided into a number of 
subgroups including slow twitch oxidative (Type I fibres), fast twitch oxidative 
(Type IIa fibres) and fast twitch glycolytic (Type IIx or IIb) (Table 1.1).  In 
sarcopaenia, muscle fibre atrophy is heavily implicated in the reduction in cross-
sectional area with age.  Type IIb fibres are particularly susceptible (29, 39, 56, 
94, 97-99) whereas the cross-sectional area of Type I fibres, although undergoing 
mild atrophy, generally appears well conserved with age (29). The reason for the 
sensitivity of ageing Type II fibres to atrophy and the resistance of Type I fibres 
remains to be elucidated. We have shown muscle group specific changes in 
atrophy markers with increasing age.  Of particular interest are the changes in 
mRNA expression of atrophy related genes in the soleus muscle (a Type I fibre 
rich muscle, which is resistant to both sarcopaenia and GC mediated myopathy). 
Genes that were not upregulated in soleus muscle (but which were elevated in 
other muscle groups) during ageing included MURF-1 and MAFbx.   
As discussed in detail in Section 1.3.5.4, within skeletal muscle, MAFbx and 
MURF-1 are two important E3 ubiquitin ligases clearly associated with many 
models of muscle atrophy such as sepsis (79, 80) and disuse atrophy (81). 
Increased MAFbx and MURF-1 mRNA expression are both associated with 
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translocation of the forkhead transcription factor (FOXO-1) into the cell nucleus 
(84).  Phosphorylation of FOXO-1 by Akt sequesters FOXO-1 from the cell 
nucleus to the cytoplasm by 14-3-3 proteins (85) preventing MAFbx and MURF-1 
upregulation.  A recent study which assessed atrogin-1 (MAFbx) and MURF-1 in 
the soleus and extensor digitorum longus of middle aged (11-13 months) and old 
age mice (25-27 months old) has reported that there is no change in MAFbx and 
MURF-1 mRNA expression, with increasing age (331). This is in agreement with 
our data with regard to soleus but the lack of changes in MAFbx and MURF-1 in 
the EDL (predominantly a Type II fibre muscle), would not be in agreement with 
our data which revealed an upregulation of both MAFbx and MURF-1 in 
quadriceps and tibialis anterior.  One possible explanation for this is that Gaugler 
et al. compared middle aged mice (11-13 months) to older mice, whereas we 
assessed younger mice (12 weeks) which may have lead to a greater distinction 
between young and old quadriceps and tibialis anterior muscle.  Importantly, in 
the FOXO1 transgenic mouse the upregulation of FOXO1 (and as a result MURF-
1 and MAFbx) within muscle is associated with downregulation of expression of 
several genes associated with structural proteins of Type I muscle, a marked 
reduction in size of both Type I and II fibres and a significant decrease in the 
number of Type I fibres in the skeletal muscle of FOXO1 transgenic mice.  
Therefore, in our results the failure of soleus muscle MURF-1 and MAFbx to 
increase with increasing age may explain why the Type I fibre rich soleus muscle 
is more resistant to sarcopaenia.  There may also be a possible link to FOXO, 
with regard to why soleus muscle is more resistant to GC mediated myopathy as 
Type I fibres have the ability to shift fuel utilisation.  In both slow and fast twitch 
skeletal muscles, GCs activate FOXO-1 and FOXO-3a, but the targets of these 
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transcription factors may change in a fibre specific manner.  In Type I (243) and 
Type II fibres, activation of FOXO-1 and FOXO-3a leads to the transcription of the 
atrophy genes.  
There was no difference in total body weight in the 11 β-HSD1KO mouse 
compared to young or old WT littermates, however this was on a normal chow 
diet and previous models have shown a resistance to weight gain (particularly 
visceral) in 11 β-HSD1KO mice on high fat diets compared to WT littermates 
(332). There was no difference in muscle weights or muscle strength in the 11 β-
HSD1KO mouse compared to young or old WT littermates.  However, there was 
an increase in adrenal weight and % A metabolites in the 11 β-HSD1KO mouse 
compared to WT littermates (both in young and old), which would be indicative of 
an activation of the HPA axis, which is in keeping with previously published 11 β-
HSD1KO mouse data (159, 330).  
There is evidence in the 11 β-HSD1KO mouse of improvement in atrophy related 
markers in the tibialis anterior with decreased levels of expression of MAO and a 
trend to decrease expression of MAFbx.  This may be interpreted as the decrease 
in locally generated cortisol leading to decreased GC mediated myopathy in these 
usually GC sensitive muscle fibres.  There is also evidence in the soleus muscle 
of the 11 β-HSD1KO of increased atrophy related genes including MAFbx, MAO 
and a trend to an increase in caplain.  Type I fibres are GC resistant and the 
decrease in locally generated GC in the 11 β-HSD1KO appears to have a 
detrimental effect.  Therefore, the local generation of active glucocorticoids by 11 
β-HSD1, rather than causing atrophy as in Type IIb fibres may be required for the 
health of Type I fibres.  One possible mechanism is the activity of hormone 
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sensitive lipase (333) which metabolises triglycerides, the main source of fuel in 
Type I fibres, is dependent on glucocorticoids, however further work is required to 
examine this relationship.  Within the soleus of 11 β-HSD1KO mice, there is also 
some evidence of increased markers of myogenesis with increased expression of 
myogenic factor V that may be interpreted as a compensatory mechanism for 
increased atrophy. 
Importantly, the local decrease in GC may be offset by increases in circulating 
GC.  11 β-HSD1KO have been previously reported to have elevated 
corticosterone levels, an exaggerated corticosterone response to restraint stress, 
with a delayed fall after stress and a decrease sensitivity to exogenous cortisol 
suppression of the HPA axis, suggesting diminished glucocorticoid feedback 
(330).  In humans with mutations in the 11 β-HSD1 or H6PDH gene [cortisone 
reductase deficiency (334) and apparent cortisone reductase deficiency (335)] 
there is also evidence of HPA axis activation, patients have hyperandrogenism 
due to the effect of increased ACTH drive on adrenal androgens. 
It should be noted that previous studies of 11 β-HSD1KO have only assessed the 
effect of this decrease in intracellular GC exposure in young animals and have 
not assessed this in older animals that have had longer exposure to elevated 
circulating corticosterone levels and HPA activation.  Another factor, which must 
be taken into account when interpreting our data and that of previous 11 β-
HSD1KO is the effect of the mouse strain on HPA axis activation in 11 β-
HSD1KO models.  Mice bred on a MF1/129 background had an increase in 
plasma corticosterone nadir and extended corticosterone peak, leading to 
increased corticosterone secretion over 24 hours in 11 β-HSD1KO compared to 
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WT (159, 330, 336). There have been conflicting results in mice developed on a 
C57BL/6 background, with studies showing no change in plasma corticosterone 
nadir or diurnal rhythm values between WT and 11 β-HSD1KO (337).  Whereas 
another 11 β-HSD1KO developed on a C57Bl6/ CBA/C3H background reported 
an increased nadir plasma corticosterone and an altered diurnal rhythm of 
corticosterone (338).  It should be pointed out that all 11 β-HSD1KO models have 
an increase in adrenal gland weight, but again there is a difference in magnitude 
of weight increase depending on strain with MF1/129 increasing by 70% (159), 
C57Bl6 increasing by 20% (337) and C57Bl6/ CBA/C3H increasing by 36% (338).  
It is not clear if these changes are related to adrenal gland hyperplasia (159) or 
hypertrophy (338) or a combination as both have been described.  In our model 
(using C57Bl6/129SVJ) we found a 45.5% increase in adrenal size between 
young KO and WT and 52.4% between old KO and WT. 
Therefore, although there was a tissue specific decrease in GC exposure due to 
absent 11 β-HSD1 oxoreductase activity in the KO mouse there was an increase 
in circulating GC concentrations as a compensatory mechanism.  This increase in 
circulating GC, but decrease in tissue specific generation of GC, may have 
resulted in similar GC tissue exposure as WT mice and thus may explain the lack 
of muscle phenotype in ageing mice.  Therefore, to further assess the role of 11 
β-HSD1 in skeletal muscle the optimum approach may be a muscle specific 11 β-
HSD1KO, which may not lead to activation of the HPA and therefore allow us to 
elucidate the role of decreased tissue specific glucocorticoid exposure with 
ageing. 
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Chapter 6 
The modulation of corticosteroid metabolism by 
hydrocortisone therapy in hypopituitarism 
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6.1.  Introduction 
Patients with pituitary hormone deficiency (hypopituitarism) have increased 
morbidity and mortality (339), however, the exact mechanisms underpinning this 
have not been fully elucidated. There are a number of possible factors, including 
metabolic and body composition changes in patients who have GH and ACTH 
deficiency and the relative impact of pharmacological therapies of these 
deficiencies.  
The studies of cardiovascular risk in hypopituitarism have either been cross-
sectional studies comparing patients on conventional replacement (but not GH) to 
control subjects or interventional studies primarily examining the impact of GH 
replacement therapy.  Patients on conventional replacement therapy for 
hypopituitarism exhibit abnormalities of protein, fat and carbohydrate metabolism, 
which contributes to the abnormal body composition observed (reduced lean 
mass and increased fat mass).  There is a propensity to central obesity and intra-
abdominal or visceral fat deposition is significantly increased compared to control 
subjects with similar BMI (340, 341).  Visceral adiposity is associated, in the 
general population, with the metabolic syndrome: insulin resistance or diabetes 
mellitus, hypercholesterolaemia and hypertension (342, 343).   
 
6.1.1. Abnormalities associated with increased morbidity in patients 
with hypopituitarism. 
There are a number of abnormalities associated with increased morbidity in 
patients with hypopituitarism including insulin resistance, lipid abnormalities, 
endothelial dysfunction and alterations in fibrinolysis.  Although blood glucose and 
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plasma insulin levels are similar to those seen in controls, patients treated for 
pituitary disease have been shown to be insulin resistant (344). In some 
hypopituitary cohorts, patients have adverse fasting lipid profiles and body 
composition including low HDL cholesterol, increased triglycerides and decreased 
LDL particle size, increased BMI (up to 32% being clinical obese BMI>30kg/m2) 
and waist circumference (345-349). Importantly, in the large cohort studies 
characterizing metabolic phenotype, interpretation of the data is hampered by 
lack of age, sex and demographically matched controls.  The serum lipid profile is 
abnormal in patients on conventional pituitary hormone replacement, with 
elevated total and low density lipoprotein (LDL) cholesterol and triglyceride levels 
(345, 350-355), HDL levels are either unchanged (352, 355) or decreased (351, 
353, 354) in hypopituitarism. The data regarding the prevalence of hypertension 
in patients with hypopituitarism compared to the general population is conflicting 
but it is unlikely to play a major role in vascular morbidity in hypopituitarism (353, 
356-362).   
Carotid intima media thickness (IMT) which is a predictor of myocardial infarction 
and cerebrovascular accident in adults aged over 65 years (363) is significantly 
increased in adults with hypopituitarism compared with age matched controls 
(348, 364, 365).  Impaired endothelial function promotes adhesion of leukocytes 
to the endothelium which migrate through it and produce an inflammatory 
response (366). Serum levels of C-reactive protein (CRP), interleukin-6 (IL-6) and 
tumour necrosis factor-α (TNF-α) are increased in patients with hypopituitarism 
(367-369).  
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Fibrinolytic activity is an important contributor to cardiovascular risk; reduced 
activity is associated with venous thromboembolic disease, stroke and ischaemic 
heart disease.  One of the major regulators of the fibrinolytic system is 
plasminogen activator inhibitor-1 (PAI-1) which regulates, through inhibition, 
tissue plasminogen activator (tPA) (370).  In the fibrinolytic system PAI-1 levels 
(which inhibits tissue plasminogen activator) are elevated in patients with 
hypopituitarism (371-374).  Devin et al. demonstrated that the 24-hour fibrinolytic 
profile was abnormal in hypopituitarism reporting a 62% increase in PAI-1 antigen 
levels (p<0.05) and a 24% reduction in tPA levels (p=0.003).  In addition the 
normal circadian rhythm of PAI-1 was lost (371).  Thus hypopituitarism treated 
with conventional replacement therapy (but not GH) is a pro-thrombotic state, 
which may contribute to the increased cardiovascular mortality observed, and this 
has been shown to be improved by GH replacement therapy in some studies 
(372, 374).  
 
6.1.2. GH deficiency and treatment 
There is now a substantial body of evidence indicating that GH replacement 
therapy has a beneficial effect upon many of the parameters outlined above.  
Body composition improves consistently with growth hormone replacement.  Lean 
mass increases and fat mass decreases significantly, particularly central adiposity 
with GH treatment (341, 346, 375, 376).  The fasting lipid profile improves with 
reductions in total and LDL cholesterol and an improvement in the total: HDL 
cholesterol ratio (346, 351, 352, 377, 378).  
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Growth hormone treatment in hypopituitary adults also impacts upon endothelial 
function, the inflammatory process and fibrinolytic profile. The markers of 
inflammation, CRP, IL-6 and TNF-α also fall during GH replacement therapy (379, 
380). Measurement of the carotid IMT also demonstrates a significant 
improvement during GH therapy (364, 365, 381).  Although these studies have 
been of relatively short duration one study compared the outcome of patients 
after ten years of treatment and demonstrated that the beneficial changes in lipid 
profile, body composition and carotid IMT were sustained over that period (382).   
These changes all reflect beneficial effects on recognized markers of 
cardiovascular risk.  However GH replacement produces changes in some 
parameters, which may have an adverse effect upon cardiovascular outcome.  
Although GH replacement therapy results in a reduction of central fat mass, 
insulin resistance is increased.  In one study of 90 patients there was an increase 
in glycosylated haemoglobin levels from 4.9% ± 0.05 to 5.07% ± 0.06 (p<0.001).  
Plasma glucose levels rose from 4.72mmol/L ± 0.06 to 5.15mmol/L ± 0.07 
(p<0.001).  These changes were evident after six months of treatment and were 
sustained for two years (383).  Lipoprotein (a) is an independent marker of 
cardiovascular risk, which increases significantly during GH replacement (384-
386).  
 
6.1.3. ACTH deficiency and glucocorticoid replacement 
Traditionally the daily dose of hydrocortisone was 30mg per day split into two 
doses (two thirds in the morning and one third in the evening).  However, cortisol 
production rates in normal subjects are considerably less than those defined from 
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isotope studies in the 1960’s-1970’s.  Esteban et al. and Kelly et al. have shown 
that the normal cortisol production rate in young adults is between 5.7mg/m2/day 
(approximately 9.9mg/day) and 5.7 + 0.3mg/m2/ day, respectively (145, 146).  In 
recent years, endocrinologists have tried to decrease glucocorticoid replacement 
doses to levels, which remain safe but do not lead to over treatment.  
Nevertheless, it is possible that subtle increased glucocorticoid exposure in 
patients on GC replacement therapy over prolonged periods might contribute to 
increased morbidity, as observed in patients with Cushing’s syndrome (1).  
Cortisol day curves reveal that median doses of hydrocortisone of 29.5 + 1.2mg 
lead to peak cortisol and mean daily cortisol concentrations above the normal 
range, which in one study lead to a change in therapy in 88% of patients (75% of 
patients received a dose reduction) (387).  Agha et al. have shown that patients 
with ‘partial ACTH deficiency’ (basal 9.00 cortisol >200nmol/l but a peak cortisol 
on insulin tolerance test of <500nmol/l) have similar day curves to healthy 
controls suggesting that these patients may be over-treated by conventional 
steroid replacement therapy (388).  Fillipson et al. (389) have described an 
adverse metabolic profile in a cohort of GH deficient hypopituitary patients on 
higher doses of glucocorticoid replacement.  They found that patients on 
hydrocortisone replacement had increased total cholesterol, triglycerides, waist 
circumference and HbA1c compared to the ACTH sufficient patients.  Importantly, 
subjects who had hydrocortisone equivalent doses of less than 20mg/day did not 
differ in metabolic endpoints compared to the ACTH sufficient patients.  However, 
when a hydrocortisone equivalent doses of more than 20mg/day was 
administered patients had an adverse metabolic profile (389).  
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6.1.3.1. Mode of glucocorticoid delivery 
Twice or thrice daily doses of glucocorticoids are recommended to mimic the 
normal circadian rhythm and changes to circulating cortisol but even so, this is 
rarely achieved.  The bioavailability of orally administered hydrocortisone is ~95% 
(390, 391) and its half-life is 60-90 minutes.  A single morning dose of 15mg 
hydrocortisone leads to supraphysiological serum cortisol concentrations one to 
two hours post oral administration and a return to subphysiological or 
undetectable levels 6-8 hours later (390, 392, 393).  There is evidence that 
continuous, prolonged compared to intermittent short exposure to glucocorticoids 
may have different effects on a number of steroid responsive enzymes (394).  
Pulsatility may also be also important as it has significant effects on the 
occupancy of the glucocorticoid receptor (394).  Circadian intravenous infusions 
of hydrocortisone can mimic the normal cortisol rhythm via a programmable pump 
resulting in beneficial effects in patients with Addison’s disease and congenital 
adrenal hyperplasia (CAH) (395); using these infusions it was also possible to 
reduce the daily dose of hydrocortisone (396).  These infusions are obviously 
cumbersome and not practical, however, over the last few years there has been a 
push to design orally active delayed or sustained release formulations of 
hydrocortisone to reproduce ‘physiological replacement’ (397).  Johannsson et al. 
recently showed that a novel modified release once daily oral hydrocortisone 
preparation (Duocort) produced a diurnal plasma cortisol profile, which mimicked 
the physiological serum cortisol profile (398).  Similar results are reported with a 
preparation originating from Sheffield, UK (Chronocort) (399, 400).  
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6.1.3.2. Morbidity associated with glucocorticoid excess 
Patients with glucocorticoid excess (Cushing’s syndrome) have significant 
morbidity and increased mortality (339).  Hypertension is present in approximately 
80% of patients with endogenous Cushing’s syndrome and rises to 95% in 
patients with ectopic ACTH secretion (1). Hypercortisolaemia has been 
associated with a hypercoagulable state and several studies have described an 
increase risk of thromboembolic disorder (suggested by high levels of factor VIII, 
IX and von Willebrand factor and evidence of enhanced thrombin generation) in 
patients with Cushing’s syndrome. (401).  
Hypercortisolism leads to hyperglycaemia and insulin resistance and stimulates 
hepatic gluconeogenesis and glycogenolysis.  In vivo glucocorticoids reduce 
glucose uptake by reducing GLUT4 translocation and increasing lipolysis (402).  
Assessment of lipid status in clinical studies of patients with Cushing’s disease is 
not well defined but patients have a low HDL, elevated total cholesterol and LDL 
cholesterol (403).  
There are many phenotypic changes in Cushing’s syndrome including 
redistribution of adipose tissue from peripheral to central parts of the body, with a 
greater increase in visceral fat (404) and loss of subcutaneous fat from the limbs. 
There is also a decrease in muscle mass with a predominantly proximal 
myopathy (Section 1.5).   Importantly, even patients who have only mild increases 
in serum cortisol levels are susceptible to changes in adipose tissue distribution 
(405).  The underlying mechanisms by which elevated levels of cortisol alter 
adipose tissue distribution are not fully understood. Changes in lipoprotein lipase 
activity, preadipocyte differentiation and survival and altered cytokine production 
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have all been implicated (406).  In vitro studies have shown that cortisol is 
associated with stimulation of differentiation of adipose stromal cells to mature 
adipocytes (407, 408).  Glucocorticoids can induce exaggerated adipocyte 
formation and hypertrophy (108, 409).  The action of insulin in conjunction with 
glucocorticoids promotes preadipocyte differentiation and lipid accumulation (410, 
411).  Expression and activity of 11 β-HSD1 enzyme has been implicated in the 
accumulation of visceral adipose tissue both in simple obesity and in Cushing’s 
syndrome (412).  There is contradictory evidence between murine models and 
human studies and depending on fat depot sampled.  Bujalska et al. first 
proposed that excessive activity of 11 β-HSD1 enzyme within visceral adipose 
tissue could lead to increased adipose tissue levels of glucococorticoids and 
‘Cushing’s disease of the omentum’ (413).  This was also suggested by 
transgenic models with over-expression of 11 β-HSD1 within adipose tissue 
resulting in increased accumulation of central fat with increased tissue 
corticosterone concentrations and an increased adipocyte size (178).  However in 
human fat there are contradictory results with some groups reporting an increase 
in 11 β-HSD1 activity and expression with obesity (414-416) and others a 
decrease (417). 
In simple obesity, despite the association of cortisol production with obesity there 
is a weak, negative association of circulating cortisol concentrations and various 
measures of adiposity including weight, body mass index (BMI), waist-hip ratio 
and waist circumference in community dwelling men (406, 418).   
In obese patients there is an elevated cortisol secretion rate but circulating 
cortisol levels are typically lower, due to an increased cortisol clearance (418, 
419).  When free cortisol levels are assessed there is no association with 
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increasing weight.  Cortisol production rate and body surface area are positively 
correlated with 24 hour plasma free cortisol levels suggesting that activation of 
the HPA axis and elevated free cortisol levels are associated with increase 
adiposity (420). 
Therefore, when you compare the metabolic and phenotypic characteristics of 
growth hormone deficiency and glucocorticoid excess there are significant 
similarities.  
 
6.1.4. GH and 11 β-HSD1 
As discussed in previous chapters and in Section 1.4.6, at the tissue level 
glucocorticoid action is modulated by isozymes of 11 beta-hydroxysteroid 
dehydrogenase (11β-HSD), type 1 and 2. 11β-HSD1 is modulated by many 
factors, including GH/ IGF-I, thyroid hormone, insulin, glucocorticoids and sex 
steroids (2).  Thus, in patients with hypopituitarism there may be alterations in 
tissue specific exposure to glucocorticoids independent of circulating values.  This 
is particularly relevant in patients with GH deficiency.   
GH acting via IGF-I inhibits the autocrine generation of cortisol through inhibition 
of 11β-HSD1 (182). The phenotype of GHD in the context of hypopituitarism may, 
in part be mediated through increased 11β-HSD1 activity (182) as in these GHD 
patients the THF+allo-THF/ THE ratio (indicative of increased 11β-HSD1 activity) 
is increased by 50% from baseline and reduces after commencing GH therapy 
(even in elderly patients) without alteration in the UFF/UFE ratio, indicative of a 
resulting decrease in 11β-HSD1 oxoreductase activity (183, 184) without any 
change in 11β-HSD2 activity. Conversely, patients with acromegaly and high IGF-
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I concentrations have decreased 11β-HSD1 activity; a defect that resolves with 
appropriate treatment of the GH excess (182). These studies are endorsed by in 
vivo studies, which show a decrease in hepatic 11β-HSD1 expression in rats 
treated with GH (185-187) and in vitro experiments have shown that GH has no 
direct effect on 11β-HSD1 but rather acts via IGF-I (i.e. IGF-I inhibits 11β-HSD1 
activity) (182, 188).  Clinically patients starting on GH may need a slight increase 
in glucocorticoid replacement dose or patients who are ACTH replete prior to GH 
replacement may need retesting once on GH treatment (421). However, in GH 
deficient patients, cortisol bioavailability is increased in key tissue such as liver, 
fat and muscle.  Therefore, many of the changes reported in GH deficiency could 
be secondary to alterations in cortisol exposure at a tissue level secondary to 
modulation of 11β-HSD1.  However, to date the impact of GH on 11β-HSD1 has 
only been examined in a few clinical studies (182-184, 422-424) (many of which 
involved patients with acromegaly) (182, 422, 424).  In these small studies, 
ranging from 6-23 participants, there were varying incidences of ACTH deficiency 
with some including no patients on hydrocortisone therapy (182) to all patients 
receiving on hydrocortisone therapy (183, 184).  
 
6.1.4.1. Measurement of 11 β-HSD1 activity in vivo using urinary gas 
chromatography/ gas spectrometry 
The metabolism of cortisol has been extensively reviewed by Tomlinson et al. (2), 
the major route comprises the interconversion of cortisol (Kendall’s compound F) 
to cortisone (Kendall’s compund E) through the activity of 11 β-HSD isozymes or 
reduction of the C4-5 bond by either 5α-reductase or 5β-reductase to yield 5α-
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THF (allo THF) and 5β-THF respectively (2) (Figure 6.1). THF, allo THF and 
tetrahydrocortisone (THE) are rapidly conjugated with glucuronic acid and 
excreted in the urine (2).  Downstream, cleavage of the THF and THE to the C19 
steroids 11 hydro or 11-oxo-androsterone or etiocholanolone occur.  Alternatively 
reduction of the 20-oxo group by 20α or 20β hydroxysteroid dehydrogenases 
yield α and β cortols and cortolones, respectively, with the subsequent oxidation 
at the C21 position to form the extremely polar metabolites cortolic and cortolonic 
acids. Approximately 50% of secreted cortisol appears in the urine as THF, allo 
THF and THE, 25% appears as cortols/ cortolones, 10% as C19 steroids, 10% 
cortolic/ cortolonic acids and remaining are free unconjugated steroids (F, E, 6β 
and 20α/ 20β-metabolites of F and E) (2). 
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Figure 6.1. The major pathways involved in cortisol metabolism (E= cortisone, F= 
cortisol, Et = etiocholanolone, An = androsterone). 
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6.2. Hypothesis 
Our hypothesis is that 11 β-HSD1 is upregulated in hypopituitarism due to 
unphysiological glucocorticoid replacement therapy and the ensuing increase in 
tissue specific cortisol generation contributes to the changes in body composition 
reported in hypopituitarism. 
 
6.3. Strategy of Research and Aims 
To assess the effect of hydrocortisone therapy on 11 β-HSD1 in vivo, the urinary 
corticosteroid metabolite profile of growth hormone deficient hypopituitary patients 
(some with ACTH deficiency compared to those with normal ACTH reserve) were 
assessed with the following aims. 
a. To assess differences in total cortisol metabolites, measures of 11 β-
HSD1 (THF +alloTHF/THE) and urinary free cortisol levels in hypopituitary 
patients, with and without ACTH deficiency. 
b. To assess the impact of hydrocortisone therapy in hypopituitarism on 
measures of body composition. 
c. To assess if corticosteroid metabolism is correlated with measures of body 
composition. 
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6.4. Methods 
6.4.1. Gas Chromatography/ Mass spectrometry for corticosteroid 
metabolites in human and mouse urine 
6.4.1.1. Principles 
GC/MS urinary steroid analysis was carried out by Beverley Hughes at the 
Institute for Biomedical Research, Centre for Endocrinology, Diabetes and 
Metabolism (CEDAM), University of Birmingham.  The GC/MS was based on the 
method described by Palermo et al. (311). The methods of sample work-up for 
GC/MS analysis (conjugate hydrolysis, extraction and derivatization) and their 
methodologies have been published in detail in several manuscripts (149, 312) 
and in depth description is beyond the scope of this thesis. 
GC/MS was used to analyse the metabolites of steroid hormones and their 
precursors.  In the CEDAM, at the University of Birmingham, approximately 40 
steroids are targeted for selected-ion-monitoring analysis, which cover all 
disorders of steroid synthesis and metabolism. A recent review by Krone et al. 
from this Department has highlighted several key features of urinary steroid 
metabolite analysis including the major shortcoming of data presentation in 
clinical GC/MS urine steroid profiling (313). Tabulating only the quantified 
amounts of steroid metabolites can be confusing and difficult to interpret, 
therefore improvement in the visual presentation of data has been made within 
the department (313). 
The pathway to steroid hormone production is commonly divided into the 
synthesis of mineralocorticoid, glucocorticoids and sex steroids (Figure 1.4). We 
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have added two groups to this classification; ‘androgen precursors’ includes the 
Δ5-steroids pregnenolone, 17OHpregenenolone, DHEA and the Δ4-steroids 
androstenedione and their metabolites as this represents the main pathway to 
active androgens. The second additional group is ‘glucocorticoid precursors’, 
which consists of the Δ4-steroids progesterone, 17OHprogesterone and 21-
deoxycortisol and their metabolites (313). Within CEDAM normal ranges have 
been developed from a large number of healthy controls. The GC/MS profile of an 
individual patient is plotted for each determined parameter against the normal 
reference population (Figure 6.2). Such profiles allow for an immediate overview 
of the complete set of metabolites (313). Most hormonal imbalances caused by 
enzyme deficiencies or “blocks” cause depletion of a steroid product and build-up 
of the upstream precursors. Thus, a ratio of metabolites of the substrate to 
metabolites of the product should indicate if there is such a block.  In this thesis 
ratios of glucocorticoid metabolites are used to determine the relative activity of 
11 β-HSD1 and 11 β-HSD2. 
 
6.4.1.2. Methods 
Quantitative data on excretion of individual steroids requires accurate 24 hour 
sampling and 1ml of a 24-hour collection for analysis.  For murine studies 
individual mouse urine was collected on filter paper and processed. 
The following isotope labelled internal standards were used; (9,11,12,12-2H) 
cortisol and (9,12,12-2H) cortisone.  The standards were calibrated by high 
performance liquid chromatography (HPLC) analysis of solubilised, non-labelled 
standard on known weight.  Free steroid was extracted using Sep-pak C18 
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cartridges (314).  Labelled steroid d4-cortisol (0.18μg), and d3-cortisone (0.12μg), 
as well as internal standards (stigmasterol and cholesteryl butyrate), 200μg were 
then added.  The samples were then derived using 100μl of 2% methoxyamine 
hydrochloride in pyridine and 50μl of trimethylsilylimidzole.  Lipidex 
chromatography was then used to purify the steroid derivative. 
GC/MS was carried out using a Hewlett Packard 5970 mass spectometer and 
15m fused-silica capillary column, 0.25mmID, 0.25μm film thickness (J&B 
Scientific, Folsom CA, USA) using 2μl of sample.  Steroids were quantified by 
comparing individual peak area to the peak area of the internal standards, for 
cortisol fragment 605m/z compared to 609 m/z and for cortisone fragment 531 
m/z compared to 534 m/z.  The relative peak area was calculated and the 
metabolite concentration expressed as μg/24hr.  A quality control (QC) was 
analysed with each batch.  The intra and inter-assay co-efficient of variance was 
<10%.   
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Figure 6.2. Representative graph of steroid metabolite excretion (μg/ 24 hours) 
assessed by 24 hour urinary gas chromatography/ mass spectrometry in healthy 
adults divided into metabolites of androgens, mineralocorticoids and 
progesterone (17-OHP and 11-deoxycortisol) and glucocorticoids.  Box and 
whisker plots represent mean and 5th and 95th percentile. 
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6.4.2.  Assays for Clinical study 
6.4.2.1. GH assay used in this study 
Serum GH was measured using DPC Immulite 1000 immunometric assay 
calibrated against IS 80/505. This standard (IS 80/505) was assigned a value in 
International Units, and therefore GH was reported in mIU/L with a conversion 
factor of 2 for µg/litre. For results < 20 mIU/L the DPC assay gave similar results 
to the RIA.  For results >20 mIU/L the DPC assay gave results between 10-20% 
lower. The assay was transferred to the Immulite 2500 when DPC was bought by 
Siemens. This did not result in any significant change in GH values. Serum GH 
levels were measured by an in house RIA in a central laboratory as previously 
described (425) (the value in mIU/litre was divided by a conversion factor of 2 to 
obtain µg/litre).  The limit of detection of the assay is 0.5µg/litre and the 
interassay CV is 5.7% at 2 µg/litre, 4.3% at 3µg/litre, 5.5% at 7.3 µg/litre and 
4.47% at 14.7 µg/litre. 
A new international standard was produced in 2001 (WHO IS 98/574). This is 
comprised of recombinant material consisting of a 22kDa growth hormone of 
>95% purity. Unlike the previous standard, IS 98/574 has been assigned values 
in both mass and International Units, allowing conversion between mass units 
and International Units such that 1μg corresponds to 3 milli-International Units. 
Although our GH assay has remained the same (Siemens Immulite 2500), it has 
now been calibrated against the new IS 98/574 and since May 12th 2008, results 
have been reported in µg/L.  
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6.4.2.1.1 GH Assays – General Description 
The measurement of GH has evolved from polyclonal radioimmunoassay (RIA) to 
modern two-site monoclonal antibodies which are now non-isotopic and have 
enhanced sensitivity.  The old assays were limited by sensitivity, being unable to 
tell unmeasurable levels from measurable low concentrations (426).    
The development of GH assays was closely linked to the invention of the classic 
immunoassay.  When enzyme immunoassays and other non-radioactive 
immunoassays became available they were also applied to GH measurement 
(427).  As the production of monoclonal antibodies became possible the 
specificity of GH assays increased as these monoclonal antibodies are directed 
against a very distinct three dimensional structure on the surface of the antigen 
and therefore are less likely to recognise isoforms and fragments of the molecule 
(427).  The most frequently used assays today are the classical sandwich-type 
immunometric assays with secondary antibody labelled by something which can 
be quantified by labelling with radioactivity (IRMA), enzyme mediated colorimetry 
(ELISA), time resolved fluorescence (IFMA) or chemiluminescence (ILMA/ ICMA).  
These sandwich type assays have sensitivities of around 0.2µg/litre and some of 
them can have sensitivities as low as 0.002µg/litre (427).  This is in contrast to 
older competitive assays, which frequently use polyclonal antibodies (which are 
the basis of many of our recommendations for diagnosis and long term follow up 
in acromegaly).  Compared to the more recent assays they are less sensitive with 
lower detection limits between 0.5 and 1 µg/litre for GH. (427) 
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6.4.2.2. IGF-I assays used in this study 
Serum IGF-I was measured using an in-house RIA with acid ethanol extraction 
performed to remove IGF-binding proteins, as previously described (428).  The 
limit of detection of the assay is 2.0nmol/litre.  The interassay CV is 5.4-8.4% 
between 16-104 nmol/litre.  Reference ranges were derived from adults with no 
known or suspected endocrine disorders.  Reference range values were 14-
48nmol/litre at 21-30 years (n=71), 13-37 nmol/litre at age 31-45 years (n=123) 
and 8.9-32nmol/litre (n=75) above 45 years.   
 
6.4.2.2.1 IGF-I assays – General description 
Several factors of IGF-I physiology are important to remember when utilising 
information from IGF-I assays and in assessing IGF-I assay performance 
including: circadian rhythms, nutrition, age, IGF-BPs, insulin, oestrogen, 
androgens, thyroxine and cortisol.(429) IGF-I levels increase from birth until 
puberty (5 fold increase) then decrease with age (3.5 fold decrease from puberty 
to old age).(429) For these reasons it is important when assessing IGF-I that 
once compares to age adjusted reference ranges.  After the age of 30 it is 
reasonable to have age related reference ranges according to decades due to the 
steady rate of decline.   
Diabetes and renal disease can lead to significant increases in IGF-BP, therefore 
if assays are used in which there is IGFBP assay interference the IGF-I value 
may be artificially high.(430) There is significant day to day sample variability in 
IGF-I levels, Milani et al. reported that serial samples (intervals of 6-12 weeks) 
from the same patient may show large variability in IGF-I (3-36%).(431) 
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All of the initial IGF-I assays were conventional radioimmunoassays (RIAs) that 
used competitive binding between radiolabelled and unlabeled IGF-I in serum and 
were therefore open to binding protein interference (429).  The degree of 
interference in these original RIA was related to the affinity of the antibody, in 
higher affinity antibodies the sample could be diluted to overcome effect of 
binding proteins (432).  Because of these problems with binding protein 
interference a large number of techniques were developed to remove or nullify 
their effect.  These included acid gel filtration chromatography (which is the gold 
standard as it has high reproducibility but is difficult to perform) and acid/ ethanol 
precipitation (which is easy to use and highly reproducibility but does not remove 
all binding proteins).  The West Midlands Regional Endocrine Laboratory uses the 
acid ethanol technique which removes the vast majority of IGF-BP3 and 5 which 
are bound to acid labile subunit but does not remove smaller binding proteins that 
do not bind to ALS such as IGF-BP1 and 4 (433, 434).  Another potential 
limitation of this method is that some of the IGF-I is also precipitated by this 
method and laboratories need to account for this if possible otherwise the IGF-I 
concentration will be an underestimation.  Some units add IGF-II to the elute from 
acid ethanol extraction to increase the removal of IGF-BP1 and 4, which 
completely eliminates IGFBP assay interference (435) but this needed an 
antibody with low affinity for IGF-II but high affinity for IGF-I.  Newer techniques 
have tried to avoid the problem of binding protein interference by using a two 
antibody capture technique (436) which does not need radiolabelled tracers and 
successfully eliminates binding protein interference.   
 
Chapter 6   11 β-HSD1 and Hypopituitarism 
 223 
6.4.2.3. Diagnosis of ACTH deficiency 
The hypothalamic pituitary adrenal axis was deficient if the + 30 minute cortisol 
response to a 250μg ‘short’ synacthen testing was <550nmol/litre (437) or less 
than 500nmol/litre following insulin induced hypoglycaemia during an insulin 
stress test. Samples were assayed for cortisol using a chemiluminescence 
immunoassay (Advia Centaur; Bayer Diagnostics, Newbury, UK) with an 
interassay imprecision of less than 10% for serum cortisol concentrations 
between 68 and 970 nmol/liter (with interassay coefficients of variation of 10.2% 
at 76 nmol/liter, 7.7% at 528 nmol/liter, and 7.4% at 882 nmol/liter) (438).  This 
assay is equivalent to the previously described Bayer ACS 180 (437) using the 
same reagents on a larger automated platform (439).  
 
6.4.2.4. Diagnosis of TSH deficiency 
The thyroid axis was deficient if the free T4 concentration was below the local 
reference range, with an inappropriately low/ normal TSH. Serum free T4, free 
triiodothyronine (T3), and TSH were measured by chemiluminescent 
immunoassay (Advia Centaur; Bayer Diagnostics, Newbury, England). The 
laboratory reference range for free T4 was 0.70 to 1.55 ng/dL (9.0-20.0 pmol/L), 
with an interassay coefficient of variation of 8.2% to 9.8% over the range of 0.64 
to 4.27 ng/dL (8.2-54.9 pmol/L). Serum TSH concentration had a reference range 
of 0.4-5.5 mU/L, with an interassay coefficient of variation of 4.4% to 10.9% over 
the range of 0.41 to 24.5 mU/L. The lower limit of reporting for the TSH assay was 
0.1 mU/L, with a mean functional sensitivity 0.02 mU/L. Free T4 and TSH 
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concentrations were determined in all; in those with serum TSH concentrations 
below the reference range, serum free T3 (reference range, 227.3-422.1 pg/dL 
[3.5-6.5 pmol/L], interassay coefficient of variation of 4.2%-6.9% over the range of 
259.7-1039.0 pg/dL [4.0-16.0 pmol/L]) was additionally measured. The reference 
ranges used for free T4, TSH, and free T3 were those recommended by the 
manufacturer and used in other studies of this cohort and studies from our unit 
(440, 441).  
 
6.4.2.5. Diagnosis of FSH and LH deficiency 
Hypothalamic-pituitary gonadal dysfunction in males was diagnosed in the setting 
of a low serum testosterone and inappropriately low/ normal gonadotropins.  In 
females hypothalamic-pituitary gonadal dysfunction was diagnosed in 
premenopausal females if the patient was amenorrheic (with normal prolactin 
levels) and in post-menopausal females if the FSH was inappropriately low 
(<35IU/ litre).   
 
 
6.4.2.6. DEXA and measurement of body composition in clinical study 
Whole body Dual Energy x-ray absorptiometry (DEXA) scanning was performed 
to assess body composition and bone mineral density using a total body scanner 
(DPX-L, Lunar Corp., Madison, WI, USA).  For total fat and lean mass 
measurements, coefficients of variation were less than 3%.  Regional fat mass 
was defined as previously reported (442).  Waist region was defined within a box 
area between the upper part of D12 and the iliac crest and the thigh region was 
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defined as a box positioned so that its upper border at the level of the inferior 
border of the hip region (see Figure 6.3).  Further division of waist fat was made 
to characterise the ‘central’ or ‘omental’ fat region.  Central fat was deemed to be 
the area overlying the vertebrae below D12 and either side of the vertebral 
column.  Muscle strength was not assessed in this study, as it was not an 
outcome at initial study design. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3.  Method of calculating central abdominal fat to peripheral fat ratio 
using whole body DEXA scanning, where area 2 = central fat and area 4 = 
peripheral fat. 
  
6.4.3. Statistical methods 
Statistical analysis was performed using Prism for Windows version 5.0 
(GraphPad Software Inc, San Diego, CA, USA) software packages.  Continuous 
data were summarised using means and standard deviations (or standard error of 
mean) if parametrically distributed or medians and inter-quartile ranges if non-
parametrically distributed.  Parametric data was compared using a paired t-test 
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and non-parametric data was analysed using a Mann-Whitney test.  Multiple 
comparisons were assessed using one-way analysis of variance (ANOVA), with 
Kruskal-Wallis for non-parametric data.  Associations between variables were 
analysed using Pearson correlation for parametric data and Spearman rank 
correlation for non-parametric data.  The level for statistical significance was 
taken at p<0.05.   
 
6.4.4. Ethics 
The study was approved by the local research ethics committee and Scientific 
Advisory Committee of the Wellcome Trust Clinical Research Facility at the 
Queen Elizabeth Hospital, Birmingham at which the study was performed.  All 
patients were recruited from the Pituitary Clinic at the Queen Elizabeth Hospital, 
Birmingham and gave informed written consent.   
 
6.5. Results 
6.5.1. Patient characteristics 
In total, 53 patients consented for the study (19 female). Baseline characteristics 
are detailed in Table 6.1.  All patients had severe GH deficiency (GHD) as 
diagnosed on either insulin tolerance test or glucagon stimulation test [of note 
32/51 (62.8%) had an IGF-I in the normal age related reference range, 
highlighting the poor sensitivity of IGF-I as a screening test for the diagnosis of 
GHD].  GHD deficient patients did not receive GH replacement therapy during this 
study.  In the female group 11/19 (52.6%) and male group 22/34 (67.6%) were 
Chapter 6   11 β-HSD1 and Hypopituitarism 
 227 
ACTH deficient, respectively, but there was no difference in rates of ACTH 
deficiency between genders (p=0.37). In the ACTH deficient group (n=33), 19 
patients received less than or equal to 20mg hydrocortisone per day (8 female) 
and 14 patients received >20mg per day (2 female).  28 patients received twice 
daily and 5 patients received thrice-daily hydrocortisone therapy.  19/53 patients 
had TSH deficiency and were receiving thyroxine therapy with freeT4 
concentrations in the normal range. 33/53 patients had hypogonadotropic 
hypogonadism and were on replacement therapy. 
 
 
 
Table 6.1.  Basic demographic, quality of life and body composition data on total 
group, male and females.  * p<0.05, ***p<0.0001, female compared to male. 
Median and interquartile ranges.  
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6.5.2. Steroid metabolite excretion rates in hypopituitary patients 
with and without ACTH deficiency 
Each patient provided a 24-hour urine collection, while taking their routine 
hydrocortisone dose and other replacement therapies, for assessment of 
corticosteroid metabolites by gas chromatography/ mass spectrometry and 
compared to healthy controls (Figure 6.2).  Patients were subdivided into patients 
who had hypopituitarism (and severe GHD) but who were not ACTH deficient 
(Figure 6.4.a) and patients who had hypopituitarism (and severe GHD) and were 
ACTH deficient (and receiving hydrocortisone therapy) (Figure 6.4.b). 
Metabolites of glucocorticoids were particularly increased in patients receiving 
hydrocortisone therapy (Figure 6.4.b, blue box) compared to both healthy controls 
and patients who had hypopituitarism (and severe GHD) but who were not ACTH 
deficient.  
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Figure 6.4. Representative graph of steroid metabolite excretion (μg/ 24 hours) 
assessed by 24 hour urinary gas chromatography/ mass spectrometry in patients 
with hypopituitarism (GHD but normal HPA axis) (a) and patients with 
hypopituitarism who were receiving hydrocortisone therapy for ACTH deficiency 
(b) divided into metabolites of androgens, mineralocorticoids and progesterone 
(17-OHP and 11-deoxycortisol) and glucocorticoids.  Metabolites of 
glucocorticoids are particularly increased in patients receiving hydrocortisone 
therapy (b, blue box).  Box and whisker plots represent mean and 5th and 95th 
percentile of healthy control group.  Symbols represent individual patient results.  
?????????????????????????? ????????????????????a 
?????????????????????????????????????????????????????????????????? ???????????????????b 
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6.5.3. Comparison of corticosteroid metabolites 
To further clarify the results of Section 6.5.2, we analysed the total cortisol (F) 
metabolites (Figure 6.5.a) (μg/ 24 hours), THF + allo-THF/THE (a measure of 
global 11β-HSD1 activity) (Figure 6.5.b) and urinary free cortisol (Figure 6.5.c) 
between patients with normal ACTH reserve and patients receiving increasing 
doses of hydrocortisone therapy (hydrocortisone doses less than or equal to 
20mg per day or greater than 20 mg per day) assessed by gas chromatography/ 
mass spectrometry of 24-hour urinary collections.  This showed an increase in 
total cortisol metabolites at higher doses of hydrocortisone (Figure 6.5.a), a 
higher THF + alloTHF/THE ratio (11 β-HSD1) (Figure 6.5.b) at both doses of 
hydrocortisone, but no change in urinary free cortisol levels between groups 
(Figure 6.5.c). 
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Figure 6.5. Differences in total cortisol (F) metabolites (a) (μg/ 24 hours), THF + 
allo-THF/THE (b) and urinary free cortisol (c) between patients with normal ACTH 
reserve and patients receiving increasing doses of hydrocortisone (HC) therapy 
(at doses less than or equal to 20mg per day or greater than 20 mg per day) 
assessed by 24 hour urinary gas chromatography/ mass spectrometry.  * p<0.05, 
** p<0.001, NS = not significant. Lines represent median and interquartile ranges. 
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6.5.4. Effect of hydrocortisone replacement therapy on body 
composition in hypopituitary patients 
The effect of ACTH deficiency and hydrocortisone therapy on body composition 
assessed by body mass index (BMI) (Figure 6.6.a), fat mass (Figure 6.6.b), and 
Waist hip ratio (WHR) (Figure 6.6.c).  There was no difference between groups 
for BMI or fat mass (Figure 6.6.a + b).  There was an increase in WHR at higher 
doses of hydrocortisone therapy (Figure 6.6.c).   
 
 
 
 
 
 
Figure 6.6. Differences in body mass index (BMI) (a), Fat mass (b) and Waist hip 
ration (WHR) (c), between patients with normal ACTH reserve and patients 
receiving increasing doses of hydrocortisone (HC) therapy (at doses less than or 
equal to 20mg per day or greater than 20 mg per day).  * p<0.05, NS = not 
significant. Lines represent median and interquartile ranges. 
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6.5.5.  Correlation of 11 β-HSD1 activity and body composition in all 
hypopituitary patients. 
The correlation between 11 β-HSD1 and BMI (Figure 6.7.a), fat mass (Figure 
6.7.b), WHR (Figure 6.7.c) and a DEXA derived ratio of central to peripheral fat 
mass (Figure 6.7.d) was assessed in the entire group of hypopituitary patients. 
There was a significant negative correlation between BMI and 11 β-HSD1 activity 
but no correlation for other markers of body composition. 
 
Figure 6.7. Correlations between total body 11 β-HSD1 activity as assessed by 
THF + alloTHF/THE ratio in by 24 hour urinary gas chromatography/ mass 
spectrometry and Body mass index (BMI) (a), fat mass (b), waist hip ratio (c) and 
ratio of central abdominal fat to thigh fat (d) in all patients.  ** p<0.001, NS = not 
significant, r = correlation coefficient. Full line = linear regression, hatched lines = 
95% confidence intervals.   
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6.5.6. Correlation between total cortisol metabolites and body 
composition in all hypopituitary patients 
The correlation between Total F metabolites and BMI (Figure 6.8.a), fat mass 
(Figure 6.8.b), WHR (Figure 6.8.c) and a DEXA derived ratio of central to 
peripheral fat mass (Figure 6.8.d) was assessed in the entire group of 
hypopituitary patients. There was a significant positive correlation between the 
DEXA derived ratio of central to peripheral fat mass and total F metabolites but 
no correlation for other markers of body composition were statistically significant. 
 
 
Figure 6.8. Correlations between total cortisol (F) metabolites as assessed by 
THF + alloTHF/THE ratio in by 24 hour urinary gas chromatography/ mass 
spectrometry and Body mass Index (a), fat mass (b), waist hip ratio (c) and ratio 
of central abdominal fat to thigh fat (d) in all patients. ** p<0.001, NS = not 
significant, r = correlation coefficient. Full line = linear regression, hatched lines = 
95% confidence intervals. 
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6.6. Discussion 
These results show that hypopituitary patients who receive hydrocortisone 
therapy have significant alterations in corticosteroid metabolism. There were 
significant abnormalities in corticosteroid metabolite profiles in ACTH deficient 
patients (receiving hydrocortisone) when compared to normal controls and 
hypopituitary patients with normal ACTH reserve.  The abnormalities reported 
were primarily due to an increase in glucocorticoid metabolites (Figure 6.4).  
There were increases in total cortisol metabolites and THF+allTHF/The ratio (a 
marker of 11 β-HSD1 activity) in patients on hydrocortisone therapy, and this was 
dose related.  Importantly, however there were no change in urinary free cortisol 
levels with increasing doses of hydrocortisone, showing that increased doses of 
hydrocortisone were not simply excreted in the urine as the reached the renal 
threshold, but rather underwent intracellular metabolism. 
 
Hypopituitarism is associated with increased morbidity and mortality (339) and we 
have previously shown that in patients with acromegaly, ACTH deficiency is an 
independent predictor for mortality and daily doses of hydrocortisone of greater 
than or equal to 25mgs per day were associated with increased mortality, 
predominantly due to cardiovascular disease (443).  In the general population, 
doses of prednisolone greater than or equal to 7.5mgs/day have also been 
associated with increased cardiovascular disease (444).  As we have shown that 
in vitro 11 β-HSD1 is upregulated by glucocorticoid exposure (Section 4.6), we 
hypothesised that this may also happen in patients with hypopituitarism who are 
receiving hydrocortisone therapy and this may have deleterious consequences.  
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Over the last few years there has been increasing awareness that the 
replacement doses of hydrocortisone that were classically used were greater than 
the cortisol production rate in healthy controls (145, 146).  This has been 
highlighted by studies which, by using cortisol day curves, reveal that median 
doses of hydrocortisone of 29.5 + 1.2mg lead to peak cortisol and mean daily 
cortisol concentrations above the normal range, which in one study lead to a 
change in therapy in 88% of patients (75% of patients received a dose reduction) 
(387).  Studies in patients with partial ACTH deficiency have shown similar day 
curves to healthy controls suggesting that these patients may be over-treated by 
conventional steroid replacement therapy (388).  Fillipson et al. (389) have 
described an adverse metabolic profile in a cohort of GH deficient (hypopituitary) 
patients on higher doses of glucocorticoid replacement therapy.  They found that 
patients on hydrocortisone replacement had increased total cholesterol, 
triglycerides, waist circumference and HbA1c compared to the ACTH sufficient 
patients.  Importantly, subjects who had hydrocortisone equivalent doses of less 
than 20mg/day did not differ in metabolic endpoints compared to the ACTH 
sufficient patients.  However, when a hydrocortisone equivalent doses of more 
than 20mg/day was administered patients had an adverse metabolic profile (389). 
These studies showing the biochemical over-replacement of patients with ACTH 
deficiency with hydrocortisone are also important at a molecular level as there is 
evidence that continuous, prolonged compared to intermittent short exposure to 
glucocorticoids may have different effects on a number of steroid responsive 
enzymes (394). 
As a result of the above evidence, there has been a recent push to design orally 
active delayed or sustained release formulations of hydrocortisone to reproduce 
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‘physiological replacement’ (397).  Johannsson et al. recently showed that a novel 
modified release once daily oral hydrocortisone preparation (Duocort) produced a 
diurnal plasma cortisol profile, which mimicked the physiological serum cortisol 
profile (398).  Similar results are reported with a preparation originating from 
Sheffield, UK (Chronocort) (399, 400).  These results are exciting, however, 
larger studies are required to fully assess the efficacy and role of these drugs in 
different cohorts of patients with adrenal insufficiency.  Given our results it would 
be interesting to assess if modified release hydrocortisone would reduce the 
abnormalities in corticosteroid metabolism reported in our patient cohort.  
There was a discrepancy between BMI and WHR and effect of increasing 
hydrocortisone dose and correlatiosn with THF+alloTHF/THE ratio. We found that 
the changes in higher hydrocortisone doses and the alterations seen in 
corticosteroid metabolites are associated with an increased visceral adiposity, as 
shown by increased WHR in patients on >20mgs of hydrocortisone per day 
(Figure 6.6.c) and the strong positive correlation between total F metabolites and 
ratio of central to thigh fat (Figure 6.8.d).  Visceral adiposity is known in the 
general population to be associated with insulin resistance or diabetes mellitus, 
hypercholesterolaemia and hypertension (342, 343).  Bujalska et al. first 
proposed that excessive activity of 11 β-HSD1 enzyme within visceral adipose 
tissue could lead to increased adipose tissue levels of glucococorticoids and 
‘Cushing’s disease of the omentum’ (413).  This was also suggested by 
transgenic models with over-expression of 11 β-HSD1 within adipose tissue 
resulting in increased accumulation of central fat with increased tissue 
corticosterone concentrations and an increased adipocyte size (178).   The 
increase in both THF+alloTHF/THE ratios and total cortisol metabolites in our 
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cohort of patients taking hydrocortisone therapy could lead to significant changes 
in adipose tissue biology. 
Visceral adiposity and decreased lean mass is also reported in patients with GHD 
and this improves following treatment with GH (341, 346, 375, 376).  It is 
interesting to speculate that many of these changes in body composition (both 
increased fat mass and decrease muscle mass) reported with GH therapy in 
patients with hypopituitarism may be due to inhibition of corticosteroid metabolism 
(in particular 11 β-HSD1) by GH treatment. Importantly, many patients in previous 
studies of GH replacement were also ACTH deficient and on hydrocortisone 
therapy. The reduction in 11 β-HSD1, following GH therapy (and the resultant rise 
in IGF-I) may decrease cortisol exposure to adipose tissue and muscle, thus 
leading to changes in body composition. 
 
One important limitation of this study is the heterogeneous nature of the cohort of 
patients with hypopituitarism (gender, body composition, rates of ACTH 
deficiency and hydrocortisone doses), which is a common feature of many 
studies of hypopituitarism and GH replacement.   Following discussion with 
statistician colleagues it was decided that multiple regression analysis may not be 
helpful in separating the effects of gender/ body composition and hydrocortisone 
replacement, given the small numbers in the study.  Instead of relying on multiple 
regression analysis we are currently performing a study in collaboration with 
Professor Chris Thompson and Dr Amar Agha at Beaumont Hospital, Dublin of 
male patients only, with ACTH deficiency, with each patient receiving 
hydrocortisone therapy at different doses in a cross-over protocol (hydrocortisone 
10mg mane and 5mg tarde. hydrocortisone 10mg mane and 10mgs tarde and 
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hydrocortisone 20mg mane and 10mg tarde).  This will allow us to assess the 
effect of different hydrocortisone exposure rates on cortisol metabolism within 
individuals. We are also currently performing a follow up double blind placebo 
controlled study of the effect of GH replacement therapy on corticosteroid 
metabolites in this patient group.  
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7.1 Discussion 
Glucocorticoids in excess lead to several adverse consequences including insulin 
resistance, hypertension, osteoporosis, obesity and muscle loss/ weakness 
(myopathy) (1).  Ageing is also associated with similar co-morbidities. In 
particular, in ageing there is a significant loss in muscle mass and strength or 
sarcopaenia as described in detail in Section 1.3.  Glucocorticoid mediated 
myopathy and sarcopaenia have several phenotypic, histological and molecular 
similarities (Section 1.3 and 1.5).  There is conflicting data with regard to changes 
in circulating levels of glucocorticoids in ageing (126, 127).  However, in recent 
years the regulation of glucocorticoids at a tissue level by isozymes of 11 β-HSD 
has received much interest (2).  In particular, 11 β-HSD1 which interconvert’s 
inactive to active GC in vivo has been shown to have an important role in adipose 
tissue, bone, liver and brain, there is however less data regarding 11 β-HSD1 in 
skeletal muscle (2).  There is evidence from our group that 11 β-HSD1 increases 
in bone and skin with age (5, 6).   
We hypothesised that 11 β-HSD1 is an important regulator of skeletal muscle GC 
exposure and may have a role in GC mediated myopathy.  Furthermore, given 
the similarities between muscle in sarcopaenic subjects and those with GC 
mediated myopathy and the potential that 11 β-HSD1 is increased with age we 
hypothesised that 11 β-HSD1 could play a key role in the sarcopaenic process by 
increasing local GC levels within muscle and leading to alterations in molecular 
pathways associated with GC mediated myopathy.    
We have shown in Chapter 3 that 11 β-HSD1 is expressed and has oxoreductase 
activity in skeletal muscle.  There was also a suggestion of fibre type 
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predominance in 11 β-HSD1 expression, however, our experiments to date have 
not fully elucidated this and further work is needed in this area. 
 
11 β-HSD1 is upregulated in the C2C12 murine skeletal muscle cell line by GC 
exposure.  Importantly, 11 β-HSD1 is upregulated by both active (corticosterone, 
B) and inactive steroids (11-dehydrocorticosterone, A). 11-dehydrocorticosterone 
requires activation to B by 11 β-HSD1 for biological activity, therefore within 
C2C12 cells the activation of A to B by 11 β-HSD1 leads to upregulation of 11 β-
HSD1.  In clinical practice the effect of exposure of skeletal muscle to 
supraphysiological glucocorticoid concentrations in serum (in endogenous and 
exogenous Cushing’s syndrome) may be further affected by 11 β-HSD1 activity 
within muscles.  Muscle specific activation of the inactive glucocorticoid cortisone 
which is produced from cortisol by the dehydrogenase activity of 11 β-HSD2 in 
the kidney (which is known to be significantly elevated in Cushing’s syndrome) 
(317) may lead to a more severe muscle phenotype.  The increase in active GC 
within C2C12 cells is associated with upregulation of key atrophy related genes. 
In addition to this upregulation of atrophy genes there is also downregulation of 
the insulin/ IGF-I-AI3K-Akt-mTOR hypertrophy pathway and in particular GC 
treatment lead to a decrease in total IRS1 and increase in the inactivating Ser307 
phosphorylation of IRS1 which has been shown to negatively regulate insulin 
signalling through multiple mechanisms including decreased affinity for the insulin 
receptor and increased degradation.  These changes can be reversed through 
the inhibition of 11 β-HSD1 with the non-specific inhibitor glycyrrhetinic acid.   
A key mechanism for muscle repair and regeneration is the proliferation and 
differentiation of myoblasts into myotubules/ myofibres (8, 11).  We have shown 
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that GCs inhibit myoblast proliferation but, interestingly, inhibition of 11 β-HSD1 
leads to increased myoblast proliferation, the exact mechanisms and 
consequences of this need to be elucidated.   
The combination of the above results show that 11 β-HSD1 impacts on both 
atrophy and hypertrophy pathways in skeletal muscle and also the availability of 
myoblasts for muscle regeneration/ repair, the net result of these changes being 
an increase in the severity of GC mediated myopathy (as summarised in Figure 
4.11). 
 
We have shown that there is increased 11 β-HSD1 activity and expression in 
some but not all tissues in old versus young mice.  This increase in local GC 
production is associated with changes in GC mediated myopathy genes.  
Importantly, however there is a fibre type specific response in these markers.  
This is important as both GC mediated myopathy and sarcopaenia show a Type 
IIb fibre Type preponderance with relatively little effect on Type I fibres.  To 
assess the role of 11 β-HSD1 on ageing muscle a global 11 β-HSD1KO mouse 
was developed.  The 11 β-HSD1KO did not show any changes in body weight or 
muscle strength compared to its WT littermates, however it did show an increase 
in adrenal weight due to HPA axis activation, which leads to increased circulating 
GC as a compensatory mechanism, as shown in previous studies (159, 330, 336, 
338).  At the molecular level, there is evidence in the 11 β-HSD1KO mouse of 
improvement in atrophy related markers in the tibialis anterior with decreased 
levels of expression of MAO and a trend to decrease expression of MAFbx.  This 
may be interpreted as the decrease in locally generated cortisol leading to 
decreased GC mediated myopathy in these usually GC sensitive muscle fibres.  
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There is also evidence in the soleus muscle of the 11 β-HSD1KO of increased 
atrophy related genes including MAFbx, MAO and a trend to an increase in 
caplain.  Type I fibres are resistant to GC mediated myopathy and the decrease 
in locally generated GC in the 11 β-HSD1KO appears to have a detrimental 
effect.  Further work is required to examine fibre type specificity of muscle 
changes in the 11 β-HSD1KO.   
 
Patients with pituitary hormone deficiency (hypopituitarism) have increased 
morbidity and mortality (339), however, the exact mechanisms underpinning this 
have not been fully elucidated. There are a number of possible factors including 
the effect of the pituitary hormone deficiencies themselves or the hormonal 
therapy used as replacement.  The main deficiencies implicated in this are GH 
and ACTH deficiency, as are their related treatments, which is covered in detail in 
Section 6.1.2 and 6.1.3, respectively.  
The treatment of ACTH deficiency with hydrocortisone is unphysiological as it 
does not fully replicate the diurnal rhythm of cortisol secretion and may lead to 
supraphysiological circulating GC concentrations. Over the last few years there 
has been increasing awareness that the replacement doses of hydrocortisone 
that were classically used were greater than the cortisol production rate in healthy 
controls (145, 146).  In ACTH deficiency, median doses of hydrocortisone of 29.5 
+ 1.2mg lead to peak cortisol and mean daily cortisol concentrations above the 
normal range, which in one study lead to a dose reduction in 75% of patients 
(387).  Studies in patients with partial ACTH deficiency have shown similar day 
curves to healthy controls suggesting that these patients may be over-treated by 
conventional steroid replacement therapy (388) and there is evidence of adverse 
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metabolic profile in hypopituitary patients on higher doses of glucocorticoid 
replacement therapy. (389).   
GH acting via IGF-I inhibits the autocrine generation of cortisol through inhibition 
of 11β-HSD1 (182). The phenotype of GHD in the context of hypopituitarism may, 
in part be mediated through increased 11β-HSD1 activity (182) as in these GHD 
patients studies have shown a decrease in 11β-HSD1 oxoreductase activity (183, 
184) without any change in 11β-HSD2 activity following GH treatment.   
It was our hypothesis is that 11 β-HSD1 is upregulated in hypopituitarism due to 
unphysiological glucocorticoid replacement therapy and the ensuing increase in 
tissue specific cortisol generation contributes to the changes in body composition 
reported in hypopituitarism.  There were significant abnormalities in corticosteroid 
metabolite profiles in ACTH deficient patients (receiving hydrocortisone) when 
compared to normal controls and hypopituitary patients with normal ACTH 
reserve.  The abnormalities reported were primarily due to an increase in 
glucocorticoid metabolites (Figure 6.4).  There were increases in total cortisol 
metabolites and THF+allTHF/The ratio (a marker of 11 β-HSD1 activity) in 
patients on hydrocortisone therapy, and this was dose related.  Importantly, 
however there were no change in urinary free cortisol levels with increasing 
doses of hydrocortisone, showing that increased doses of hydrocortisone were 
not simply excreted in the urine as they reached the renal threshold, but rather 
underwent intracellular metabolism.  
We found that the changes in higher hydrocortisone doses and the alterations 
seen in corticosteroid metabolites are associated with an increased visceral 
adiposity, as shown by increased WHR in patients on >20mgs of hydrocortisone 
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per day (Figure 6.6.c) and the strong positive correlation between total F 
metabolites and ratio of central to thigh fat (Figure 6.8.d).  Visceral adiposity is 
known in the general population to be associated with insulin resistance or 
diabetes mellitus, hypercholesterolaemia and hypertension (342, 343).  Bujalska 
et al. first proposed that excessive activity of 11 β-HSD1 enzyme within visceral 
adipose tissue could lead to increased adipose tissue levels of glucococorticoids 
and ‘Cushing’s disease of the omentum’ (413). The increase in both 
THF+alloTHF/THE ratios and total cortisol metabolites in our cohort of patients 
taking hydrocortisone therapy could lead to significant changes in adipose tissue 
biology. 
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7.2. Future Directions 
The results in this thesis increase our knowledge of the role of 11 β-HSD1 in 
skeletal muscle and its potential roles in glucocorticoid mediated myopathy, 
sarcopaenia and the cortisol metabolism in patients receiving cortisol 
replacement therapy, however, there are many areas to be clarified further.  
 
7.2.1. Lab based studies currently underway within the unit 
1. Elucidation of molecular markers of changes in proliferation associated with 
glucocorticoid excess and inhibition of 11 β-HSD1. 
 
2. Development of a muscle specific 11 β-HSD1KO mouse to study the effect of 
tissue specific decrease in glucocorticoid exposure without the compensatory 
hypothalamic pituitary adrenal axis activation seen in the global 11 β-HSD1KO 
mouse. 
 
3. Rodent model to assess the impact of 11 β-HSD1 pharmacological inhibition 
on glucocorticoid induced myopathy in mice treated with high dose 
glucocorticoids.  
 
4. Microarray analysis of soleus and tibialis anterior of old WT vs. 11 β-HSD1KO 
to assess fibre specific changes further. 
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7.2.2. Clinical studies currently underway within the unit 
1. We have recently received funding from the European Research Council to 
further investigate the role of carry out a clinical study assessing the role of 11 β-
HSD1 in ageing.  This will involve a clinical study assessing 11 β-HSD1 activity 
and expression with increasing age and correlate this with markers of muscle 
strength and mass. 
 
2. To investigate the effect of hydrocortisone replacement on corticosteroid 
metabolites we are currently performing a study in collaboration with Professor 
Chris Thompson and Dr Amar Agha at Beaumont Hospital, Dublin which will 
involve a cross over study of male patients only, with ACTH deficiency with each 
patient receiving hydrocortisone therapy at different doses (hydrocortisone 10mgs 
mane and 5mgs tarde. hydrocortisone 10mgs mane and 10mgs tarde and 
hydrocortisone 20mgs mane and 10mgs tarde).  This will allow us assess the 
effect of different hydrocortisone exposure rates on corticosterone metabolism 
within individuals.  
 
3. To assess further the effect of GH treatment on 11 β-HSD1 and corticosteroid 
metabolites (in patients with and without co-existing ACTH deficiency) we are 
also currently performing a follow up double blind placebo controlled study of the 
effect of GH replacement therapy on corticosteroid metabolites. 
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7.3 Conclusions 
11 β-HSD1 is biologically active in skeletal muscle and may play a key role in the 
development of glucocorticoid-mediated myopathy and age related sarcopaenia.  
The development of 11 β-HSD1 inhibitors, which are being developed mainly for 
treatment of the metabolic syndrome, may have a role to play in age related 
sarcopaenia. Patients treated with unphysiological hydrocortisone replacement 
therapy have significant alterations in cortisol metabolites, which is associated 
with an adverse body composition.  
Further studies are required to assess in more detail the role of 11 β-HSD1 in GC 
mediated myopathy (in particular the fibre specificity), the impact of 11 β-HSD1 
on sarcopaenia in muscle specific KO models and inhibitor studies and the impact 
of the new modified release hydrocortisone on cortisol metabolism.  
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11-Hydroxysteroid Dehydrogenase Type 1 Regulates
Glucocorticoid-Induced Insulin Resistance in Skeletal
Muscle
Stuart A. Morgan,1 Mark Sherlock,1 Laura L. Gathercole,1 Gareth G. Lavery,1 Carol Lenaghan,2
Iwona J. Bujalska,1 David Laber,2 Alice Yu,2 Gemma Convey,2 Rachel Mayers,2 Krisztina Hegyi,3
Jaswinder K. Sethi,3 Paul M. Stewart,1 David M. Smith,2 and Jeremy W. Tomlinson1
OBJECTIVE—Glucocorticoid excess is characterized by in-
creased adiposity, skeletal myopathy, and insulin resistance, but
the precise molecular mechanisms are unknown. Within skeletal
muscle, 11-hydroxysteroid dehydrogenase type 1 (11-HSD1)
converts cortisone (11-dehydrocorticosterone in rodents) to ac-
tive cortisol (corticosterone in rodents). We aimed to determine
the mechanisms underpinning glucocorticoid-induced insulin
resistance in skeletal muscle and indentify how 11-HSD1 inhib-
itors improve insulin sensitivity.
RESEARCH DESIGN AND METHODS—Rodent and human
cell cultures, whole-tissue explants, and animal models were
used to determine the impact of glucocorticoids and selective
11-HSD1 inhibition upon insulin signaling and action.
RESULTS—Dexamethasone decreased insulin-stimulated glu-
cose uptake, decreased IRS1 mRNA and protein expression, and
increased inactivating pSer307 insulin receptor substrate (IRS)-1.
11-HSD1 activity and expression were observed in human and
rodent myotubes and muscle explants. Activity was predomi-
nantly oxo-reductase, generating active glucocorticoid. A1 (se-
lective 11-HSD1 inhibitor) abolished enzyme activity and
blocked the increase in pSer307 IRS1 and reduction in total IRS1
protein after treatment with 11DHC but not corticosterone. In
C57Bl6/J mice, the selective 11-HSD1 inhibitor, A2, decreased
fasting blood glucose levels and improved insulin sensitivity. In
KK mice treated with A2, skeletal muscle pSer307 IRS1 decreased
and pThr308 Akt/PKB increased. In addition, A2 decreased both
lipogenic and lipolytic gene expression.
CONCLUSIONS—Prereceptor facilitation of glucocorticoid ac-
tion via 11-HSD1 increases pSer307 IRS1 and may be crucial in
mediating insulin resistance in skeletal muscle. Selective 11-
HSD1 inhibition decreases pSer307 IRS1, increases pThr308 Akt/
PKB, and decreases lipogenic and lipolytic gene expression that
may represent an important mechanism underpinning their insu-
lin-sensitizing action. Diabetes 58:2506–2515, 2009
The pathophysiological effects of glucocorticoidsare well described and impact upon almost allorgan systems within the body. This is high-lighted in patients with glucocorticoids excess,
Cushing’s syndrome characterized by central obesity, hy-
pertension, proximal myopathy, insulin resistance, and in
some cases overt type 2 diabetes. In addition, up to 2.5% of
the population are taking prescribed glucocorticoids (1),
and their side effects represent a considerable clinical
burden for both patient and clinician.
Glucocorticoids induce whole-body insulin resistance
(2); however, the precise molecular mechanisms that
underpin this observation have not been deﬁned in detail.
In simple obesity and insulin resistance, circulating corti-
sol levels are not elevated (3), but in key insulin target
tissues including liver, fat, and muscle, glucocorticoid
availability to bind and activate the glucocorticoid recep-
tor is controlled by 11-hydroxysteroid dehydrogenase
type 1 (11-HSD1). 11-HSD1 is an endo-lumenal enzyme
that interconverts inactive (cortisone in humans and 11-
dehydrocorticosterone [11DHC] in rodents) and active
glucocorticoids (cortisol in humans and corticosterone
[CORT] in rodents) (4). Critically, the directionality of
11-HSD1 activity is cofactor (NADPH) dependent that is
supplied by a tightly associated endo-lumenal enzyme,
hexose-6-phopshate dehydrogenase (H6PDH). Decreases
in H6PDH expression and activity decrease 11-HSD1
oxo-reductase and increase dehydrogenase activity (5).
Despite this bidirectional potential, the predominant direc-
tion of activity in liver, adipose, and muscle is oxo-
reductase generating active glucocorticoid (cortisol and
CORT), therefore, amplifying local glucocorticoid action.
Binding of insulin to its cell surface receptor leads to a
conformational change and tyrosine autophosphorylation.
Consequently, the insulin receptor substrate (IRS) family
of adaptor proteins are recruited to the intracellular do-
main of the receptor and are phosphorylated at multiple
tyrosine residues by the receptor tyrosine kinase to permit
the docking of phosphatidylinositol-3-kinase (PI3K) and
subsequent generation of PI(3,4,5)P3. Generation of this
second messenger acts to recruit the Akt/PKB family of
serine/threonine kinases to the plasma membrane where
they are then activated (6). Further downstream, activated
Akt1/protein kinase B (PKB) phosphorylates a rab-GAP
(GTPase) protein, AS160, which is a crucial regulator of
the translocation of GLUT4 GLUT storage vesicles to the
plasma membrane (7). It is this mechanism that permits
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insulin-stimulated glucose entry into target tissues includ-
ing skeletal muscle (8).
The molecular mechanisms underpinning insulin resis-
tance are complex and variable. Serine/threonine phos-
phorylation of IRS1 (in particular Ser307 phosphorylation)
has been shown to negatively regulate insulin signaling
through multiple mechanisms including decreased afﬁnity
for the insulin receptor and increased degradation (9,10).
The interaction of glucocorticoids and the insulin sig-
naling cascade has only been examined in a small number
of studies that have offered variable explanations for the
induction of insulin resistance (11–14). Importantly, the
role of serine phosphorylation and the impact of prerecep-
tor glucocorticoid metabolism have not been explored.
The 11-HSD1 knockout mouse is relatively insulin sensi-
tive (15), and speciﬁc inhibitors of 11-HSD1 improve lipid
proﬁles, glucose tolerance, and insulin sensitivity and have
considerable potential as therapeutic agents (16–18).
However, the molecular mechanisms that underpin these
observations remain to be deﬁned.
Therefore, we have characterized the impact of glu-
cocorticoids upon the insulin-signaling cascade and ana-
lyzed the expression, activity, and functional impact of
11-HSD1 in vitro and using in vivo mouse models.
RESEARCH DESIGN AND METHODS
Cell culture. Mouse skeletal muscle cell line, C2C12 myoblasts (ECACC,
U.K.), were grown in DMEM (PAA, U.K.) supplemented with 10% FBS (37°C,
5% CO2). Cells were grown to 60–70% conﬂuence before differentiation
(initiated by replacing growth media with DMEM with 5% horse serum). After
8 days, myoblasts had fused to form multinucleated myotubes. Before
treatment, cells were washed out with serum-free media for 4 h. For
experiments examining Ser24 phosphorylation, C2C12 cells stably overex-
pressing myc-rIRS1 were generated and used as described previously for
3T3-L1 adipocytes (19).
Primary human myoblasts were obtained from PromoCell (Heidelberg,
Germany). Myoblasts were cultured to conﬂuence, as per the manufacturer’s
guidelines using the supplied media. Once conﬂuent, media was changed to a
chemically deﬁned media (PromoCell, Germany) including 2% horse serum
and cells differentiated into myotubes for 11 days. After differentiation, cells
were incubated with serum-free media for 4 h before treatment.
Unless otherwise stated, for all cell culture experiments investigating
insulin-signaling cascade protein phosphorylation, media was spiked with
human insulin (0.1 g/ml, Sigma, U.K.) for the ﬁnal 15 min of the treatment
period to achieve insulin stimulation. In experiments using the glucocorticoid
receptor antagonist, RU38486, cells were pretreated with RU38486 (10 mol/l)
for 10 min before adding Dexamethasone (Dex). Treatments and reagents
were supplied by Sigma, Poole, U.K. unless otherwise stated. Selective
11-HSD1 inhibitors (A1 and A2, 95% and 99% purity, respectively) were
provided through material transfer agreements with AstraZeneca (Maccles-
ﬁeld, U.K.). Inhibitor properties are presented within the results section.
RNA extraction, reverse transcription PCR, and real-time PCR. Total
RNA was extracted from cell lysates using the Tri-Reagent system and from
whole-tissue explants using RNeasy Fibrous Tissue Mini Kit (Qiagen). Integ-
rity, concentration, and reverse transcription were performed as we have
previously described (20). Speciﬁc mRNA levels were determined using an
ABI 7500 sequence detection system (Perkin-Elmer Applied Biosystems,
Warrington, U.K.). Reactions were performed in 20 l volumes on 96-well
plates in reaction buffer containing 2  TaqMan Universal PCR Master mix
(Applied Biosystems, Foster City, CA). Probes and primers for all genes were
supplied by applied biosystems ‘assay on demand’ (Applied Biosystems). All
reactions were normalized against 18S rRNA as an internal housekeeping
gene.
Data were obtained as ct values (ct  cycle number at which logarithmic
PCR plots cross a calculated threshold line) and used to determine ct values
with ct  (ct of the target gene) – (ct of the housekeeping gene). Data are
expressed as arbitrary units using the following transformation (expression
105  [2ct] arbitrary units [AUs]). When used, fold changes were calculated
using the following equation: [fold increase  2difference in ct].
Genecard analysis. Taqman 348-well custom arrays were purchased from
Applied Biosystems containing 45 custom genes and 3 housekeeping genes.
Five hundred nanograms of cDNA were mixed with Taqman universal PCR
master mix (Applied Biosystems), and the array was run on an ABI 7900HT
Fast Real-Time PCR System (Applied Biosystems). Data were obtained as ct
values and fold changes calculated. Results were validated with standard
Taqman RT-PCR.
Protein extraction and immunoblotting. Cells were scraped into 100 l
RIPA buffer (50 mmol/l Tris pH 7.4, 1% NP40, 0.25% sodium deoxycholate, 150
mmol/l NaCl, 1 mmol/l EDTA), 1 mmol/l phenylmethylsulfonyl ﬂuoride, and
protease inhibitor cocktail (Roche, Lewes, U.K.), incubated at80°C (10 min)
on ice (30 min), and centrifuged at 4°C (10 min, 14,000 rpm). The supernatant
was transferred to a fresh tube and total protein concentration determined by
a commercially available assay (Bio-Rad Laboratories, Hercules, CA).
Twenty micrograms of protein was resolved on an SDS-PAGE gel (acryl-
amide percentage varied according to protein size). Proteins were transferred
onto nitrocellulose membrane, Hybond ECL (GE Healthcare, Chalfont St.
Giles, U.K.). Primary (anti-IRS1, anti-pSer307 IRS1, anti-IRS2, and anti-AS160
from Upstate, Dundee, U.K.; anti-PKB/akt, anti-pSer473 PKB/akt [recognizing
isoforms 1 and 2], and anti-Thr308 Akt/PKB from R&D Systems, Abingdon,
U.K.; and anti-pTyr608 IRS1 from Biosource, Nivelles, Belgium) and secondary
antibodies (Dako, Glostrop, U.K.) were used at a dilution of 1/5,000. Mem-
branes were reprobed for -actin and primary and secondary antibodies used
at a dilution of 1/5,000 (Abcam plc, Cambridge, U.K.). Bands were visualized
using ECL detection kit (GE Healthcare, Chalfont St. Giles, U.K.) and
quantiﬁed with Genesnap by Syngene (Cambridge, U.K.).
Glucose transport assay. Glucose uptake activity was analyzed by measur-
ing the uptake of 2-deoxy-D-[3H] glucose as described previously (21). After
treatment, cells were washed three times with Krebs-Ringer-Hepes (KRP)
buffer and incubated with 0.9 ml KRP buffer at 37°C for 20 min. Insulin (0.5
g/ml) was then added, and the cells were incubated at 37°C for 20 min.
Glucose uptake was initiated by the addition of 0.1 ml KRP buffer and 37MBq/l
2-deoxy-D-[3H] glucose (GE Healthcare) and 7 mmol/l glucose as ﬁnal concen-
trations. After 60 min, glucose uptake was terminated by washing the cells
three times with cold PBS. Cells were lysed and radioactivity retained by the
cell lysates determined by scintillation counting.
11-HSD1 assay. Brieﬂy, intact cells were incubated with 100 nmol/l 11DHC
and tritiated tracer for 2–24 h dependent upon assay system. In studies using
selective 11-HSD1 inhibitors, cells were incubated for 24 h with inhibitor
before 11-HSD1 assay being performed. Steroids were then extracted using
dichloromethane, separated using a mobile phase consisting of ethanol and
chloroform (8:92) by thin layer chromatography, and scanned using a Bioscan
3000 image analyzer (Lablogic, U.K.). Protein levels were assayed using a
commercially available kit (Bio-Rad, Richmond, CA).
Mouse protocols. The selective 11-HSD1 inhibitor A2 was used in two
separate mouse protocols. All experimental procedures were conducted in
accordance with the Animal Scientiﬁc Procedures Act 1986, Animal Welfare
Act 2006, and local guidelines. First, male C57Bl6/J mice (6 weeks of age) were
maintained for 20 weeks on a diet comprising 48 kcal% fat/10 kcal% fructose
(Research Diets RD06072801, New Brunswick, NJ). Mice were housed with a
standard light cycle (06:00 h on/18:00 h off), and A2 was administered (20
mg/kg b.i.d) by oral gavage for 28 days and compared against vehicle-control
and pair-fed, vehicle-treated animals (n  9–10). Food intake was assessed
over the 28-day period, and on day 24 after 12-h fast, an oral glucose tolerance
test (OGTT, 2 g/kg) was performed. Conscious tail-prick samples were
analyzed for glucose using the Accu-Chek Aviva system (Roche) and for
insulin using Ultra Sensitive Mouse Insulin ELISA kits (Crystal Chem #90800,
Downers Grove, IL).
Separately, the impact of A2 upon skeletal muscle gene and protein
expression in an additional hyperglycemic model were determined (male
KK/Ta Jcl mice aged 7 weeks; CLEA Japan, Tokyo, Japan). Animals had free
access to water and irradiated RM3 (E) diet composed of 11.5 kcal% fat, 27
kcal% protein, and 62 kcal% carbohydrate (Special Diets Services, Witham,
U.K.). Compound A2 (20 mg/kg) or vehicle (10 ml/kg) was administered by
oral gavage at 08:00 and 20:00 h for 4 consecutive days. After the administra-
tion of the third dose of A2, mice were anesthetized by inhalation of 2–3% v/v
isoﬂurane (vaporized by oxygen at 1.6 l/min ﬂow rate) and a 5 mg slow-release
cortisone pellet (	8 mg  kg1  day1 in a 29 g mouse) implanted subcuta-
neously in the lateral aspect of the neck (Innovative Research of America,
Sarasota, FL). On day 4, 1–2 h after the seventh oral dose of A2, a rising-dose
carbon dioxide concentration was used to humanely kill mice in the fed state
and femoral quadriceps muscles were removed and snap frozen in liquid
nitrogen.
Statistical analysis. Where data were normally distributed, unpaired Stu-
dent’s t tests were used to compare single treatments to control. If normality
tests failed, then nonparametric tests were used. One-way ANOVA on ranks
was used to compare multiple treatments, doses, or times (SigmaStat 3.1;
Systat Software, Point Richmond, CA). Statistical analysis on real-time PCR
data was performed on mean ct values.
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RESULTS
Glucocorticoid impact upon the insulin-signaling
cascade. In agreement with published data, treatment
with the synthetic glucocorticoid Dex (1 mol/l, 24 h)
decreased insulin-stimulated glucose uptake (2.1 
 0.3 vs.
1.7 
 0.2 dpm  105, P  0.05, n  4) consistent with the
induction of insulin resistance in differentiated rodent
C2C12 skeletal myocytes.
Using real-time PCR, Dex (1 mol/l, 24 h) decreased
mRNA expression of IRS1 (8.7 
 0.7 vs. 4.5 
 0.4 AU, P 
0.05, n  5), an effect that was blocked by the glucocor-
ticoid antagonist RU-38486 (Table 1). In contrast, IR,
Akt/PKB2, PI3K, AS160, and GLUT4 expression all in-
creased after Dex treatment. RU38486 reversed only the
effects of Dex upon GLUT4 and AS160 expression. Al-
though Dex treatment did not alter 11-HSD1 expression,
H6PDH expression increased (0.10 
 0.01 vs. 1.30 
 0.07
AU, P  0.001) and was reversed by coincubation with
RU38486 (0.18 
 0.02 AU, P  0.001 vs. Dex). Absolute
mRNA expression data after Dex treatment with and
without the glucocorticoid receptor antagonist RU38486
are presented in Table 1.
At the protein level, treatment with Dex decreased IRS1
total protein expression (0.4-fold, P  0.05) that was
recovered by coincubation with RU38486 (Fig. 1A and B).
Insulin-stimulated, activating Tyr608 phosphorylation of
IRS1 was unchanged with Dex treatment (Fig. 1A and B).
However, we observed enhanced inactivating Ser307 phos-
phorylation (3.3-fold, P  0.05) after Dex treatment that
was prevented by RU-38486 (Fig. 1A and B). Total IRS2
protein expression was increased by Dex (1.7-fold, P 
0.001) (Fig. 1A and C). Further downstream, Akt/PKB
protein expression did not change with Dex treatment, but
activating Ser473 phosphorylation decreased (0.5-fold, P 
0.05) (Fig. 1A and D). Dex treatment increased AS160
expression 1.5-fold (P  0.05), which was blocked by
coincubation with RU38486 (Fig. 1A and E).
Diacylglycerol (DAG)-dependent protein kinase C
(PKC) isoforms have been implicated in the phosphoryla-
tion of IRS1 at Ser24, and this has been linked to the
pathogenesis of insulin resistance (19). We examined the
effect of Dex using C2C12 cells stably overexpressing
IRS1. Although Dex increased Ser307 phosphorylation in
this model, there was no detectable impact upon Ser24
phosphorylation or ectopic IRS1-myc protein levels
(Fig. 1F).
To determine whether our observations with synthetic
glucocorticoids were applicable in a physiological context,
further experiments were performed using endogenous
rodent glucocorticoids (11DHC and CORT). Consistent
with our observations using Dex, CORT caused a dose-
and time-dependent decrease in IRS1 total protein expres-
sion (dose: 1.0 [control] vs. 0.59-fold [100 nmol/l], P 0.01,
0.47-fold [250 nmol/l], P  0.05, 0.44-fold [500 nmol/l], P 
0.01, 0.38-fold [1,000 nmol/l], P  0.01; time: 1.0 [control]
vs. 0.19 
 0.04 [48 h], P  0.05) (Fig. 2A and B). This was
accompanied by a dose- (1.0 [control] vs. 2.80-fold [250
nmol/l], P  0.01, 3.99-fold [500 nmol/l], P  0.01, 4.37-fold
[1,000 nmol/l], P  0.001) (Fig. 2A) and time- (1.0 [control]
vs. 3.0 
 0.08 [48 h], P  0.05) (Fig. 2B) dependent
increase in Ser307 phosphorylation.
11-HSD1 in rodent and human skeletal muscle. 11-
HSD1 mRNA was highly expressed in C2C12 cells. Expres-
sion was also detected in whole-tissue explants of mouse
quadriceps muscle, although levels were lower than those
seen in liver and adipose tissue (Table 2). In all systems
(C2C12 cells, human primary cultures, and whole-tissue
explants from mice), functional, bidirectional 11-HSD1
activity was demonstrated with predominant oxo-
reductase activity (Fig. 3A and B). In mouse quadriceps
explants, oxo-reductase activity was signiﬁcantly de-
creased after coincubation with the nonselective 11-HSD
inhibitor, glycyrrhetinic acid (2 mol/l, 2 h) (114.0
 5.7 vs.
44.6 
 11.1 pmol  g1  h1, P  0.05) (Fig. 3A and B). A1
and A2 are selective 11-HSD1 inhibitors provided through
an investigator-led collaboration with AstraZeneca. A1 has
a half-maximal inhibitory concentration (IC50) for human
recombinant 11-HSD1 of 0.3 nmol/l and for rat 637 nmol/l,
mouse 33 nmol/l, and human 11-HSD2 15 mol/l. A2
has an IC50 for human recombinant 11-HSD1 of 7 nmol/l
and for rat 94 nmol/l, mouse 26 nmol/l, and human
11-HSD2 15 mol/l. Treatment with A1 (1 mol/l, 24 h),
signiﬁcantly decreased oxo-reductase activity in mouse
quadriceps whole-tissue explants, differentiated C2C12
cells, and primary cultures of differentiated human skele-
tal myocytes (Fig. 3C).
Functional impact of 11-HSD1 inhibition
Rodent and human cell lines and primary cultures.
Paralleling our observations with Dex and CORT, 11DHC
(250 nmol/l, 24 h) decreased IRS1 total protein expression
(0.5-fold, P  0.05) and increased pSer307 IRS1 (2.0-fold,
P  0.05) in C2C12 cells. Coincubation with the nonselec-
tive 11-HSD inhibitor glycyrrhetinic acid (2.5 mol/l,
24 h) reversed 11DHC-induced pSer307 IRS1 to levels seen
in control untreated cells (1.1-fold, P  0.56 vs. control)
(Fig. 4A). Glycyrrhetinic acid treatment alone was without
effect (data not shown). Similarly, observations with the
selective 11-HSD1 inhibitor A1 (2.5 mol/l, 24 h) mir-
rored those with glycyrrhetinic acid, completely blocking
the effects of 11DHC to decrease total IRS1 expression and
increase pSer307 IRS1 (Fig. 4B). Extending these ﬁndings,
in primary cultures of human skeletal muscle, cortisone
(250 nmol/l, 24 h) decreased insulin-stimulated pThr308
Akt/PKB without altering total Akt/PKB protein expres-
sion. These observations were completely abolished fol-
lowing coincubation with A1 (Fig. 4C).
TABLE 1
mRNA expression of key components of the insulin-signaling
cascade and glucocorticoid metabolism in C2C12 rodent skeletal
myocytes measured using real-time PCR after treatment with
Dex (1 mol/l, 24 h) with or without the glucocorticoid receptor
antagonist, RU38486 (10 mol/l)
Gene Control
Dexamethasone
(1 mol/l, 24 h)
Dexamethasone
(1 mol/l, 24 h) 
RU38486 (10
mol/l, 24 h)
InsR 4.4
 0.4 6.1
 0.5† 5.4
 0.5
IRS1 8.7
 0.7 4.5
 0.4* 7.5
 0.7§
AKT1 45.2
 5.4 39.4
 2.8 45.1
 3.4
AKT2 1.5
 0.3 2.3
 0.1* 1.9
 0.3
PI3K(p85) 1.4
 0.2 2.2
 0.2* 2.2
 0.1
GLUT4 2.3
 0.3 13.1 
 1.5‡ 3.7
 0.4
11HSD1 32.9
 2.9 27.6
 2.7 35.6 
 3.6
H6PDH 0.10
 0.0149 1.30
 0.07‡ 0.18
 0.02¶
AS160 0.12
 0.02 0.23
 0.02* 0.12
 0.01§
Data are the mean values from n  5 experiments and expressed as
AUs 
 SE (*P  0.05, †P  0.01, and ‡P  0.001 vs. control; §P 
0.05, P  0.01, and ¶P  0.001 vs. Dex).
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Mouse in vivo studies
Food intake, glucose tolerance, and insulin
sensitivity. Food intake decreased within the ﬁrst 48 h in
the A2-treated animals in comparison with vehicle-treated
controls. However, by day 4 and for the remainder of the
28-day protocol, food intake did not differ between the
groups (day 4: 15.4 
 0.7 vs. 16.5 
 0.7 kcal/day [A2 vs.
control], P  0.08). At day 28, fasting blood glucose and
insulin levels were lower in the A2-treated animals com-
pared with both vehicle-treated and pair-fed controls
(glucose: 6.8 
 0.3 vs. 7.4 
 0.35 vs. 7.7 
 0.3 mmol/l, P 
0.05; insulin: 0.60 
 0.10 vs. 0.82 
 0.14 vs. 0.91 
 0.11
ng/ml, P  0.05, A2 vs. vehicle vs. pair-fed vehicle).
Similarly, homeostasis model assessment values were
lower (4.2 
 0.9 vs. 6.0 
 0.98 vs. 7.1 
 0.9 [A2 vs. vehicle
vs. pair-fed vehicle], P  0.05) as was insulin secretion
(area under curve, AUC) across an OGTT (2.29 
 0.23 vs.
2.95
 0.37 vs. 2.94
 0.21 ng  ml1  h1 [A2 vs. vehicle vs.
pair-fed vehicle], P  0.05). Glucose levels across the
OGTT (AUC) did not change signiﬁcantly (22.4 
 0.46 vs.
24.2 
 0.42 vs. 22.9 
 0.45 mmol  l1  h1 [A2 vs. vehicle
vs. pair-fed vehicle], P  not signiﬁcant).
Gene and protein expression in skeletal muscle from
KK mice. Cortisone pellet–implanted KK mice treated
with A2 for 4 consecutive days had increased total IRS1
protein expression, decreased Ser307 phosphorylation, and
increased Thr308 phosphorylation of Akt/PKB in whole-
tissue quadriceps explants. Tyr608 phosphorylation did not
change (Fig. 5A). Genecard analysis of quadriceps mRNA
expression following A2 treatment is shown in Table 3.
Positive ﬁndings were endorsed with real-time PCR (Fig.
5B). 11-HSD1 expression decreased (0.48-fold) (Table 3,
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FIG. 1. Dex treatment (1 mol/l, 24 h) in C2C12 rodent skeletal myocytes decreases IRS1 total protein expression, increases pSer307 IRS1, but
does not change pTyr608 IRS1. These observations are reversed by coincubation with the glucocorticoid antagonist RU38486. IRS2 expression
increased after Dex treatment. Although Akt/PKB expression does not change, activating pSer473 Akt/PKB decreases but is not recovered by
coincubation with RU38486. Total AS160 protein expression increased after Dex pretreatment and was reversed with RU38486. Representative
Western blots are shown in panel 1A with quantitation relative to -actin as internal loading control shown in subsequent panels (IRS1 [total
IRS1: black bars, pSer307 IRS1: white bars, pTyr608 IRS1: gray bars] [B], IRS2 [C], akt/PKB [total Akt/PKB: black bars, pSer473 Akt/PKB: white bars]
[D], and AS160 [E]) (*P < 0.05 vs. control, †P < 0.05, ††P < 0.01 vs. Dex). In C2C12 cells stably overexpressing IRS1, Dex increases Ser307 but
does not induce Ser24 phosphorylation (F). Ctrl, control. PMA, phorbol myristate acetate.
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Fig. 5B) without effect on glucocorticoid receptor or
H6PDH expression. In agreement with our protein expres-
sion data, IRS1 mRNA expression increased after selective
11-HSD1 inhibition (Fig. 5B). The regulatory subunit of
PI3K p85 decreased 0.25-fold after treatment with A2 with
no change in catalytic subunit (p110) expression (Table 3,
Fig. 5B). PI3K activity was not measured as part of this
study. A2 treatment decreased expression of key target
genes involved in lipogenesis (ACC1 0.3-fold, DGAT 0.4-
fold), lipolysis (HSL 0.3-fold, ATGL 0.39-fold) and lipid
oxidation (ACC2 0.6-fold) (Table 3, Fig. 5B). In addition,
PDK4 increased 1.7-fold (Fig. 5B).
DISCUSSION
In this study, we have characterized in detail the impact of
both synthetic and endogenous glucocorticoids upon in-
sulin signaling in the rodent skeletal muscle cell line,
C2C12. In addition, we have characterized expression and
activity of 11-HSD1 in both rodent and human skeletal
muscle, ascribed a functional signiﬁcance to its activity in
terms of insulin sensitization, and have begun to explore
the mechanisms by which this occurs.
Glucocorticoids impair insulin signaling at multiple lev-
els, importantly decreasing total IRS1 protein expression
and increasing Ser307 phosphorylation. IRS-1 serine phos-
phorylation at this site has been reported to decrease the
afﬁnity of IRS1 for the insulin receptor and increased IRS1
degradation (9,10), and this may account for the decrease
in total protein expression that we observed. It is also
sufﬁcient to account for the glucocorticoid-induced de-
crease of insulin-stimulated glucose uptake. The pivotal
role of IRS1 in skeletal muscle insulin signaling is high-
lighted by IRS1 knockout mice (22–24) that develop
marked insulin resistance. Serine phosphorylation of IRS1
at numerous residues has been implicated in the develop-
ment of insulin resistance (19,25–27). Speciﬁcally, Ser307
phosphorylation is a negative regulator of IRS1 function.
Inﬂammatory cytokines including tumor necrosis factor-
and C-reactive protein increase Ser307 phosphorylation
(28,29), and insulin itself has been described to have
similar effects (30,31). Although several kinases have been
implicated in serine phosphorylation of IRS1 (32), PKC is
believed to have a critical role, notably after free fatty acid
(FFA) exposure (33,34). PKC knockout animals resist
lipid-induced skeletal muscle insulin resistance (35), and
rodent models with muscle-speciﬁc targeted serine-to-
alanine substitutions at residues within IRS1 including
Ser307 resist fat-induced insulin resistance (36). Glucocor-
ticoid induction of lipolysis and consequent FFA genera-
tion (37) as well as increased FFA uptake will activate
PKC, and this may well be an important contributor to the
insulin resistance induced by glucocorticoid. This is en-
dorsed by our gene expression analysis of lipogenic/
lipolytyic genes in rodent muscle after 4-day treatment
with the selective 11-HSD1 inhibitor A2 (see discussion
below). In addition, the lack of Ser24 phosphorylation
may also add weight to this hypothesis. PKC does
not contribute to phorbol-12-myristate-13-acetate–induced
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FIG. 2. The endogenous rodent glucocorticoid, CORT, induces a dose- (A) and time- (B) dependent decrease in total IRS1 protein expression
(black bars) and increase in pSer307 IRS1 (white bars). Data presented are the means of n  4–6 experiments with representative Western blots
inserted above (*P < 0.05, **P < 0.01 vs. control).
TABLE 2
Comparative mRNA expression of 11-HSD1, glucocorticoid receptor, and H6PDH in mouse skeletal muscle and C2C12 myotubes
Gene C2C12 Quadriceps Liver Adipose
11-HSD1 32.9
 2.9 0.29
 0.03 18.40
 1.96 1.26
 0.14
H6PDH 0.10
 0.015 0.1
 0.006 0.12
 0.005 0.11 
 0.0009
Glucocorticoid receptor 0.56
 0.022 5.67
 0.29 3.33
 0.36 3.9
 0.68
Data are expressed as AUs (AU means 
 SE, n  3–5 experiments). Expression in rodent liver and adipose tissue are provided as a
quantitative reference.
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Ser24 phosphorylation but instead is dependent upon PKC
activation (19).
Other studies have also highlighted the pivotal role of
IRS1 in glucocorticoid-associated insulin resistance, al-
though serine phosphorylation has not been examined.
The results of these studies do show a degree of variability
and some but not all have shown decreased activating
tyrosine phosphorylation of IRS1 (11–13). Others have
reported changes in insulin receptor expression and acti-
vation, PI3K activity and expression, and IRS2 expression
and phosphorylation (12,38,39). The explanation for these
inconsistencies is not entirely clear but may reﬂect differ-
ences between animal and cell models and speciﬁc inves-
tigative protocols.
Downstream of IRS1, we observed decreased activating
pSer473 Akt/PKB and pThr308 Akt/PKB, and we propose
that this may be a direct consequence of reduced insulin
signaling capacity through enhanced IRS1 inactivation. In
addition, we observed an increase in AS160 protein ex-
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FIG. 3. Functional 11-HSD1 enzyme oxo-reductase (A) and dehydroge-
nase (B) activity is present in explants of mouse quadriceps muscle with
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activity is also observed in differentiated C2C12 rodent skeletal myocytes
(data presented as picomole per milligram of protein per hour for C2C12
cells). Although dehydrogenase activity is present, the predominant
activity is oxo-reductase generating active glucocorticoid. Coincubation
of skeletal muscle explants with the nonselective 11-HSD inhibitor,
glycyrrhetinic acid, signiﬁcantly decreases activity (data shown are the
means SE of n 3–6 experiments, *P< 0.05). In addition, the selective
11-HSD1 inhibitor, A1 (1 mol/l, 24 h), decreases oxo-reductase activity
in rodent whole-tissue quadriceps explants, differentiated C2C12 skeletal
myocytes, and primary cultures of human skeletal myocytes (C) (data
shown are themeans SE of n 3–6 experiments, *P< 0.05, §P< 0.005)
(control  black bars, A1  white bars). GE, glycyrrhetinic acid.
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experiments with representative Western blots inserted (*P < 0.05,
**P< 0.01 vs. control, †P< 0.05 vs. 11DHC or cortisone). Ctrl, control.
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pression. AS160 is a recently identiﬁed protein with Rab-
guanosine triphosphate (GTP)ase activity. Under basal
conditions, it is resident within GLUT4-containing vesicles
and limits the GTP availability that is necessary for vesicle
translocation to the cell membrane to permit glucose
entry. Upon phosphorylation by activated Akt/PKB, AS160
dissociates from the vesicle, allowing GTP to bind to Rab
proteins and vesicle translocation to the cell membrane to
occur (7). While regulation of AS160 phosphorylation at
differing sites by growth factors including IGF-1 and EGF
has been described (40), glucocorticoid regulation has not
been explored. Our data show that glucocorticoids in-
crease both AS160 protein and mRNA expression in a
glucocorticoid receptor–dependent mechanism. These ob-
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Gene expression from whole-tissue quadriceps explants obtained from cortisone pellet–implanted KK mice treated for 4 days with the selective
11-HSD1 inhibitor, A2 (white bars), or vehicle (black bars) (*P < 0.05, **P < 0.01) (n  3 per group) (B).
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servations are interesting and point toward a separate
mechanism of regulation rather than simply a downstream
consequence of decreased IRS1 activation.
Although the net effect of glucocorticoid was to induce
insulin resistance, we did observe an increase in IRS2
mRNA and protein expression. In addition IR, PI3K (p85
subunit), and GLUT4 mRNA expression increased, al-
though protein expression was not examined in this study
nor was PI3K-speciﬁc activity. It is possible that this
represents a compensatory mechanism to preserve insulin
sensitivity in an attempt to compensate for the inhibition
of signaling through IRS1. However, overall the effect of
TABLE 3
Quadriceps skeletal muscle Genecard analysis of 45 preselected gene targets implicated in the pathogenesis of glucocorticoid-
induced insulin resistance
Gene of interest
Cortisone  vehicle
(means ct 
 SE)
Cortisone  A2
(means ct 
 SE)
Fold change in
gene
expression
after M1
treatment
Insulin signalling cascade
Insr 15.9
 0.2 16.5
 0.2 0.65
Irs1 16.9
 0.1 16.6
 0.1 1.27
Irs2 17.2
 0.2 16.3
 0.8 1.93
Pik3r1 (p85) 14.9
 0.2 16.9
 0.4 0.25
Pik3cb (p110) 19.4
 0.3 19.8
 0.1 0.79
Pdk1 15.9
 0.2 16.9
 0.1 0.49
Akt1 16.3
 0.1 17.1
 0.2 0.59
Akt2 17.7
 0.3 18.2
 0.3 0.74
Prkcz (PKC) 19.2
 0.3 20.6
 0.6 0.37
Prkci (PKC) 19.6
 0.1 20.2
 0.1 0.62
Tbc1d1 15.7
 0.3 16.5
 0.1 0.58
Tbc1d4 (AS160) 17.2
 0.3 18.1
 0.3 0.53
Rab10 11.7
 0.3 12.3
 0.1 0.68
Slc2a1 (GLUT-1) 16.8
 0.2 17.0
 0.1 0.91
Slc2a4 (GLUT-4) 14.1
 0.1 14.1
 0.1 1.03
Ptpn1 (PTP-1b) 17.8
 0.1 18.8
 0.1 0.52
Ptpn11 (SHP2) 16.1
 0.2 16.4
 0.1 0.77
Pten 15.8 
 0.1 16.6
 0.1 0.60
Ppp2r1a (PP2A) 14.9
 0.2 15.2
 0.1 0.81
Socs1 21.5
 0.4 21.2
 0.4 1.20
Socs3 19.4
 0.2 19.4
 0.1 0.98
Frap1 (mTOR) 16.5
 0.2 17.3
 0.3 0.55
Foxo1 16.9
 0.2 17.4
 0.1 0.75
Foxo3a 15.9
 0.1 16.7
 0.5 0.58
Prkaa2 (AMPK) 14.8
 0.1 15.0
 0.3 0.91
Ppargc1a (PGC-1) 16.9 
 0.2 17.1
 0.1 0.93
Glucocorticoid
metabolism and action
H6pd 15.6
 0.1 16.2
 0.3 0.66
Hsd11b1 (11-HSD1) 17.5
 0.6 18.5
 0.8 0.48
Nr3c1 (GR) 15.8
 0.1 16.3
 0.2 0.72
Lipid metabolism
Acaca (ACC1) 15.1
 1.0 16.7
 0.2 0.33
Acacb (ACC2) 13.6
 0.3 14.4
 0.2 0.60
Lpl 12.6
 0.2 13.2
 0.1 0.68
Lipe (HSL) 16.4
 0.6 18.1
 0.1 0.30
Pnpla2 (ATGL) 13.7
 0.5 15.1
 0.1 0.39
Dgkd (DGK) 21.3
 0.5 21.4
 0.1 0.97
Pparg (PPAR) 21.2
 0.5 22.4
 0.3 0.43
Ceramide metabolism
Sptlc1 (SPT1) 17.8
 0.1 18.6
 0.0 0.59
Ugcg (glucosylceramide synthase) 18.8
 0.1 19.5
 0.1 0.61
Asah1 (acid ceramidase) 19.0
 0.1 19.3
 0.1 0.82
Lass1 16.9
 0.1 17.3
 0.1 0.77
Lass6 20.5
 0.4 21.1
 0.0 0.68
Other genes
Prkca (PKC-) 16.6
 0.2 16.6
 0.1 0.94
Prkcb1 (PKC-) 22.7 
 0.3 22.8
 0.3 0.96
Prkcc PKC-) 22.6
 0.1 23.1
 0.7 0.69
Ppara (PPAR) 18.7
 0.3 19.0
 0.1 0.85
Internal controls
Ppib (cyclophilin B) 18.1
 0.2 18.4
 0.1 0.79
Hprt1 16.5
 0.2 17.1
 0.0 0.69
Cortisone pellet–implanted KK mice were treated with a selective 11-HSD1 inhibitor, A2, or vehicle for 4 days before animals were killed
(n  3 per group, for detailed protocol see RESEARCH DESIGNS AND METHODS). Data presented as means ct 
 SE for both groups of animals
relative to 18 s as an internal housekeeping gene, higher ct values corresponding with lower gene expression. Fold changes in gene
expression were calculated as described in RESEARCH DESIGNS AND METHODS. Speciﬁc target genes and all changes 2-fold increase or 0.5-fold
decrease vs. vehicle (highlighted in bold) were endorsed with real-time PCR (see Fig. 5).
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glucocorticoid exposure is to limit insulin-stimulated glu-
cose uptake.
In addition to the effect of exogenous glucocorticoids,
we have shown that prereceptor metabolism of endoge-
nous glucocorticoid by 11-HSD1 is a crucial regulator of
insulin sensitivity in skeletal muscle. 11-HSD1 is ex-
pressed and biologically active in human skeletal muscle
(41). Overexpression of 11-HSD1 has been described in
rodent skeletal muscle in models of diabetes (42) and
myotubes isolated from patients with insulin resistance
and type 2 diabetes (43,44). However, this is not a consis-
tent ﬁnding (45), and its precise contribution to metabolic
and muscle phenotype is still to be clariﬁed. Selective
11-HSD1 inhibitors are currently in development; in
rodents and primates they limit local glucocorticoid avail-
ability and improve glucose tolerance, lipid proﬁles, and
insulin sensitivity (16,46). Very recently, studies using in
vitro differentiated primary in human myoblasts have
shown that 11-HSD1 inhibition (pharmacological or
siRNA) can limit cortisone- but not cortisol-induced
changes in glucose uptake, glycogen synthesis, and palmi-
tate oxidation. However, in this model, an insulin-sensitiz-
ing action could not be demonstrated (47). In our study,
we have clearly shown expression and activity of 11-
HSD1 in human and rodent skeletal muscle that is blocked
by selective and nonselective 11-HSD1 inhibitors. This is
functionally important and not only restores IRS1 protein
levels to control values but also decreases pSer307 IRS1,
enhances Akt/PKB activation, and may represent an im-
portant insulin-sensitizing mechanism of selective 11-
HSD1 inhibitors. These observations appear consistent in
both our in vitro and rodent in vivo models. A2 has an
insulin-sensitizing action as evidenced by decreased fast-
ing glucose and insulin levels, decreased homeostasis
model assessment scores, and reduced insulin secretion
across an OGTT. Unfortunately, clamp studies were not
performed as part of this protocol but have been reported
elsewhere with other selective 11-HSD1 inhibitors (16).
In addition to the actions described above, A2 administra-
tion to mice in vivo decreased lipogenic gene expression
(ACC1, FAS, and DGAT) and increased FFA utilization
(decreased ACC2 leading to a decrease in the malonyl
CoA-mediated inhibition of -oxidation) in agreement with
published observations (48). Furthermore, decreased HSL
and ATGL will afford decreases in FFA and DAG genera-
tion. Interestingly, we also observed a 1.7-fold increase in
PDK4 expression with A2 treatment in vivo. PDK4 is a
negative regulator of the pyruvate dehydrogenase com-
plex, limiting acetyl CoA generation. Rodents with dele-
tion of PDK4 have increased glucose oxidation (49), and in
cell culture systems, glucocorticoids increase PDK4 ex-
pression (47). The discrepancies with our data, where A2
increased PDK4 expression, almost certainly reﬂect the
complexities of whole-animal versus cell culture models
(we too have observed decreased PDK4 expression after
Dex treatment in C2C12 myotubes [data not shown]).
Importantly, the increase in PDK4 with selective 11-
HSD1 inhibitors may further serve to drive lipid oxidation
at the expense of glucose oxidation. The net effect of all
these observations will be to decrease intramyocellular
lipid accumulation as well as local FFA and DAG genera-
tion. Consequently, PKC activation will be decreased, and
this may be responsible for the reduction in Ser307 phos-
phorylation after selective 11-HSD1 inhibition. However,
this hypothesis remains to be proven and needs to be
addressed in future studies.
In conclusion, Ser307 phosphorylation of IRS1 is a novel
mechanism of glucocorticoid-induced insulin resistance.
The prereceptor modulation of glucocorticoid availability
is an important regulator of glucocorticoid action in
skeletal muscle. Selective 11-HSD1 inhibitors enhance
insulin action, and we propose that this may predomi-
nantly be through modulation of lipid metabolism within
skeletal muscle. Clinical data utilizing 11-HSD1 inhibitors
are beginning to emerge in obese patients and those with
type 2 diabetes (50); it is likely that their efﬁcacy in muscle
will provide an additional pharmacological beneﬁt in the
treatment of type 2 diabetes and insulin resistance.
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